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Abstract 
The work presented in this thesis reports the development of semi-solid anesthetics 
formulations, for topical application. Two different drugs were used: tetracaine and 
ropivacaine hydrochloride, an anesthetic with a fast and a slow onset of action, 
respectively. 
The efficacy of a drug applied topically depends on its ability to cross the stratum 
corneum, the outermost layer of the skin, and reputedly its main barrier. 
A detailed introduction to the work is presented on Chapter 1. Chapters 2, 3, 4 and 5 
report in detail the development and characterization of systems and strategies with the 
purpose of improving the permeation of the two local anesthetics mentioned above. 
Chapter 6 describes the in vivo studies of TC and RPC loaded hydrogels and liposomal 
formulations optimized in the previous Chapters using the tail-flick test. The overall 
conclusions are summarized in Chapter 7. 
The work presented in Chapter 2 focused on strategies to improve the solubility of 
tetracaine in aqueous formulations. Two different hydrophilic and ionizable cyclodextrins 
(β-CD e HP-β-CD) were used to improve tetracaine solubility, stability and bioavailability 
in aqueous environment. A wide set of solubility studies, fluorescence microscopy, 
nuclear magnetic resonance, in vitro release studies and kinetic studies were performed 
in order to gain new insights about the system. The results allowed the determination of 
the ideal concentration of cyclodextrin needed to solubilize the desired amount of 
tetracaine without compromising its release from the drug-loaded formulations. 
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Chapters 3 and 4 report in detail the evaluation of several aminoacids-based surfactants 
(lysine and serine, respectively) as chemical permeation enhancers for drugs delivered 
topically. The effects of these compounds were assessed by means of in vitro 
permeation studies, in Franz diffusion cells, across newborn porcine skin. The toxicity of 
the compounds and the morphological changes in the skin structure were also 
evaluated. Complementary molecular dynamic studies were carried out to obtain a 
mechanistic vision and to provide understanding on the mechanism of action of these 
molecules on lipid membranes. 
In Chapter 3, the compounds evaluated were neutral and negatively charged surfactants, 
derived from the aminoacid lysine, with different alkyl chain lengths tails (10Lys10; 
12Lys12; 14Lys14 and 16Lys16). In Chapter 4 the compounds under study were neutral 
and positively charged gemini surfactants, derived from the aminoacid serine, with 
structural differences both in the nature of the hydrophobic tails and spacer (10Ser)2N5 
(12Ser)2N5 (14Ser)2N5 (12Ser)2N10). The results obtained show that these class of 
compounds were able to increase the permeation of both drugs, especially in the case of 
the hydrophilic drug ropivacaine hydrochloride. Optical microscopy and scanning 
electron microscopy studies showed that the use of this compounds and methodology 
did not determine major morphological changes in the skin structure. Cytotoxicity studies 
in human epidermal keratinocytes cell lines were performed to establish the relative 
toxicity of the compounds. The results obtained gave a positive indication about their 
future use in formulations to be applied topically. 
Chapter 5 addresses the development of a liposome-based formulation as a strategy to 
improve the permeation across the skin, simultaneously, of two local anesthetics, aiming 
a sustained and prolonged therapeutic effect. Liposomes were prepared using various 
lipids, namely phosphatidylcholine and cholesterol, following thin layer evaporation 
methodology. In order to improve its properties and consequently, seeking to obtain 
higher drug permeation, some liposomes were modified by adding aminoacid-based 
surfactants previously optimized in Chapter 3 and Chapter 4. Liposomes were 
characterized for size, polydispersivity index, zeta potential and encapsulation efficiency. 
In vitro permeation studies across newborn pig skin were carried out from drug-loaded 
liposome formulations.  
Additionally in Chapter 6, tail-flick test in Wistar rats was performed to determine the in 
vivo efficacy of the selected formulations, either hydrogels or liposomes compared with a 
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commercially available formulation (Ametop®). Chapter 7 compiles the most significant 
conclusions of the work presented in this dissertation. 
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Resumo 
Em termos gerais, os trabalhos desenvolvidos nesta tese tiveram como principal 
objectivo o desenvolvimento de formulações anestésicas semi-sólidas de aplicação 
tópica que visam alcançar de um modo rápido e sustentado a analgesia. Para o efeito 
farmacológico pretendido foram utilizados dois tipos de anestésicos locais, um de acção 
rápida, a tetracaína e outro de acção farmacológica prolongada, a ropivacaína. 
A eficácia clínica de um fármaco aplicado por via tópica depende da sua capacidade de 
ultrapassar o estrato córneo, a camada mais exterior da epiderme e reconhecidamente 
a sua principal barreira. 
No capítulo 1 é feita uma introdução pormenorizada do tema que é desenvolvido nos 
capítulos seguintes. Os capítulos 2, 3, 4 e 5 abordam em pormenor o desenvolvimento e 
caracterização de sistemas e estratégias específicas com o objectivo de melhorar a 
eficiência da permeação dos dois anestésicos locais através da pele. O capítulo 6 
descreve os estudos in vivo das formulações finais previamente optimizadas nos 
capítulos 3, 4 e 5. As conclusões gerais são apresentadas no capítulo 7. 
O trabalho apresentado no capítulo 2 teve como objectivo a maximização da 
solubilidade da tetracaína em formulações aquosas. Duas ciclodextrinas hidrófilas e 
ionizáveis (β-CD e HP-β-CD) foram utilizadas com o objectivo de promover o aumento 
da solubilidade em meio aquoso, estabilidade e biodisponibilidade do fármaco. No 
âmbito deste trabalho foram realizados estudos de solubilidade, de microscopia de 
fluorescência, de ressonância magnética nuclear, estudos de libertação in vitro e de 
cinética e calculadas as constantes de estabilidade. Os resultados obtidos permitiram 
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determinar a quantidade ideal de ciclodextrina para solubilizar a tetracaína sem 
comprometer a sua libertação a partir das formulações. 
Os capítulos 3 e 4 descrevem detalhadamente a avaliação em termos de eficácia e de 
citotoxicidade, de um conjunto de tensioactivos derivados de aminoácidos (lisina e 
serina, respectivamente) como promotores químicos da permeação dos fármacos 
através pele. O efeito destes compostos como promotores da absorção transdérmica, foi 
investigado através de ensaios de permeação in vitro, em células de difusão vertical de 
Franz, através de pele de leitão. Estudos de dinâmica molecular permitiram obter uma 
visão mecanicista e elucidar a acção destas moléculas sobre membranas lipídicas. No 
capítulo 3, o objecto de estudo foram tensioactivos neutros e carregados negativamente, 
derivados do aminoácido lisina, com cadeias alquílicas de diferentes comprimentos 
(dez, 10Lys10; doze, 12Lys12; catorze, 14Lys14 e dezasseis, 16Lys16 átomos de 
carbono). No capitulo 4 foram avaliados tensioactivos “gemini” neutros e carregados 
positivamente, derivados do aminoácido serina e com variações estruturais impostas no 
comprimento da cadeia e do espaçador ((10Ser)2N5 (12Ser)2N5 (14Ser)2N5 
(12Ser)2N10). Os resultados obtidos demonstraram que ambas as classes de 
compostos foram eficazes e capazes de aumentar significativamente a cedência 
dérmica dos fármacos, especialmente no caso da ropivacaína, que por ser um fármaco 
hidrófilo, atravessa a pele em pequena extensão. Adicionalmente foram efectuados 
estudos de microscopia óptica e electrónica de varrimento para averiguar a integridade 
da pele utilizada após a sua utilização nos ensaios de permeação e potenciais efeitos 
tóxicos causados pelos promotores de absorção e metodologia utilizada. Ambas as 
técnicas demonstram a inexistência de alterações significativas do ponto de vista 
morfológico e estrutural. Foram também realizados estudos de citotoxicidade em linhas 
celulares de queratinócitos da epiderme humana, que permitiram estabelecer perfis de 
toxicidade relativa para os diferentes promotores. Estes resultados deram indicações 
positivas quanto à utilização segura destes compostos como promotores da absorção 
em formulações para administração tópica.  
O capítulo 5 visa o desenvolvimento de uma formulação lipossomal como estratégia 
para promover a permeação conjunta dos dois anestésicos locais aumentando a sua 
biodisponibilidade e prolongando o seu efeito terapêutico. Os lipossomas foram 
preparados recorrendo a diversos lípidos (fosfatidilcolina e colesterol) e o método de 
preparação foi a evaporação em camada fina. Alguns lipossomas foram modificados 
com a adição de tensioactivos criteriosamente escolhidos (capítulos 3 e 4) de modo a 
torná-los mais flexíveis e por consequente aumentar os perfis de permeação. Os 
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lipossomas foram caracterizados relativamente ao tamanho, índice de polidispersão, 
potencial zeta e eficiência de encapsulação. No capítulo 6 são apresentados os 
resultados do estudo de farmacodinâmica recorrendo ao teste tail-flick, de modo a 
avaliar a biodisponibilidade in vivo das formulações optimizadas comparando com uma 
formulação de mercado (Ametop®). O capítulo 7 conjuga as principais conclusões deste 
trabalho. 
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Chapter 1 
1. General introduction 
In the last decades, many drug delivery systems for topical administration were 
developed. The work presented in this dissertation focused on the evaluation of novel 
biocompatible chemical permeation enhancers and liposomes to improve the delivery of 
two local anesthetics applied topically. 
The selection of the variables explored in this thesis was based on the physicochemical 
properties of the drugs, biocompatibility and toxicity of the vehicles and chemical 
permeation enhancers used. The main objective was to improve the delivery of both 
drugs, in order to achieve sustained analgesic effects. 
The structure, composition and different skin permeation strategies will be subsequently 
described in detail. 
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1.1. Topical administration 
Topical administration is one of the most preferred administrations by patients with acute 
or chronic pain conditions since it is a noninvasive system of administration allowing a 
greater adherence to treatment. In addition, this route avoids the 1st hepatic effect and 
the degradation of the drug in the gastrointestinal tract among others adverse effects that 
occurs with other routes. However the skin is a biological membrane poorly permeable 
due to a layer, called stratum corneum (SC), with 15-20 m of keratinized cells which is 
the mainly barrier to the passage of substances. It is thus important to have a 
background of the physiology and functions of a healthy human skin and the principal 
routes of administration, followed by a review of some of the chemical and technological 
modulation for topical and transdermal drug delivery. 
1.1.1. The skin 
Human skin is a unique organ that enables the body to interact most intimately with its 
environment. It is the largest organ of the human body, accounting for more than 10% of 
the body mass of an average person, and it covers an average area of 1.7 m2 (Benson, 
2011; Brown et al., 2006). Such large and easily accessible organ apparently offers ideal 
conditions and multiple sites to administer therapeutic agents for both local and systemic 
effect. However human skin is a highly efficient self-repairing barrier designed to keep 
'the insides in and the outside out'. 
1.1.2. Functions of the skin 
Human skin constitute a sixth of the total weight of the body and it is constantly being 
regenerated. Numerous functions have been attributed to this highly complex organ. 
Skin can act as an environmental barrier providing physical, chemical and 
microbiological barrier protection crucial for terrestrial life (Benson, 2011; Elias, 2005; 
Madison, 2003a). Other functions of the skin are related to the neurosensory activity 
associated to pressure, pain and metabolism. Skin also plays an important role in the 
preservation of the homeostasis by regulating thermal hemodynamics. Basically, the 
body temperature is regulated by the constriction of the blood vessels that preserve heat 
and dilate to dissipate heat. Besides that, also hair helps thermal insulation, whereas 
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sweating facilitates heat loss by evaporation (Benson, 2011). Skin is also important as 
an immunological effector axis by having Langerhans cells process antigens and as an 
effector axis by setting up an inflammatory response to an external aggression. In 
addition skin is an endocrine organ and is a target for androgens that regulate sebum 
production, a complex mixture of lipids that function as antibacterial agents and for 
insulin, which regulates carbohydrate and lipid metabolism. The integument plays a role 
in metabolizing keratin, collagen, melanin, lipid, carbohydrate, and vitamin D as well as 
in respiration and in biotransformation of xenobiotics (Nancy, 2005). For the purpose of 
dermal drug delivery, the structure and composition of human skin will be described and 
will be categorized. 
1.1.3. Structure and composition 
With regard to its histology, skin is composed of three distinct tissue layers: the 
epidermis, the dermis and the hypodermis that is the dermis continuity. (Elias, 2005). 
There are also several associated appendages such as hair follicles, sweat ducts, 
apocrine glands and nails (Figure 1.1). 
 
Figure 1.1 A diagrammatical illustration of the skin. The epidermis is the stratum surface coating formed by 
stratified squamous epithelium; the dermis is deeper stratum composed of dense connective tissue; and the 
hypodermis is the dermis continuity, rich in adipose tissue From reference (McGrath and Uitto, 2010). 
1.1.3.1. Viable epidermis  
The epidermis is itself a complex multiply layer membrane (Figure 1.2), whose thickness 
varies between 70 and 120 m and is the most superficial and non-vascularized layer of 
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the skin. Due to the absence of blood vessels, and in order to maintain tissue integrity, 
the nutrients and waste products must diffuse across the dermo-epidermal layer. Also, 
molecules must cross this layer in order to reach the systemic circulation. Its structure is 
mainly composed of keratinocytes (95%), that go through a process of proliferation, 
differentiation and keratinization from the basal layer to the surface turning into 
corneocytes (Benson, 2011; Brown et al., 2006).  
During the process of migration, cells undergo dehydration and flattening, the core 
disappears and the content of keratin increases. This process of cell renewal takes 
approximately 28 days (Walters, 2002b). The epidermis has other specialized cells such 
as melanocytes responsible for melanin synthesis, Merkel cells, associated with sensory 
nerve endings functions and Langerhans cells, dendritic cells with immune function 
(Foldvari, 2000). 
The epidermis contains four histologically distinct layers which, from the inside to the 
outside, are the stratum basale or germinativum, stratum spinosum, stratum granulosum 
and the stratum corneum. A fifth layer, the stratum lucidum, is sometimes described but 
is more usually considered to be the lower layers of the stratum corneum (Figure 1.1).  
1.1.3.1.1. Stratum Basale  
Stratum basale is the deepest layer of the epidermis and is in contact with the 
germination membrane which is responsible for the renewal of the epidermis, forming the 
Malpighian body mucous. In this layer the cells contain typical organelles such as 
mitochondria, ribosomes, and the cells are metabolically active. Among other specialized 
cell types, this layer is composed mainly of keratinocytes that are undifferentiated cells 
with polyhedral shape, linked to each other by desmosomes and connected to the basal 
membrane (which separates the epidermis from the dermis) by hemidesmosomes. This 
layer is rich in aminoacids that origins the cysteine necessary for the biosynthesis of 
keratin which is a structural protein of skin (Woodley, 1987). Also, the melanocytes 
synthesize the pigment melanin from tyrosine and make surface contact with adjacent 
keratinocytes through dendritic connections, and this allows the pigment granules to 
pass from the melanocytes to the keratinocytes (Lai-Cheong and McGrath, 2009). 
Melanin provides protection against ultraviolet (UV) radiation and from free-radical 
scavengers (Benson, 2011). Langerhans cells are dendritic cells and can be also found 
within the stratum basale. Langerhans are recognized as the major antigen-presenting 
cells of the skin and plays an important role when allergic contact dermatitis occur 
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because the antigens readily bind to the cell surfaces (Lai-Cheong and McGrath, 2009). 
One other specialized cell type presented in this stratum, corresponds to the Merkel cells 
that are found mainly around the touch-sensitive sites of the body, such as lips and 
fingertips. These cells appear to be related in cutaneous sensation since are associated 
with nerve endings (Chilcott, 2008). The cells originated in the stratum basale migrate 
then upwards to the next layer. 
1.1.3.1.2. Stratum Spinosum  
The stratum spinosum is the thickest layer of the epidermis, consisting of two to six rows 
of keratinocytes that change morphology from columnar to polygonal cells maintaining 
their structural integrity. The spiky appearance is due to the abundance of desmosomes. 
Desmosomes connecting the cell membranes of adjacent keratinocytes are responsible 
for maintaining a distance of approximately 20 nm between the cells. Cells in this layer 
exhibit lipid-rich structures, the lamellar bodies (Odland bodies) and are richer in keratin 
filaments when compared to the cells in the stratum basale (Benson, 2011; Menon, 
2002). 
1.1.3.1.3. Stratum Granulosum  
Stratum granulosum corresponds to 3-5 layers of flattened keratinocytes showing clearly 
granules of keratohyalin, particularly significant due to its major role in the aggregation 
and alignment of keratin filaments (Menon, 2002). In this layer the keratinocytes continue 
to differentiate, synthesize keratin and start to flatten. The enzymes present in this layer 
start a lysis phenomenon of cytoplasmic organelles that result from the activation of 
lysosomal enzymes (Egelrud, 1993). Numerous granulations are present such as the 
Odland bodies that, at this stage, are larger and more abundant. During the process of 
differentiation of keratinocytes, they enclose multiple lipidic lamellar units and hydrolytic 
enzymes, namely proteases, lipases and glycosidases. As the migration and 
differentiation takes place, Odland bodies migrate to the cell membrane, fusing with the 
plasma membrane next to the last layer of the epidermis and releases its lipid content to 
the outside, a fundamental process in the formation of the SC extracellular lipid matrix 
(Schmitz and Müller, 1991). 
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Figure 1.2 Representation of the epidermis (Wickett and Visscher, 2006). During the process of cell 
differentiation, epidermal cells move from the basal layer (SB) through the spinous layer (SS) and the 
granular layer (SG) towards the SC. 
1.1.3.1.4. Stratum corneum 
The stratum corneum and represents an effective barrier to penetration of substances 
due to its well organized structure, very high density and low hydration (10-30%) (Elias, 
2005). This thin layer consists in dehydrated, anucleate and keratinized cells, the 
corneocytes. The corneocytes are the final product of the keratinocyte differentiation 
process that takes place along the epidermis and are continuously renewed, in a process 
denoted as desquamation, completing a total turnover in 2-3 weeks (Turesson and 
Thames). The corneocytes are connected by desmosomes (corneodesmosomes) and 
represent 12-25 layers of cells (Fartasch et al., 1993), embedded in a complex matrix of 
stacked intercellular lipids arranged similarly to a “brick and mortar” model (Elias, 1983; 
Nemes and Steinert, 1999). The lipid matrix allows for survival of terrestrial animals 
without desiccation. The SC also serves to regulate water loss from the body whilst 
preventing the entry of harmful materials, including microorganisms (Chilcott, 2008; 
Elias, 2007). Water plays a key role in maintaining SC barrier integrity and may mediate 
the activity of some hydrolytic enzymes since environmental humidity affects the 
activities of enzymes involved in the desquamation process. The barrier nature of the SC 
depends critically on its unique constituents and strongly defines the performance of the 
skin properties where 75-80% is protein and 5-15% is lipid with 5-10% unidentified on a 
dry weight basis (Bleck et al., 1999; Elias, 2005; Motta et al., 1995; Ponec et al., 1988; 
Robson et al., 1994). The protein is positioned mainly with the keratinocytes and 
basically is constituted by 70% of alpha-keratin with approximately 10% of beta-keratin 
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and a proteinaceous cell envelope (around 5%). 15% of the protein component consists 
in enzymes and other proteins where the cell envelope protein is highly insoluble and for 
that reason is very resistant to chemical attack. The lipid envelope is bound to the 
keratinocyte through glutamate moieties of the protein envelope. This surface 
keratinocyte protein plays an important role in structuring and ordering the intercellular 
lipid lamellae of the SC. Proteases have been demonstrated to degrade the desmosomal 
proteins (Egelrud and Lundström, 1991; Lundström and Egelrud, 1991; Suzuki et al., 
1994), and it appears that hydrolysis of cholesterol sulfate also accompanies cell 
shedding (Long et al., 1985). The drug flux through the tissue is basically regulated by 
the mixture of lipids that constitutes the SC. Although varies between individuals and 
with body site (Lampe et al., 1983a), these intercellular lipids are specially ceramides 
(CER) (45-50% by weight), cholesterol (CHO) (25%), free fatty acids (FFA) (10-15%) 
and cholesterol sulfate (<5%) ordered in a multiply bilayer lipid arrangement (Madison, 
2003a). Some studies have been devoted to probing the lipid composition of the 
intercellular domains, particularly by Downing, Wenz, Elias and co-workers (e.g. Elias, 
1983; Wertz et al" 1985). At least nine extractable ceramide subclasses (Ponec et al., 
2003; Robson et al., 1994; Stewart and Downing, 1999; Wertz et al., 1985) present in the 
lipid matrix were extracted from human SC and are classified as CER1 to CER9 which, 
together with the fatty acids, CHO and cholesterol sulfate, provide the amphiphilic 
properties necessary to form lipid bilayers. Different classes of ceramides possess 
various functions in the stabilization of SC lipid bilayers. All of the ceramides and the 
fatty acids found in SC are rod-like or cylindrical in shape, and these physical properties 
make these lipids suitable for the formation of highly ordered gel phase membrane 
domains. Gel phase domains will be less fluid, hence, less permeable than their liquid 
crystalline counterparts. In addition CHO is a ubiquitous membrane lipid and is capable 
of either fluidizing membrane domains or of making them more rigid, depending on the 
physical properties of the other lipids and the proportion of cholesterol relative to the 
other components. The role of CHO in the epidermal barrier is probably to provide a 
degree of fluidity to what could otherwise be a rigid, possibly brittle membrane system. 
This may be necessary for the pliability of the skin (Wertz, 2000). In addition to the 
keratinocytes and lipid lamellae, water plays a key role by regulating enzymes that are 
involved in the generation of natural moisturizing factor (NMF). NMF is a highly efficient 
humectant synthesized and hence is located within the SC (Hachem et al., 2005). A 
proteolytic product from filaggrin, NMF is essentially a mixture of free aminoacids, 
aminoacid derivatives and salts; serine, glycine, pyrrolidone carboxylic acid, citrulline, 
alanine and histidine are the major components with lesser amounts of arginine, 
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ornithine, urocanic acid and proline. This hygroscopic mixture retains moisture within the 
SC and helps to maintain suppleness. 
1.1.3.1.5. Stratum Lucidum 
The stratum lucidum consists of some clear layers of flattened, compacted, anucleated 
cells, fully keratinized, whose nucleus and organelles undergone enzymatic digestion 
and is especially rich in eleidin, a product of keratohyalin and precursor of keratin 
transformation. This layer tends to be seen most clearly in relatively thick skin 
specimens, such as from the load-bearing areas of the body (soles of feet and palms). 
Indeed, some dermatologists question whether this layer is functionally distinct from the 
other epidermal layers, or if it is an artefact of tissue preparation, most researchers tend 
to view the stratum lucidum as the lower portion of the stratum corneum and hence 
bracket these two layers together (Benson, 2011). 
1.1.3.2. Dermis 
The dermis (or corium) is typically 3-5 mm thick and is the major constituent of human 
skin. It is composed of a dense connective tissue, rich in collagen fibrils providing 
support, elastic tissue providing flexibility and reticular fibers embedded in a 
mucopolysaccharide blend (Hussain et al., 2013). The dermis lies under the epidermis 
and is the principal mechanical support structure of the skin having also major roles in 
skin nutrition, thermal regulation and immune response. Adjacent to the epidermis is the 
papillary dermis which is a lax, vascularized and innervated stratum with free nerve 
endings (Lai-Cheong and McGrath, 2009). The extensive vasculature of the skin is 
essential for regulation of body temperature, delivering oxygen and nutrients to the 
tissue, removing toxins and waste products and plays an important role in wound repair. 
The rich blood flow, around 0.05 mL/min per mg of skin, is very efficient for the removal 
of molecules that have traversed the outer skin layers. In terms of transdermal drug 
delivery, this layer is often viewed as essentially gelled water, and thus provides a 
minimal barrier to the delivery of most polar drugs, although the dermal barrier may be 
significant when delivering highly lipophilic molecules. Furthermore, the blood supply 
thus maintains a concentration gradient between the applied formulation on the skin 
surface and the vasculature, across the skin membrane. It is this concentration gradient 
that provides the driving force for drug permeation (Benson, 2011; Ryman-Rasmussen et 
al., 2006). The main cells found in the dermis are the fibroblasts which produce the 
connective tissue components of collagen, elastin, and amorphous substance. There are 
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also cells with immune functions such as mast cells which are involved in the immune 
and inflammatory responses and melanocytes involved in the production of the pigment 
melanin. Other structures like blood and lymphatic vessels, sweat and sebaceous 
glands, sensory nerve endings and hair follicles are also found in this layer (Riviere, 
2006; Walters, 2002a). The lymphatic system extends to the dermo-epidermal layer and 
promotes immunological responses to microbial assault and waste removal by regulating 
the interstitial pressure. The lymphatic vessels maintains the driving force for permeation 
removing the permeated molecules from the dermis (Cross and Roberts, 1993; 
Scheuplein and Ross, 1974). The skin surface pH is maintained around 5, due to the 
sebaceous gland associated with the hair follicle that secretes sebum composed of FFA, 
waxes and triglycerides. The appendages (hair follicles, sweat ducts) may offer a 
potential route for molecules to enter through the intact barrier provided by SC. These 
'shunt routes' can be used by large polar molecules and for electrical enhancement. 
However, because the fractional area offered is so small, the predominant pathway for 
molecules to traverse the tissue remains across the bulk of the skin surface.  
1.1.3.3. Hypodermis 
Hypodermis or subcutaneous fat layer is the deepest skin structure, relatively thick, that 
links the overlying dermis and the underlying body constituents. This layer of adipose 
tissue insulates the body and provides mechanical protection against physical shock. 
Fibroblasts and macrophages are also present in this layer. However the predominant 
cells are the adipocytes, specialized in the storage of energy in the form of fat and 
providing a readily available supply of high-energy molecules, whilst the principal blood 
vessels and nerves are carried to the skin in this layer. (Riviere, 2006; Walters, 2002a)  
1.1.4. Permeation skin pathways 
The most of the molecules the stratum corneum is the principal barrier to the 
percutaneous absorption. Due to the high organization level of the skin, drug molecules 
applied on its outer surface must follow tortuous paths, crossing all the skin cell layers 
and intercellular lipids, in order to reach the circulatory system in the dermis (Hadgraft 
and Walters, 1994). There are essentially three pathways by which a molecule can 
traverse intact SC: via the appendages (via sweat glands and hair follicle); through the 
extracellular lipid domains (intercellular); or by a transcellular route (intracellular), where 
both are transepidermal pathways (Figure 1.3) (Trommer and Neubert, 2006).  
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Figure 1.3 Illustration of possible drug transportation pathways through the stratum corneum. Adapted from 
(Simonsson, 2011). 
The majority molecules probably will pass through the SC by a combination of these 
pathways. The relative contribution of each route depends on the solubility, partition 
coefficient and diffusivity of the drug. For that reason the relative contributions of these 
pathways to the flux will depend basically on the physicochemical properties of the 
permeant (Barry, 2001). 
1.1.4.1. Transappendageal transport (shunt route transport)  
The hair follicles and the sweat ducts possess pores that allow the transport of the drugs 
through the stratum corneum. This appendage area only occupies around 0.1 % of the 
total skin surface area (Moser et al., 2001; Scheuplein, 1967) and its contribution is 
negligible to the steady state drug flux, being particularly relevant for ions and large polar 
molecules that struggle to cross intact SC (Scheuplein and Blank, 1971). This route is 
important for delivering vesicular structures to the skin, and for targeting their contents to 
the pilosebaceous units, despite the extensive debate as to whether vesicles can 
traverse the SC intact (Lauer et al., 1996). The use of electrical charge to drive 
molecules to the skin (iontophoretic drug delivery) depends on this route, since the 
charge is carried through the SC via the path of least resistance and the shunt routes 
provide less resistance than the SC bulk.  
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1.1.4.2. Transepidermal routes  
The transepidermal pathway involves the passage of the drug through the epidermis 
cells (transcellular or intracellular way) or by lipoprotein matrix existing between cells 
(intercellular way). 
In both pathways, the drug penetrates the stratum corneum by diffusing through the 
intercellular lipid matrix (Boddé et al., 1989). However, the intercellular route appears to 
be predominant, and therefore many enhancement techniques aim to disrupt or bypass 
the molecular architecture of bilayers of the SC. 
1.1.4.2.1. Intracellular route 
This pathway is often regarded to provide a polar route for a molecule to traverse the 
stratum corneum. The highly hydrated keratin present in the cellular components 
(corneocytes) provides an effective aqueous environment that consequently increases 
the diffusion of hydrophilic molecules (Bolzinger et al., 2012). Since the keratin-filled cells 
are bound to a lipid envelope that connects to the intercellular multiply bilayer lipid 
domains, the apolar molecule faces numerous repeating hurdles to cross the intact SC 
(Wertz et al., 1987). The nature of the permeant influences the flux, for highly hydrophilic 
molecules the intracellular route predominates at pseudo-steady state. The multiply 
bilayer lipids that the molecule must traverse is the rate-limiting barrier for permeation via 
this route. The use of solvents can remove lipids from the SC and subsequently 
increases drug flux for even highly hydrophilic molecules. The intercellular pathway is an 
alternative for apolar molecules because the intercellular medium is rich in lipids 
arranged in bilayer (Marjukka Suhonen et al., 1999) 
1.1.4.2.2. Intercellular route 
The intercellular lipid route provides the principal pathway by which most small and 
uncharged molecules traverse the stratum corneum (Abraham et al., 1995; Roberts et 
al., 1996). The lipid bilayers represent 1% of the SC diffusional area and provides a 
continuous phase within the membrane with a great variety of ceramides (Trommer and 
Neubert, 2006). The composition of these bilayers is different to all other lipid membrane 
bilayers within the body, where phospholipids are absent and the SC lipids exist in a 
variety of states. The transdermal delivery of small molecules has been considered as a 
process of interfacial partitioning and molecular diffusion through the SC. A typical 
mathematical model considers the SC as a two-phase protein-lipid heterogeneous 
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membrane having the lipid matrix as the continuous phase (Elias, 1983; Elias, 1988; 
Michaels et al., 1975). Several theoretical skin-permeation models have been proposed 
which can predict the transdermal flux of a drug based on some of its physicochemical 
properties (Kirchner et al., 1997; Lee et al., 1997; Potts and Guy, 1992; Pugh and 
Hadgraft, 1994; Tojo, 1987). A domain mosaic model for the SC lipids has proposed by 
Forslind (Forslind et al., 1997). This model combines the heterogeneity of lipid packing 
with segregated areas of crystalline/gel domains with borders of more fluid liquid 
crystalline regions. This organization allows the water loss regulation allowing sufficient 
water to enter the tissue to maintain keratinocyte hydration. The lipid bilayers is the 
mainly limiting barrier to drug flux, where the intercellular transport is through the lipid 
domains and the intracellular permeation requires the lipid lamellae to be crossed and 
depends of the thickness of the stratum corneum. The intercellular route is extremely 
tortuous and the permeants needed to move through the continuous lipid domains 
between the keratinocytes. However the pathlength taken by the molecule is 
considerably greater than that of the SC thickness (Hadgraft, 2004). 
1.1.5. Mathematical theoretical basis of percutaneous absorption 
Human skin is a uniquely system with multiply layered and a heterogeneous biological 
tissue that is different between species. For that reason is impractical to describe this 
behavior with ideal mathematical models. Despite these complexities, Fick's first law of 
diffusion is a relatively simple mathematical that can be applied to data obtained from 
experiments. 
1.1.5.1. Pseudo-steady state permeation (infinite dose):  
Drug absorption across human skin is controlled by a passive diffusion mechanism and it 
can be described in physical terms, by the Fick’s First Law of diffusion (Higuchi, 1960). 
Fick's first law of diffusion states that the rate of transfer of diffusing substance through 
unit area of a section is proportional to the concentration gradient measured normal to 
the section. In permeation experiments, Fick’s first law is used to describe steady state 
diffusion and to analyze permeation data, 
𝐽 =
𝐷𝐶0𝑃
ℎ
          (1.1) 
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where J stands for the steady-state flux per unit of area, i.e. the amount of a material 
passing through a unit area per unit time, D is the diffusion coefficient of the drug in the 
SC, C0 represents the drug concentration in the vehicle, P is the partition coefficient 
between vehicle and the skin and h is the diffusional path length. Since the drug 
concentration applied (capp) to the skin is much larger than the concentration under the 
skin (infinite dosing) Eq. 1.1 can be simplified to, 
𝐽 = 𝑘𝑝 𝑐𝑎𝑝𝑝           (1.2) 
where kp is a permeability coefficient (= DP / h) and is a heterogeneous rate constant 
having the units, for example, cm h−1. The parameter h cannot be accurately estimated 
as it is related to the tortuosity of the intercellular channels, which is imprecise (Guy and 
Hadgraft, 2003; Hadgraft, 2001). 
The cumulative amount of drug permeating through the skin (Qn) is given by Eq. 1.3, 
𝑄𝑛 =  (𝐶𝑛  × 𝑉0 +  ∑ 𝐶𝑖  ×  𝑉𝑖
𝑛−1
𝑖=1 )/𝐴      (1.3) 
where Cn corresponds to the drug concentration in the receptor medium, Ci is the 
concentration in the sample, A is the diffusion area, V0 and Vi stand for the volumes of 
the receptor compartment and the sample.  
The concentration gradient is influenced by the ability of the drug to partition into the skin 
and its ability to partition out of the skin into the underlying tissues and should maintain 
the sink conditions that is defined as “the volume of medium at least three times that 
required in order to form a saturated solution of drug substance” when performing a 
dissolution procedure. 
The steady-state flux can be calculated from the slope of the linear part of the 
permeation profile, extrapolated to the time axis and the value of the lag time is obtained 
by the intercept at Q=0 i.e., corresponding to a cumulative amount of drug permeating 
through the skin equal to 0. The lag time method is commonly used for analysis of the 
permeation data from in vitro experiments with an infinite dosing technique, that is, 
where the skin separates an infinite reservoir of drug on the donor side and a perfect 
sink as receptor. However, the lag time method could be subjective as it requires an 
evaluation to determine the linearity of the permeation profile (Banga, 1998). 
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1.2. Experimental design 
1.2.1. In vitro vs. in vivo studies 
The ideal situation to evaluate formulations for in vivo use is to employ and monitor drug 
delivery directly in human volunteers. Performing in-vivo studies has benefits such as the 
generation of realistic measures for the amounts of drug that would enter the skin or 
systemic circulation. However, due to experimental and ethical difficulties, most of the 
transdermal drug delivery studies tend to use skin ex-vivo (in vitro). In-vitro experiments 
can provide conditions to mimic the circulation and also can maintain the barrier 
properties of excised skin, however inherently reduce the natural complexity where the 
regeneration stops, immune responses cease and metabolic activity is usually lost in 
these studies, especially for the prolonged periods. Even though in vitro permeation 
studies are widely used to investigate the permeability of drugs, it should be noted that 
data obtained from excised skin may not translate directly to the in-vivo situation. Most of 
in vitro techniques are carried out using diffusion cells. This system has a donor 
compartment (where the vehicle containing the drug is placed) and a receptor chamber 
(containing receptor medium) separated by a membrane (e.g. skin), under controlled 
temperature conditions. 
1.2.2. Membranes for in vitro studies 
The most appropriate membrane for transdermal drug delivery studies is the human skin. 
However, due to ethical and legal restrictions on obtaining this kind of skin, alternative 
membrane models from animal sources or synthetic have been used with the same 
purpose. The use of model membranes can be useful for transdermal studies, but the 
results obtained, may not transfer directly to human skin either in vitro or in vivo, and 
results should be treated with careful. For formulation development, excised skin from 
different animal models (primates, pig, mouse, rabbit, rat, guinea pig and snake), can 
offer great value and are certainly more readily available and easier to store and handle. 
These types of membranes can be more reproducible than that from donated human 
tissue, because experiments can be performed in vivo and hence data concerning 
metabolism and distribution of absorbed materials can be obtained. The animal model 
choice depends on the similarity to human skin regarding physiological aspects such as 
blood perfusion, morphology and chemical composition. It has been reported that the 
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hairless mouse skin is an unacceptable model for predicting human skin permeation 
because mouse skin differs markedly from human tissue in terms of structure, lipid 
content that is greater than that in human stratum corneum, and because is thinner. In 
addition these tissue loses its integrity rapidly, whereas the human SC barrier remains 
intact for longer periods of time (Roberts and Mueller, 1990). Guinea pig SC can be an 
alternative to mimic human skin diffusion behavior, in terms of thickness, versatility and 
the skin behind the ears possesses no hair follicles or sebaceous glands, thus offering 
opportunities to study the role of shunt route permeation. In alternative to these models 
in terms of physiological responses and behavior, macaque monkey and dog skin has 
provided evidence for the efficacy of drugs as a model for the human membrane 
(Barbero and Frasch, 2009b; Bartek et al., 1972; Godin and Touitou, 2007; Reifenrath et 
al., 1984). However, the use of primates is restricted due to ethical concerns. Hereupon 
porcine skin seems to be the best model membrane to explore formulation modifications 
or for hazard evaluation, because the SC of the pig is similar to the human membrane in 
terms of thickness, lipid content and so it has remarkably similar permeability properties 
(Schmook et al., 2001). It is well documented that porcine skin has similar physiological 
properties and anatomical features of human skin and has an added advantage in that it 
may be relatively easy to acquire (Barbero and Frasch, 2009a; Davies and Trotter, 1981; 
Mowafy and Cassens, 1975; Schmook et al., 2001). Some studies designed to predict 
skin permeation in man reported that similar permeation values were obtained when 
porcine and human skin were tested under similar conditions in vitro (Bartek et al., 1972; 
Schmook et al., 2001). Also It has been reported that both the morphology of the 
epidermis and upper dermis vasculature and functions of endothelial cells (e.g. 
plasminogen activator) in the pig were similar to that in man (Forbes, 1969). Hence, in 
this work, porcine skin was selected to be used in substitution of human skin because it 
is functionally and structurally similar to the latter.  
1.2.3. Artificial membranes 
In some studies it is not necessary to use human and animal skin for comparison or 
optimization of formulations, since simple physicochemical rules govern permeation. 
More simplistic model membranes, like artificial “chemical” membranes have been widely 
used in drug delivery studies because offer the advantages of reproducibility and control. 
The membrane is isotropic, having no regional variability, and permeation can be 
described by simple mathematical rules. However, it has disadvantages in terms of 
poorly representing human tissue in vivo since there is no metabolism, there is minimal 
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variability, and the permeation process is simple permeation processes compared to the 
more complex multiple processes occurring in the heterogeneous human skin. 
A great variety of synthetic membranes have been tested as model membranes in 
permeability studies (Hadgraft and Guy, 1992; Houk and Guy, 1988). Liquid membranes 
enclosing lipids as isopropyl myristate (Hadgraft and Ridout, 1987), dipalmitoyl 
phosphatidylcholine, linoleic acid and tetradecane (Hadgraft and Ridout, 1988) and 
others (Hadgraft et al., 1985) or polymeric membranes based on polymers or 
combination of polymers such as polydimethylsiloxane (Silastic®) (Pellett et al., 1994), 
poly-(2-hydroxyethylmethacrylate), cellulose acetate (Neubert et al., 1991; Neubert et al., 
1995), silicone cellulose (Nastruzzi et al., 1993), silicone polycarbonate urethane 
(Carbosil®) (Russeau et al., 2009) are examples of artificial membranes used with the 
objective of reproducing SC barrier properties. The most popular artificial systems used 
to study percutaneous absorption are simple inert polymer membranes, most commonly, 
polydimethylsiloxane (silastic or PDMS membranes) that provides a 'non-porous' 
hydrophobic reproducible barrier and is used in formulation optimization studies and for 
testing physicochemical principles. In these work a dialysis membrane was selected as 
model membrane to evaluate and optimize the kinetics of the formulations using 
mathematics models (Chapter 2). 
1.2.4. Diffusion cells for in vitro studies 
The literature contains various designs of diffusion cells that range from the very simple 
to the highly complex. Diffusion cells can assume multiple aspects and different 
complexity levels, varying from two-compartment static diffusion cells (vertical or 
horizontal) (Franz, 1975a) to multi-jacketed ”flow-through” cells (Bronaugh and Stewart, 
1985). Most simply Vertical Franz diffusion cells (Figure 1.4) are the most widely used in 
vitro percutaneous absorption studies and are usually made of glass (Franz, 1975b). 
These devices comprise two compartments with a membrane properly clamped between 
the donor (available for application of the permeant) and receptor compartment with a 
fixed volume. Such display allows the determination of a drug permeation profile across 
a specific membrane, to a receptor medium that is kept continuously stirring, most 
commonly with a magnetic bar stirrer at a controlled temperature (water bath, usually at 
37°C to maintain surface skin temperature at 32°C as an in-vivo mimic). These cells are 
thus widely used for evaluating drug uptake into membranes, finite dose permeation or 
steady-state flux of a drug either alone or in formulations as the relatively large and open 
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donor compartment allows simple application of semi-solid formulations to the skin 
surface. The receptor compartment allows removal of receptor fluid at required time 
intervals for analysis with an appropriate analytical method (e.g. High Performance 
Liquid Chromatography - HPLC). Special attention must be taken while choosing the 
receptor medium. Ideally, it should simulate as accurately as possible the corresponding 
in vivo fluid (e.g. blood) and must ensure “sink conditions” for the drug under 
investigation (Skelly et al., 1987). Generally, in vitro methods allow a better control of the 
experimental conditions and are particularly useful during the earlier stages of research, 
limiting the number of expensive in vivo studies in humans and animals (Walters, 
2002b). 
 
Figure 1.4 Schematic representation of a vertical Franz diffusion cell (PermeGear, 2012).  
1.2.5. Formulation application considerations  
1.2.5.1. Finite or infinite dose 
The quantity of the preparation to be applied to the skin surface depends on the aim of 
the study. For example, when a cream is applied to the skin and thus permeation is from 
a finite dose, it is expected to deplete on the skin surface. In contrast, the application of 
an infinite dose to the skin surface is normally used to determine the fundamental 
permeation behavior of a material, because steady-state flux data and the effects of 
penetration enhancers on drug permeation through the skin are usually obtained. In this 
case, the permeant concentration in the donor phase should not fall by more than 10% 
from saturation during the experimental period. To avoid donor depletion, saturated drug 
solutions are used (Chantasart et al., 2013). In general terms, the experimental 
conditions including application dosages, exposure times and procedures should mimic 
as closely as possible the in vivo situation in order to provide appropriate data. 
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1.2.5.2. Vehicle effect 
Depending on the experiments, the choice of vehicle to apply the drug can also differ, 
but it is desirable that it mimics the in vivo conditions as closely as possible. For example 
if the permeant is lipophilic and displays a low aqueous solubility, it will traverse the 
tissue relatively easily, and that, this donor depletion during the experiments can occur. 
The selection of vehicle for permeation studies is crucial to ensure that the vehicle does 
not interact with the membrane and if that happens should not affect the structure or 
integrity of the membrane. Usually a control formulation containing only the same vehicle 
for comparison of different formulations is used. Interactions between the drug and the 
vehicle or between the drug and other excipients in the formulation can also modify the 
permeation behavior of the penetrant (Williams et al., 1998).  
1.2.6. Permeant detection 
It is important to choose the most suitable method for detection of the permeant that 
traverses through the membrane. Chromatographic methodologies have the 
advantage of being versatile and adaptable to numerous permeants that across the 
skin. HPLC is commonly selected for analyzing the permeant in the receptor fluid. With 
appropriate selection of columns, mobile phases and detectors the compounds that 
permeate through the skin can be analyzed simultaneously, relatively rapid and easy. 
This technique is effective due to several features such high reproducibility, ease of 
selectivity manipulation and high recoveries. In one step the individual components of 
a mixture can be separated and quantified with excellent resolution. The separation 
depends on the interaction and the affinity of the molecules for the stationary phase. 
The process is based on the higher affinity of the molecules to the stationary phase 
that will be retained more than other molecules with low affinity for the stationary 
phase. The affinity degree is highly dependent on the structure and the interaction of 
the solute and the immobilized ligands. In the case of reverse-phase chromatography 
the mobile phase employed are mostly water-based solutions (polar) and separations 
are based on hydrophobic interactions where the stationary phase is hydrophobic. The 
aim of a successful separation protocol is the ability to manipulate the retention time of 
the molecule to quantify from other non-target compounds. 
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1.3. Skin permeation strategies 
As was mentioned before, the stratum corneum is a highly efficient and effective barrier 
that possesses multiple bilayer lipids providing the principal pathway for permeation of 
drugs, especially small and moderately lipophilic molecules (Naik et al., 2000b). Efforts 
have been made to employ enhancement technologies to controllably, reversibly, and 
safely reduce the resistance of the SC and expand the range of molecules available for 
transdermal drug delivery. Some strategies include physical, biochemical and chemical 
methods. One of the strategies to enhance drug flux through the skin is based by 
working directly on SC barrier components, for example, the use of chemical permeation 
enhancers (CPE) or electroporation to disrupt the bilayer lipids. Alternative methods 
have been developed by some workers without directly altering the skin properties such 
modifying the thermodynamic activity of permeants in vehicles to alter the driving force 
for permeation and thus modified uptake into and flux through the membrane. On the 
other hand, in some studies the aim of permeation modification is to reduce permeant 
flux across the skin, such in cosmetic formulations or when designing a barrier cream to 
protect against pesticide exposure. The techniques that have emerged over the years 
can be generally categorized into passive or active (Figure 1.5). In order to choose the 
best strategies for each case it is important to understand the mechanism of action of a 
variety of chemical permeation modulation, and understand the advantages and 
disadvantages associated with each approach.  
 
Figure 1.5 Passive and active methods for optimizing dermal drug delivery. 
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1.3.1. Passive enhancement of skin permeation 
Based on Fick’s first law, there are some permeation strategies that can increase the 
passive flux of a drug through the SC: by increasing the diffusion coefficient of the drug 
in the skin by increasing the drug solubility in the skin and by increasing the degree of 
saturation of the drug in the vehicle, often referred as the super saturation approach. 
While the latter is based on the interaction between the drug and the vehicle, the two first 
strategies involve an effect of the vehicle on the barrier properties of the skin. Therefore, 
the most recent dosage forms have been developed in order to enhance the driving force 
of drug diffusion (thermodynamic activity) and/or to increase the permeability of the skin. 
Such approaches include the use of chemical permeation enhancers (CPE) (Michniak et 
al., 2005; Michniak et al., 1998; Michniak et al., 1995; Teixeira et al., 2014a; Williams 
and Barry, 2004), supersaturated systems (Davis et al., 2002), prodrugs or metabolic 
approach (Elias et al., 2002; Tsai et al., 1996), liposomes and other vesicles that will be 
discussed in the section below (Bouwstra et al., 2003; Cevc, 2002, 2004; El Maghraby et 
al., 2008; Godin and Touitou, 2003; Heuschkel et al., 2008; Mezei, 1993; Schreier and 
Bouwstra, 1994; Sheihet et al., 2008; Touitou et al., 2000; Touitou et al., 1994). 
1.3.2. Chemical penetration enhancers 
Chemical penetration enhancers (or absorption promoters) facilitate the permeation of 
drugs through the skin. These chemical agents partition into the stratum corneum, 
interact with tissue components and reduce the barrier properties of the membrane 
temporarily and reversibly. An effective CPE may increase the diffusion coefficient of the 
drug in the SC, may increase the effective concentration of the drug in the vehicle, may 
improve partitioning between the formulation and the SC or can decrease the skin 
thickness. A chemical penetration enhancer to apply on human skin should have some 
desirable properties (Woodford and Barry, 1986). It should provide pharmacologically 
inert, non-toxic, non-irritating, non-allergenic and at the same time must be suitable for 
formulation into topical preparations and be compatible with drugs and excipients. It 
should provide a rapid onset of action, and the duration of effect should be predictable 
and reproducible. It should work in just one direction (i.e. should allow therapeutic agents 
into the body while preventing the loss of endogenous material) and when the CPE is 
removed from the skin, the barrier resistance should return fully and rapidly. Finally, and 
not less important, it should be cosmetically acceptable with appropriate skin feel 
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(odorless, tasteless, colorless), inexpensive and with good solvent properties (Barry, 
1993). 
The CPEs used in some topical and transdermal formulations rarely possess all the ideal 
properties. However there are an enormous range of compounds that have been 
evaluated and demonstrate some or several of the above characteristics such as 
sulfoxides (i.e. dimethylsulfoxide), laurocapram (commercially known as azone), 
pyrrolidones, fatty acids, alcohols, fatty alcohols, glycols, surfactants, urea, essential oils 
(i.e. terpenes and terpenoids), phospholipids and solvents. Some of these compounds 
will be summarize in the next section. 
1.3.2.1. Azone 
Azone (1-dodecylazacycloheptan-2-one or laurocapram) was the first molecule designed 
as a skin penetration enhancer and is a reference for comparison. Azone is a highly 
lipophilic molecule (log P close to 6.2) and for that reason it is compatible with most 
organic solvents, including alcohols and propylene glycol (PG). Azone has low irritancy, 
very low toxicity (oral LD50 in rat of 9 g/kg) and little pharmacological activity. Therefore, 
azone appears to possess many of the desirable qualities, and it is a potent and versatile 
enhancer for a wide variety of drugs including steroids, antibiotics and antiviral agents 
(Brown et al., 2006; Hadgraft et al., 1996; Lambert et al., 1989a; Riviere and Heit, 1997). 
Like other CPE, the efficacy of azone appears to be concentration dependent and is also 
influenced by the choice of vehicle from which it is applied (Srinivasan et al., 1989). 
Although azone has been in use for so many years, its mechanism of action is still 
controversial and object of study. Considering the chemical structure (possessing a large 
polar head group attached to a lipid alkyl chain), azone probably exerts its penetration 
enhancing effects through interactions with the lipid domains of the SC, causing the 
disruption of the bilayer lipids arrangement (Hadgraft et al., 1996; Jampilek and 
Brychtova, 2012; Lambert et al., 1989b). Surprisingly, azone is most effective at low 
concentrations (typically less than 10% in the formulations, and often at around 1-3%), 
although the amount of azone necessary to provide optimum enhancement varies 
between drugs and between formulations.  
1.3.2.2. Surfactants 
Surfactants (surface active agents) are present in many existing therapeutic, cosmetic 
and agrochemical preparations and usually are added to formulations used as 
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emulsifiers, wetting, solubilizing, and stabilizing agents. Therefore, and due to the great 
potential to solubilize/disrupt the lipid structure within the stratum corneum, they can be 
employed as CPE. Generally, surfactants are composed of a lipophilic alkyl or aryl fatty 
chain, linked to a hydrophilic head group, with amphiphilic properties. Surfactants are 
often described in terms of the nature of the hydrophilic moiety: the hydrophilic portion 
can be nonionic, ionic (anionic and cationic) or zwitterionic. The mechanism of action 
when applied in topical formulations is based on formation of diffusional paths for drug 
molecules, resulted of the interfacial defects and structure disruption and it is belief that 
can interact with the lipid molecules of skin, intercalating into lipid bilayers. Surfactants 
have generally low chronic toxicity, and most have been shown to enhance the flux of 
materials permeating through biological membranes. Some studies focus on the 
enhancement effect of surfactants on permeation of drugs through skin. The literature 
reports surfactant facilitated permeation of drugs such as diazepam, lorazepam, 
prazosin, piroxicam, hydrocortisone, lidocaine, etc. through various skin membranes, 
with significant flux enhancement (Cappel and Kreuter, 1991; Nokhodchi et al., 2003; 
Shin et al., 2001; Shokri et al., 2001; Walters et al., 1993b). Nevertheless depending on 
the amphiphilic structure and concentration employed local irritation of skin may be 
observed. Among the surfactant classes, the nonionic surfactants tend to be widely 
regarded as safe, while anionic and cationic surfactants are more likely to damage 
human skin. Most studies have focused on anionic and nonionic surfactants (Goreti Silva 
et al., 2012; Silva et al., 2013a; Silva et al., 2012). Anionic surfactants are negatively 
charged compounds that include sodium lauryl sulphate, and examples of cationic 
surfactants that exhibit positive charge are trimethylammonium bromide derivatives. The 
nonionic surfactants have modest enhancement effect in human skin whereas anionic 
surfactants can have a more pronounced effect  
Some topical formulations, like creams that are stabilized by mixed emulsifiers contain 
ionic surfactants and their therapeutic efficacy depend, in part, on the penetration 
enhancement activity of the surfactants. These compounds are able to interact with skin 
constituents in many ways, for example, affecting proteins, and consequently inactivate 
enzymes and bind well within the SC. The anionic surfactants can swell the SC and 
modify the binding of water to the SC, probably by uncoiling the keratin fibers and 
altering the α-helices to a β-sheet conformation. Surfactants are also able to extract 
lipids from the SC by disrupting the lipid bilayer packing within the tissue. Surfactants 
can also modify the donor solution, altering the thermodynamics within the system to 
modify percutaneous drug delivery (Silva et al., 2013a). Gemini surfactants are a new 
class of surfactants, created to overcome problems such as irritancy and low 
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enhancement activity. The novel gemini surfactants derived from aminoacids such lysine 
and serine will be discussed in detail in Chapter 3 and 4. 
1.3.2.3. Terpenes   
Terpenes are essential oils and have been used as medicines, flavorings, fragrance 
agents and as penetration enhancers. Essential oils are complex mixtures of aromatic 
and aliphatic chemicals and the principal constituents are carbon, hydrogen and oxygen 
atoms. Terpenes are classified by their chemical structure, being based upon isoprene 
units (C5H8). The monoterpenes (C10) contain two isoprene units, sesquiterpenes (C15) 
have three and diterpenes (C20) have four isoprene units. The application of 
monoterpenes and sesquiterpenes in topical and transdermal drug delivery has been 
extensively investigated by Barry and his co-workers (Cornwell and Barry, 1994; 
Williams and Barry, 1991). The principal terpene component of eucalyptus oil is 1,8-
cineole, and this molecule was one of a series of 17 monoterpenes and terpenoids 
evaluated as enhancers for the 5-fluorouracil (a model hydrophilic drug) (Williams and 
Barry, 1989). Pre-treatment of human epidermal membranes with 1,8-cineole provided a 
near 100-fold increase in the permeability coefficient of 5-fluorouracil. Similar results 
were reported for the permeation of lipophilic molecule, indomethacin, traversing rat skin, 
also hydrocarbon terpenes, especially limonene, were as effective as azone in promoting 
drug flux. A synergistic effect for terpene efficacy has also been shown when PG was 
used as the vehicle (Williams and Barry, 1989). Terpenes also have the ability to modify 
drug diffusivity through the membrane and a reduction in the lag time for permeation is 
usually seen. Small-angle X-ray diffraction studies have indicated that d-limonene and 
1,8-cineole disrupt SC bilayer lipids, whereas nerolidol (a long-chain sesquiterpene) 
reinforces the bilayers (Cornwell et al., 1996; Cornwell et al., 1994). Spectroscopic 
evidence has also suggested that, as with azone and oleic acid, terpenes could exist 
within separate domains in SC lipids. 
1.3.2.4. Phospholipids 
Phospholipids have been used as vesicles, to form liposomes that have the ability to 
carry drugs into and through human skin. However, some studies focus on using 
phospholipids in a non-vesicular form as penetration enhancers. For example, 1% egg 
phosphatidylcholine (PC) in PG (a concentration at which liposomes would not form) was 
used to enhance permeation of theophylline through hairless mouse skin. Likewise, the 
same phospholipid was used to enhance indomethacin flux through rat skin, and 
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hydrogenated soybean phospholipids have been reported to enhance diclofenac 
permeation in vivo through rat skin. The mechanism of action it is not well described. 
However considering the phospholipids physicochemical properties and structure, it is 
expected that they interact directly with SC lipid packing. Phospholipids can also occlude 
the skin surface and therefore improve tissue hydration allowing an increase on drug 
permeation. When phospholipid vesicles are applied, they fuse with the SC and the 
permeation is facilitated when the structure collapses and then releases the permeant 
into the vehicle in which the drug may be poorly soluble. 
1.3.3. Chemical modulation of topical and transdermal permeation 
1.3.3.1. Cyclodextrins  
Cyclodextrins (CD) are known for nearly 100 years and are host molecules able to form 
inclusion complexes in solid and in solution phases (Del Valle, 2004). It was only during 
the last decades that CD have been used as potential drug carriers in delivery systems 
(McCormack and Gregoriadis, 1998). CD possess a cyclic structure containing six, 
seven or eight α (1–4) linked glucopyranose units designated by α, β and γ, respectively, 
and are called natural CD (Figure 1.6) (Szejtli, 1998). They take the shape of a truncated 
cone, instead of a perfect cylinder as a result of glucopyranose units in chair 
conformation (Loftsson and Brewster, 1996).  
 
Figure 1.6 Schematic representation of α-CD (a), β-CD (b) and γ-CD (c). Adapted from (Davis and Brewster, 
2004). 
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The hydroxyl groups are orientated to the exterior together with the primary hydroxyl 
groups of the glucose residues at the narrow edge of the cone and the secondary 
hydroxyl groups at the wider edge, resulting in a hydrophilic outer surface. The central 
cavity is lined by skeletal carbons and ethereal oxygens, which provides a lipophilic 
environment, thus allowing them to entrap apolar drugs (Arun Rasheed, 2008; Loftsson 
and Masson, 2001).  
The use of CD is a practical and economical way to improve the physicochemical and 
pharmaceutical properties of administered drug molecules (Vyas et al., 2008). The 
traditional solubilizing agents such as organic co-solvents (ethanol and propylene glycol) 
and nonionic surfactants (Tween 80 or Cremophor®), or extreme pH conditions, may not 
be enough to solubilize drugs for their therapeutic efficacy (McCormack and Gregoriadis, 
1998). So, an alternative approach to improve the water-solubility of drugs involve the 
use of CD which can form water soluble inclusion complexes with hydrophobic 
molecules (McCormack and Gregoriadis, 1998), (Uekama et al., 1998). Molecular 
encapsulations of the drug, in the appropriate CD, are able to overcome some problems 
and facilitate safe and efficient delivery of drugs (Vyas et al., 2008). 
1.3.3.1.1. Derivatives 
The naturally occurring CD and their complexes are hydrophilic but, however their 
aqueous solubility is rather limited, especially the β-CD (Loftsson et al., 2007). For that 
reason, many derivatives have been synthesized (Figure 1.7) and usually are produced 
by amination, esterification or etherification of the primary and secondary hydroxyl 
groups (Booij, 2009). 
 
Figure 1.7 Location of the hydroxyl groups in the structure of β-CD (Uekama et al., 1998). 
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Depending on the substituent, the solubility of the CD derivatives will be different from 
that of their parent CD (Ventura et al., 2005). The most common CD derivatives currently 
used in drug formulations include hydroxypropyl-β-CD (HP-β-CD) used in this work, 
randomly methylated-β-CD (RM-β-CD), sulfobutylether-β-CD (SBE-β-CD), maltosyl-β-
CD (ML-β-CD) and (2-hydroxypropyl)-γ-CD (HP-γ-CD). All of these five derivatives, as 
well the natural α-CD, β-CD and γ-CD, can be used in topical drug formulations (Loftsson 
and Masson, 2001). The aqueous solubility of these derivatives is usually 50–70% (w/v). 
Focusing on this aspect, the natural CD (α, β and γ) are the less hydrophobic CD and for 
example the HP-β-CD with the same cavity diameter as β-CD is less hydrophobic. On 
the other hand, 2,6 -dimethyl-β-CD (Dimeb) and 2,3,6-trimethyl-β-CD (Trimeb) have a 
deeper cavity and are more hydrophobic than β-CD (Piel et al., 2006).   
1.3.3.1.2. Inclusion complexes 
The most important property of CD is their ability to form complexes with a great variety 
of organic substances. The physicochemical properties of the included substances are 
altered upon complexation and CD are widely used for enhancement of aqueous 
solubility, stability and bioavailability of apolar drugs (Castronuovo and Niccoli, 2006; 
Mosher, 2002). The host-guest mechanism works like a dimensional fit between a guest 
molecule and the internal cavity. This lipophilic cavity has the appropriate environment 
for connecting the end of non-polar guest molecule, and during the formation of the 
inclusion complex, no covalent bonds are involved and drug molecules bound in the 
complex are in rapid equilibrium with free solubilized drug molecule (Figure 1.8) 
(Loftsson and Brewster, 1996; Loftsson and Duchêne, 2007). 
The ability of a CD to form an inclusion complex with a guest molecule is a function of 
two key factors. The first is steric and depends on the relative size of the CD to the size 
of the guest molecule or certain key functional groups within the guest. The second 
critical factor is the thermodynamic interaction between the different components of the 
system (CD, guest, solvent) (Del Valle, 2004). In an aqueous environment, CD form 
inclusion complexes with many lipophilic drug molecules through a process in which 
water molecules located inside the central cavity are replaced by either the whole drug 
molecule or more frequently, by some lipophilic structure of the molecule. In this process, 
no covalent bonds are formed or broken and drug molecules located within the cavity are 
in a very dynamic equilibrium with free drug molecules out in the solution. In aqueous 
solutions drug/CD complexes are constantly being formed and broken at rates very close 
to the diffusion controlled limits (Stella and Rajewski, 1997).  
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In some cases, the complexation efficiency is not very high and, therefore relatively large 
amounts of CD are needed to complex small amounts of a certain drug (Loftsson and 
Masson, 2001). The drug molecule to be complexed with CD, it should have certain 
characteristics such has more than five atoms (C, P, S, N) forming the skeleton of the 
drug molecule, a melting point temperature below 250 ºC and solubility in water less than 
five condensed rings in its structure, a molecular weight between 100 and 400 (Szejtli, 
1998, 2005; Vyas et al., 2008). 
 
Figure 1.8 Scheme of drug complexation by CD and consequent release. Adapted from (Uekama et al., 
1998). 
1.3.3.1.3. Safety and stability of cyclodextrins on drug bioavailability 
CD complexation has the advantage of promoting drug stabilization from hydrolyses, 
oxidation and photodecomposition (Loftsson and Brewster, 1996). The enhancement of 
drug stability induced by the CD is a result of inhibition of the drug interaction with 
vehicles and/or inhibition of drug bioconversion at the absorption site (Matsuda and 
Arima, 1999). The volatile components can also be stabilized by reducing liquids volatility 
or reducing the sublimation in the case of solids. Physical instabilities like sedimentation 
or recrystallization of substances may also be prevented or reduced by complexation 
with CD (Loftsson and Brewster, 1996). In addition CD has been used to prevent 
irritation caused by drugs that are irritant to the stomach, skin or mucous membranes by 
reducing drug toxicity and by making the drug effective at lower doses (Rajewski and 
Stella, 1996). The complexation with CD reduces the local concentration of free drug at 
the molecular level preventing their direct contact with biological membranes and thus 
reducing their side and local irritation with no drastic loss of therapeutic benefits (Challa 
et al., 2005; Scalia et al., 1999). With the dissociation of the complex, the drug is 
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absorbed by the body, always keeping the concentration of free drug within the desirable 
range (Rajewski and Stella, 1996)  
1.3.3.1.4. Cyclodextrins as penetration enhancers 
CD can also act as release enhancers contributing for the drug dissolution even if there 
is no complexation in the solid state (Challa et al., 2005). CD are also able to increase 
the permeability of hydrophobic drugs by increasing the drug solubility, dissolution and 
thus making the drug available at the surface of the biological barrier, from where it 
partitions into the membrane without disrupting the lipid layers of the latter. In such cases 
it is important to use just enough CD to solubilize the drug in the aqueous vehicle since 
excess may decrease the drug availability as will be discussed in Chapter 2. Also 
complexation with CD may increase drug concentration in aqueous vehicles, forming 
saturated solutions with a high thermodynamic potential, promoting the affinity of the 
drug to the SC and increasing the permeation flux. Nevertheless, only the free drug 
penetrates the skin and the promoting effect seems to be dependent on the amount of 
CD (Matsuda and Arima, 1999). 
Due to CD high molecular weight (from 972 to over 2000 Da) and a low octanol/water 
partition coefficient (Log Po/w from less than - 3 to almost 0) it is not expected that they 
penetrate biological membranes. However it is believed that some hydrophilic CD with a 
Log Po/w < 3, can penetrate lipophilic biological membranes such as the skin and 
gastrointestinal mucosa (Lipinski et al., 2001). Hydrophilic CD can modify the rate of 
drug release, which can be used for the enhancement of drug absorption across 
biological barriers, serving a potent drug carrier in the immediate release formulations 
(Dahan et al., 2009). 
The use of CD in transdermal drug delivery is still controversial. Some authors found that 
CD and their derivatives can extract the lipids and some proteins from the SC (Legendre 
et al., 1995; Vollmer et al., 1994). In contrast other authors reported that there are no 
interactions with the skin components, although increased delivery for some materials 
could be explained though a solubilizing effect of the CD on drug in donor solutions. 
Further, excess of complexing host molecules in a formulation can reduce the flux of a 
permeant (Loftsson et al., 1994; Williams et al., 1998). 
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1.3.3.2. Production and characterization of cyclodextrin complexes 
Cyclodextrin complexes are prepared by adding an excess of drug, to different 
concentrations of CD in the desired media. The solution is left stirring until reaching the 
equilibrium and then is filtered using nylon 0,22 µm filters. The concentration of the drug 
is determined using a UV spectrophotometer or HPLC. Data acquisition and analysis are 
performed using proper software. The concentration of drug is determined by 
comparison to a calibration curve make up in an equivalent media (Diane and Gerold, 
2013). 
1.3.3.2.1. Phase-solubility studies 
The stability constant of the complex can be determined based on changes that occur 
during the process of complexation (Echezarreta-López et al., 2002). Phase solubility is 
the most common method used to determine the formation of the inclusion complex, the 
complex type and calculate their stability constant when the drug molecule is slightly 
soluble in water (Dittert et al., 1964). In this method, the solubility of the drug changes in 
the presence of increasing concentrations of CD. The thermodynamic equilibrium is 
achieved by stirring the samples at constant temperature and the results are presented 
graphically as solubility phase diagrams represented in Figure 1.9, 
 
Figure 1.9 Solubility diagram types according to Higuchi and Connors (Siepmann and Peppas, 2011). 
The solubility diagrams are divided into two groups: diagram type A that shows the 
formation of soluble complexes and diagrams type B that indicates the complex 
formation with intrinsic solubility less than the guest molecule solubility (S0). In the 
diagrams of type A, the total apparent solubility of the guest molecule (St) increases 
linearly due to the formation of soluble inclusion complex of any concentration of 
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complexing agent. In the AL type diagrams the total solubility of the substrate (St) 
depends on the linearity of the concentration of CD, obtaining complexes of first order. 
An AP type diagram corresponds to the formation of complexes of higher molecular order 
with respect to CD, which means that the complexation of the guest molecule needs one 
or more molecules of CD, showing a positive deviation from linearity at higher CD 
concentrations. Systems that originate diagrams type AN are related with a negative 
deviation of linearity at higher CD concentrations. It is one of the least observed in 
practice systems and their occurrence can be explained by self-association of the 
complexes in solution and by changing the nature of the solvent due to high 
concentrations of CD. The diagrams of type B indicate the formation of inclusion 
complexes with limited solubility. In the diagrams type BS the solubility of the complex 
increases linearly due to the formation of soluble complexes. However, at point A, the 
solubility of the complex achieves the limit. The St of the guest molecule is constant 
between points A and B, indicating that the equilibrium is reached in the complex 
formation. After point B, since the guest molecule is completely consumed in the solid 
state with the addition of a larger amount of CD, the concentration of uncomplexed guest 
molecule in solution decreases, due to formation and precipitation of insoluble complex. 
This translates into a decrease in the solubility to a constant value corresponding to the 
solubility of the inclusion complex (SC). The diagram of the type Bi is interpreted in the 
same way, with however the complex formed is so insoluble that the initial increase in 
solubility of the guest molecule is not detectable (Loftsson et al., 2005). The stability 
constant of the complex formed and the efficiency of complexation can be calculated 
based on the phase-solubility diagrams and equilibrium association and dissociation in 
the formation of inclusion complexes 
𝐾 =  
𝑆𝑙𝑜𝑝𝑒
S0 (1−𝑆𝑙𝑜𝑝𝑒)
          (1.4) 
where S0 is the intrinsic solubility of the drug in the medium, obtained from the origin 
intercept and the slope is obtained from the linear regression of the data points.  
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1.3.4. Physical and technological modulation of topical and 
transdermal drug delivery 
1.3.4.1. Liposomes 
Encapsulation of drugs or cosmetics into vesicular systems has been used for various 
delivery systems especially in topical preparations. Liposomes were described for the 
first time in 1960 by Bangham and his co-workers (Schmid and Korting, 1996) but it was 
in 1988 that the first antifungal drug econazole topical formulation (Pevaryl Lipogel, Cilag 
Corp., Switzerland) was marketed (Schmid and Korting, 1996). Liposomes are 
characterized by concentric and microscopic vesicles in which an aqueous volume is 
entirely enclosed by a lipid bilayer membrane. This lipid bilayer is mainly composed of 
natural or synthetic phospholipids, with or without CHO, water and possibly electrolytes. 
The most common liposomes are prepared using lecithin of egg or vegetable origin (soy 
bean) and the lipids may be arranged in one or more bilayers (Barenholz, 2001; Meisner 
and Mezei, 1995). The choice of the lipid composition affects the liposome surface, that 
can be positive (stearylamine), negative (phosphatidic acid), or neutral (lecithin) (Meisner 
and Mezei, 1995) and the addition of relatively small amounts of CHO tends to stabilize 
the membrane and therefore the liposome tend to be more rigid (Schmid and Korting, 
1996). Liposomes are amphiphilic molecules, with a hydrophilic head and a lipophilic tail, 
which means that they can incorporate hydrophilic molecules within their aqueous 
regions and lipophilic molecules within the membrane and hold them in route to their 
destination (McCormack and Gregoriadis, 1998; Meisner and Mezei, 1995). 
Various methods have been proposed, but the most common is the thin layer 
evaporation method (TLE). 
 
Figure 1.10 Preparation of lipid for hydration in TLE (adapted from Avanti polar lipids). 
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The TLE technique (Figure 1.10) is based on the evaporation of a volatile solvent 
containing the mixture of lipids to ensure the complete homogenization. After forming a 
thin film of lipids onto the walls of a vessel, this film is hydrated with the aqueous solution 
(water or buffer) containing the material to be entrapped. Depending on the method of 
preparation, on their size, on the lamellarity of liposomes they can be classified 
differently. 
The unilamellar lipid vesicles are found when a single bilayer enclosing an aqueous 
compartment is obtained. According to their size, they are known as small unilamellar 
vesicles (SUV) or large unilamellar vesicles (LUV). If more bilayers occur, as  they are 
called multilamellar vesicles (MLV) (Figure 1.11), (Meisner and Mezei, 1995). The MLV 
are typically 0.1 to 10/µm in diameter, they usually form spontaneously when the film is 
rehydrated at temperatures above the phase transition temperature of the lipids. Since 
the size and lamellarity of these MLVs are difficult to control, usually these structures are 
processed by sonication or extrusion through membrane filters that will considerably 
reduce the lamellarity to form LUV (generally 1 to 5/µm in diameter) or even SUV with 
0.1 to 0.5/µm of diameter. To remove any free drug from the system, a filtration or 
dialysis step is considered after the preparation of encapsulated liposomal formulations 
(Vemuri and Rhodes, 1995). 
 
Figure 1.11 Mechanism of vesicle formation. The types of liposomes depend on size and number of 
lamellae. 
1.3.4.1.1. Liposomal formulations 
Liposomes are used to administer drugs by several routes such as the oral, parenteral 
and also promote dermal delivery of drugs which have to act topically, such as local 
anesthetics. In addition, they enhance transdermal delivery of drugs intended for 
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systemic use, being very effective in exploiting this non-invasive alternative route to oral 
administration (Maestrelli et al., 2006; Manosroi et al., 2004).  
The liposomal formulations are widely used in the pharmaceutical field as drug delivery 
systems due to their versatility and clinical efficacy (Schmid and Korting, 1996). Besides, 
and compared to conventional formulations,  drugs encapsulated in liposomes increase 
their effect, and liposomes are biodegradable and generally  more effective and non-
toxic than conventional topical formulations such as ointments, creams or lotions 
(Honzak et al., 2000a; Reimer et al., 1997). 
It should be noted that the hydrophilic or lipophilic properties of the encapsulated drug 
affects the encapsulation efficiency of the drug in the liposomes (Glavas-Dodov et al., 
2002). Among the substances that are able to be incorporated into liposomes, local 
anesthetics together with anticancer, antifungal and antibiotic agents are considered the 
most used, because they satisfy all the requirements necessary for topical application 
and localized drug delivery (Glavas-Dodov et al., 2002; Schmid and Korting, 1996).  
Liposomes work like drug penetration enhancers into the skin and after topical 
application they can assume different functions. Usually they improve drug deposition 
into the skin at the site of action providing a local effect with little or no systemic activity 
and for that reason minimize side effects (Maghraby et al., 2006). The mechanism of 
action is not completely clear and consequently there is significant conjecture. However, 
most authors suggests that liposomes are effective on drug permeation and enhance 
clinical efficacy, due to the similarity to the biological membrane, which makes them 
suitable to encapsulate hydrophilic and lipophilic substances in their different phases. 
Furthermore, liposomes prepared with similar lipids to those found in the SC showed to 
be the most effective for topical drug delivery which penetrating the epidermal barrier to 
a larger extent thanother dosage forms (McCormack and Gregoriadis, 1994a; Verma et 
al., 2003a, b). 
However there is a general problem concerning to the efficacy of topical drugs. It is 
necessary to reach the site of action and stay in an effective concentration for a certain 
time (Schmid and Korting, 1996). Another problem is that the permeability characteristics 
of the SC could be altered due to the fact that some lipids from the liposomes could 
penetrate into the latter and thereby modifying its endothermic profile (Weiner et al., 
1994). 
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Classical liposomes (200-400 nm in diameter) are too big and unable to deform, for that 
reason they have some limitations as carriers for transdermal drug delivery as they do 
not penetrate skin deeply and thus are restricted to the outer layers of the SC (Elsayed 
et al., 2007). In order to target deeper the underlying skin tissue, intensive research led 
to the introduction and development of a new class of lipid vesicles, the highly 
deformable (elastic or ultraflexible) liposomes, which have been called Transfersomes® 
(Cevc and Blume, 1992). 
1.3.4.1.2. Highly deformable liposomes 
The possibility that intact vesicles can permeate through skin membranes and release 
the drug into the systemic circulation is still controversial. To overcome this problem, a 
new class of highly deformable liposomes namely transfersomes have been developed. 
These elastic and ultraflexible vesicles comprise a phospholipid (e.g. 
phosphatidylcholine) as main component together with 10 to 24 wt% of a surfactant 
added. The flexibility of the liposome is given by the high radius of curvature of the 
surfactant that acts as an 'edge activator' and some research has shown that it is able to 
squeeze through a pore of about 20 nm diameter (Cevc, 2002). The edge activator 
present in the formulation has the capability to accumulate at the high stress sites within 
the vesicles and form a highly curved area of the vesicle which, to maintain stability, will 
then move through narrow skin pores to the more hydrated environment within the 
deeper skin layers. 
According to the inventors, these vesicles are able to penetrate intact into the deeper 
skin and even reach systemic circulation (Cevc et al., 1997; Cevc et al., 1996; Cevc et 
al., 1998). Whilst there is still some reservation and contradiction on the mechanisms by 
which ultra-deformable or highly flexible liposomes improve drug delivery, some workers 
proved that these vesicles can deliver increased amounts of therapeutic agents to and 
through the skin (Jianxin Guo, 2000; Maghraby et al., 2001a, b; van den Bergh et al., 
2001). A lot of work has been developed to evaluate the influence of liposome fluidity on 
drug delivery of new therapeutic agents to be formulated (Cevc and Blume, 2001; 
Duangjit et al., 2013; Khan et al.; Nuria Perez-Cullell, 2000; Zhang et al., 2014). 
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1.3.4.2. Liposomes production and characterization 
1.3.4.2.1. Size 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy is a 
technique for measuring the size of very small particles (Goldburg, 1999). The measure 
of the particle size is influenced by the fluctuation of the intensity of the scattered light of 
a laser beam caused by particle Brownian motion (Figure 1.12). The Brownian motion 
will be slower the larger is the particle, and the later will diffuse more slowly than the 
smaller ones. The velocity of the particle Brownian motion is defined by translational 
diffusion coefficient (D). Therefore the size of a particle is calculated from the 
translational diffusion coefficient by using the Stokes-Einstein relation 
𝑑(𝐻) =  
𝐾𝐵𝑇
3𝜋𝜂𝐷
          (1.5) 
 where d(H) corresponds to the hydrodynamic diameter, KB to the Boltzmann’s constant, 
T the absolute temperature, η the viscosity and D stands for the translational diffusion 
coefficient. This equation shows that, for large particles, D will be relatively small, and, 
thus, the particles will move slowly while for smaller particles, D will be larger and the 
particles will move more rapidly. Therefore, by observing the motion and determining the 
diffusion coefficient of particles in liquid media, it is possible to determine their size. 
 
Figure 1.12 Determination of particle size by dynamic light scattering. 
The diffusion coefficient is obtained by fitting the correlation function with a suitable 
algorithm, such as the cumulants analysis, which determines a mean size and 
polydispersity index (PI). The PI is a dimensionless measure of the broadness of the size 
distribution, ranging from 0 to 1. A PI value lower than 0.1 might be associated with a 
Chapter 1 
37 
 
high homogeneity in the particle population (monodisperse), whereas high PI values 
suggest a broad size distribution (polydisperse) or even several populations 
(plurimodal).The latter situations suggest potential problems with the stability of the 
formulation, and the probability of aggregation of the particles has to be considered. 
1.3.4.2.2. Zeta potential 
Zeta potential is a physical property exhibited by most colloidal particles when dispersed 
in liquids being related to its surface charge. This parameter predicts the stability of long 
term colloidal systems. The technique is based on the particles that move towards the 
electrode that has an opposite charge and an electric field is applied to the cell that 
contains the particle suspension. If zeta potential is high, the particles are stable due to 
high electrostatic repulsion between particles. On the contrary, a low zeta potential value 
(approaching zero) increases the probability of particles colliding and therefore, forming 
particle aggregates. Thus, zeta potential is used as an index of the dispersion stability of 
particles (Sudo et al., 2013). 
1.4. Topical and transdermal formulations 
Most preparations to be applied topically are semi-solids since they have good adhesion 
to the skin and can be used to deliver therapeutic agents over a period of time. Despite 
the various possibilities of vehicles used in dermal drug delivery systems, special 
emphasis will be given to gels, particularly water-based gels (or hydrogels) that were 
used in this work as vehicle as shown later. 
1.4.1. Matrix formers 
The physicochemical properties and the performance of the formulation depend of the 
nature of the matrix. For devices that incorporate the drug in a matrix, the composition of 
the latter can regulate permeant release. The matrices are usually prepared using simple 
polymer mixtures with the drug dispersed and then after forming the gel the permeant 
will be incorporated in the latter. Generally the degree of polymer cross-linking and the 
level of hydration of the gel control the diffusion of the permeant through the polymer 
matrix. Hydrogels are alternative matrices formed from a network of hydrophilic polymers 
that are waters swollen. 
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1.4.2.  Hydrogels  
Hydrogels are naturally formed by adding a thickness agent to a liquid phase exhibiting 
an intermediate behavior between solid and liquid materials. Hydrogels can be defined 
as three-dimensional, hydrophilic and polymeric network. The network is composed by a 
liquid phase that essentially forms a continuous phase where the solvent can be polar 
(water or alcohol) or non-polar. Numerous thickening agents are available and the 
selection is based on the physicochemical properties of the permeant. Simple gels can 
be prepared from water thickened with typically 1 and 5% in the formulation of natural 
polymers (carageenans or pectin) or synthetic polymers (hydroxypropylmethylcelulose - 
HPMC or Carbopol). 
Hydrogels are biocompatible with proteins, as well as living cells and body fluids, due to 
their high water content and soft texture (Chandak and Verma, 2008b; Krishnaiah and 
Al-Saidan, 2008). For that reason, hydrogels are nowadays widely used in various 
therapeutic applications, e.g. tissue engineering, controlled drug delivery and diagnostic 
devices, e.g. medical and biological sensors, microarrays, diagnostic imaging. In terms 
of controlled drug delivery from gels, they have played a vital role as intelligent carriers. 
The continuous liquid phase allows free diffusion of molecules through the polymer 
scaffold, and hence release should be equivalent to that from a simple solution. Drug 
release from the polymer can be easily modulated by very large molecules 
(macromolecules), highly viscous gels and in particular, by permeants that bind to the 
polymer in the gel.(Roy et al., 2009). 
1.4.2.1. Hydroxypropylmethylcellulose 
HPMC has been tested as a matrix former in the design of patches of several drugs such 
as propranolol hydrochloride (Guyot and Fawaz, 2000), flurbiprofen (Verma and Murthy, 
1997), tramadol (Chandak and Verma, 2008c), methotrexate (Chandak and Verma, 
2008a), trimetazidine (Krishnaiah and Al-Saidan, 2008) and metformin (Jahan et al., 
2011) widely used in oral and topical formulations. HPMC is a flexible hydrophilic 
polymer available in different grades and has been shown to yield clear films because of 
the adequate solubility of the drug in the polymer. 
Matrices of HPMC without rate-controlling membranes have been observed to exhibit a 
burst effect during dissolution testing because the polymer was hydrated easily and 
swelled, leading to the fast release of the drug (Guyot and Fawaz, 2000). Moreover, 
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HPMC is also chemically unreactive and therefore it is compatible with all active and 
non-active ingredients.  
Due to all reasons listed, HPMC was the polymer selected to be the matrix-former in the 
preparation of drug-loaded hydrogels in the permeation studies presented in the 
following Chapters of this thesis. 
1.5. Drug information  
Tetracaine (TC) (Figure 1.13) is a potent amino ester type local anesthetic, indicated for 
anesthesia before venipuncture or venous cannulation and is primarily used for surface 
anesthesia and spinal block (Covino, 1987). Due to its high systemic toxicity, the use in 
other anesthetic techniques is limited. Tetracaine has been shown to pass through the 
skin (Fisher et al., 1998; Romsing et al., 1999; Teixeira et al., 2014a). However adverse 
effects of its topical administration include mild erythema at the site of the application 
and less frequently slight edema, pruritus and blistering of the skin. This molecule is a 
white or light yellow, very slightly soluble in water and soluble in organic solvents and is 
stable under ordinary conditions. It has a pKa of 2.24 and 8.39 and a LogP of 2.79, 
which compared to the other anesthetics, makes this molecule a suitable candidate to 
undergone skin permeation. Tetracaine is commonly used as the hydrochloride form in 
solutions and creams and as the base form in ointments or gels. A 1% cream or a 0.5% 
ointment is normally used for topical anesthesia, while a 4% gel is employed for a 
percutaneous local anesthesia before venipuncture or venous cannulation. Tetracaine is 
reported to be about 15% bioavailable after application of a 4% gel to intact skin, with a 
mean absorption and elimination half-life of about 75 minutes (Berman et al., 2005; 
McCAFFERTY et al., 1989; Romsing et al., 1999; Schecter et al., 2005). 
 
Figure 1.13 Chemical structure of tetracaine. 
Ropivacaine hydrochloride (RPC) (Figure 1.14) it is a long-acting local anesthetic. 
Ropivacaine is used for epidural block, peripheral nerve block, infiltration anesthesia and 
field block, but is contra-indicated for obstetric paracervical block and for use in 
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intravenous regional anesthesia (Bier’s block). At high doses ropivacaine produces 
surgical anesthesia, whereas at lower doses it is used for the management of acute pain 
such as labour pain and in postoperative analgesia. Ropivacaine has a differential 
blocking effect on nerve fibers and, at the lowest concentration used, there is good 
differentiation between sensory and motor block. The onset and duration of sensory 
block produced by ropivacaine is generally similar to that obtained with bupivacaine but 
the motor block is often slower in onset, shorter in duration, and less intense. 
Ropivacaine hydrochloride is administered in concentrations of 0.2 to 1%. The dosage 
depends on the site of injection and the procedure used, as well as the status of the 
patient. The dose of ropivacaine should be reduced in the elderly, and in acutely ill or 
debilitated patients. A test dose of lidocaine with adrenaline should be given before 
starting epidural block with ropivacaine to detect inadvertent intravascular administration 
(McClellan and Faulds, 2000; McCrae et al., 1995; Zink and Graf, 2004). 
 
Figure 1.14 Chemical structure of ropivacaine. 
1.6. Scope 
The work presented in this thesis aims at the development of different formulations 
strategies to improve the efficacy and permeation of two distinct local anesthetics across 
the skin. The first part gathers a comprehensive set of data obtained from several 
complementary techniques regarding the nature of the association between two forms of 
TC and CD and how this interaction affects the transport across a model membrane. The 
second part is addressed in Chapter 3, 4 and 5, and consists of a detailed data of 
aminoacid-based surfactants and liposomes as chemical permeation enhancers for both 
local anesthetics. The final optimized formulations were subsequently tested in vivo and 
are presented in Chapter 6. 
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Chapter 2 
2. Effect of cyclodextrins and pH on the permeation of 
tetracaine: supramolecular assemblies and release 
behavior 
Tetracaine is a lipophilic molecule and cyclodextrins are known to increase the solubility 
of lipophilic molecules in water. This Chapter focuses on the interaction mechanism 
between tetracaine with different cyclodextrin (β-CD e HP-β-CD) and how such 
interaction affects the transport of the latter. The kinetics and mechanism of tetracaine 
release from HPMC gels was also discussed in this Chapter giving an insight on the role 
of cyclodextrin on the tetracaine transport. The present observations allow demonstrate 
that cyclodextrins increase the solubility of tetracaine in water which is successfully 
released from the formulations at a controlled rate. 
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2.1. Introduction 
It is generally believed that the interaction of the anesthetic with membrane lipids and 
proteins leads to the inactivation of neuronal ion channel activity (Ragsdale et al., 1994). 
Tetracaine is reported to be about 15% bioavailable after application of a 4% gel to intact 
skin, with a mean absorption and elimination half-life of about 75 minutes (O’Brien et al., 
2005). This drug can suffer hydrolysis, resulting in equilibria between three different 
absorbing species: tetracaine base form (TC) and tetracaine ionized forms (TCH+ and 
TCH2
2+) depending on the pH (Figure 2.1). The ability of this drug to cross biological 
membranes is also pH-dependent. It has been reported that tetracaine in its base form 
can permeate the skin (Liu et al., 2005). The ionic form (TCH+), is dominant at 
physiologic pH of the skin (pH ~ 4.2 – 6.5) and it is generally accepted that the cationic 
form binds to the sodium channels on the nerve membrane, blocking the initiation and 
transmission of nervous impulses(Chekirou et al., 2012).  
 
Figure 2.1 Schematic representation of ionization equilibrium of tetracaine, exhibiting two ionizable groups 
(pKa’s 3.41 and 8.24) (Iglesias-García et al., 2010). 
The bioavailability of most topically applied drugs is generally very low and various 
approaches have been developed to enhance drug diffusion across the skin (Hadgraft, 
1999; Thomas and Finnin, 2004). One of them involves the use of cyclodextrins. These 
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compounds are known to have the ability to form complexes with a wide range of organic 
molecules, both in solution and in solid state (Másson et al., 1999; Ventura et al., 2006). 
CD have been recognized as promising drug carriers and delivery systems but how they 
function to modify topical administration has not as yet been fully elucidated (McCormack 
and Gregoriadis, 1998). Host-guest like complexes may improve the properties of the 
guest molecule, e.g. the drug, such as solubility enhancement (Loftsson and Brewster, 
2012; Yuan et al., 2013) and stability improvement (Yuan et al., 2013). Additionally, CD 
act as efficient drug carriers, providing a controlled and sustained release, avoiding 
undesirable toxic effects (Castronuovo and Niccoli, 2006; Mosher, 2002). Although the 
naturally occurring CD (in particular the β-CD) and their complexes are hydrophilic, their 
aqueous solubility is limited. The synthesis of new CD derivatives (such as HP-β-CD) 
has allowed overcoming the solubility issue (Booij, 2009; Loftsson et al., 2007). As 
previously mentioned, the neutral TC permeates the skin, however that occurs at pH 
higher than 8, clearly above the skin physiological pH. This Chapter reports a 
comprehensive analysis regarding the transport of TC across a model membrane. 
Studies using a simple inert barrier model are very useful for optimization of formulations 
in earlier stages of research. The dialysis membrane was selected as a model 
membrane because it is isotropic and homogeneous (see section 1.2.3.). In these 
conditions, release data can be described by simple mathematical models. Essentially, 
this work focused on the complexation phenomenon occurring between aqueous 
solutions of two forms of tetracaine and β- and HP-β-CD and how the CD concentration 
on the formulation alters the release profile of tetracaine. In vitro release studies across 
dialysis membrane using different tetracaine formulations were carried out at two distinct 
pH values (4.1 and 9.0). The mechanism of release was evaluated on the basis of the 
interactions established between tetracaine and HP-β-CD. 
Mathematical models appear as useful tools to correlate material properties, interaction 
parameters, kinetic events, and transport behavior within complex hydrogel systems 
(Korsmeyer et al., 1983; Siepmann and Peppas, 2001; Siepmann and Peppas, 2011).   
Although the interactions between tetracaine and CD, at neutral pH, have already been 
reported elsewhere (Fernandes et al., 2007; Franco de Lima et al., 2012; Van Santvliet 
et al., 1998), no studies have been presented with acetate buffer at acidic pH (ca. pH 4). 
At this pH, the pKa of tetracaine in the presence of CH3COO
- and the CD decreases, 
however the predominant structure remain the same. CD:TC complexes were 
characterized using different techniques: i) stoichiometry, association constants, and 
HPLC, fluorescence and nuclear magnetic resonance (NMR) spectroscopies to analyze 
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topology of complexation of the inclusion complexes. The tetracaine concentration during 
the experiments was kept below the critical micelle concentration - cmc (128 mM), as 
reported elsewhere (Dukhin, 2005). The results obtained were rationalized and the 
conclusions are new, significant and provide solid physicochemical knowledge of these 
systems that are crucial for future delivery studies with local anesthetics and 
cyclodextrins. 
2.2. Experimental section 
2.2.1. Materials 
Tetracaine base, acetic acid, 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt 
(TSP), ammonium acetate, sodium acetate and β-CD were acquired from Sigma Aldrich 
(St. Louis, M. O. United States of America). Millipore water was used to prepare sodium 
acetate buffer aqueous solution. HP-β-CD with 97% of purity, with an average degree of 
substitution of 2 to 6 units of 2-hydroxypropyl (C3H7O) per glucose unit, and with an 
average molecular weight of 1380 g/mol, was purchased from Acros Organic (Geel, 
Belgium). Methanol (MeOH) and acetonitrile (ACN) HPLC grade were purchased from 
LiChroSolv Merck (Darmstadt, Germany). Phosphate buffer saline tablets (PBS) were 
purchased from TIC Gums (Belcamp, MD, USA). Dialysis membrane (Spectra/Por) with 
a 6-8.000MWCO, was bought from Spectrum Laboratories, Inc. (Broadwick St., Rancho 
Dominguez, US & Canada). Deuterated water (D2O) (99.9%) for preparing NMR samples 
was purchased from Eurisotop (Saint-Aubin Cedex, France). HPMC - Methocel K15M 
Premium, 19%-24% methoxyl and 7-12% hydroxypropyl, Mw=4.310
5 Da) was a kind gift 
from Dow Chemical. All reactants were used as received. 
2.2.2. Phase - solubility studies 
Phase-solubility diagrams were carried out to assess the solubility of tetracaine and 
determine the association constants with the cyclodextrins. Phase solubility studies were 
performed according to the procedure reported by Higuchi and Connors and as 
mentioned in section 1.3.3.2.1. (Siepmann and Peppas, 2011). The studies were 
performed at room temperature, by adding an excess of TC base to deionized water 
(pH=9) and sodium acetate buffer aqueous solution (pH=4.1) containing increasing 
amounts of β-CD (1-15 mM) and HP-β-CD (1-45 mM), stirred during 72h. The solutions 
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were filtered using a MCE 0.45 µm filter syringe (Fioroni filters, Ingré, France) (n=3). An 
aliquot of solution was removed, diluted in a filtered and degassed mobile phase (MeOH, 
ACN and ammonium acetate) and quantified by using HPLC (Shimatzu LC-20AD) (see 
section 2.2.5.2. The apparent stability constants (K) of the complexes were calculated 
from the slope of the straight lines of the phase-solubility diagrams and the drug solubility 
in the medium using Eq. 1.4 (Connors and Mollica, 1966),  
2.2.3. Fluorescence studies 
Fluorescence spectrophotometry is usually the method of choice for quantitative 
analytical purposes, if applicable. It has assumed a major role in analysis, particularly the 
determination of trace contaminants in our environment, industries and bodies, because 
for applicable compounds fluorescence spectrometry gives high sensitivity and high 
specificity. The selectivity of fluorescence methods is greater than that of absorption 
methods, as fewer substances fluoresce than absorb radiation in the UV or visible 
region. Furthermore, fluorescence is more selective because both the emission and the 
absorption spectra can be obtained. Fluorescence is usually also more sensitive than 
absorption methods, as it is always easier to measure a small signal against a very small 
zero background than to measure a small difference between large signals. However, 
the phenomenon of fluorescence itself is subject to more rigorous constraints on 
molecular structure than is absorption. 
In order to characterize the stability constants between TCH+ and CD, the fluorescence 
emission spectra of TCH+ were collected and analyzed. Changes in the intrinsic 
fluorescence of TC using different CD molar ratios of complexation were also 
investigated. A batch of buffered acetate aqueous solutions with a fixed concentration of 
TC (10 µM) were prepared (n=3) by adding increasing amounts of β-CD and HP-β-CD. 
The pH of each solution was fixed at 4.1 and maintained constant during the 
experiments. The solutions were subsequently mixed at 25°C during 72 h. The 
measurements were performed using a Horiba-Jobin-Ivon SPEX Fluorolog 3-22 
spectrophotometer at 25°C. The excitation wavelength was fixed in 311 nm and the 
emission spectra were collected from 320 to 500 nm. The emission and excitation slits 
used were fixed at 5 nm. 
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2.2.3.1. Modeling stoichiometry and association constants 
Assuming that a 1:1 complex between β-CD and HP-β-CD with ionized tetracaine, TCH+ 
(a proof for this assumption will be presented in the section 2.3.1) is formed 
K
CD TCH CD TCH           (2.2) 
the stability of the complex CD:TCH+ can be described in terms of an association 
constant, K,  
 
f f
CD TCH
K
CD TCH


  
  
         (2.3) 
where [CD]f and [TCH
+]f represent the concentration of free (non-complexed) species, β-
CD or HP-β-CD and ionized tetracaine, respectively, and [CD:TCH+] is the concentration 
of the 1:1 complex. 
From Eq. 2.3 and the mass balance equations 
   
T f
CD CD TCH CD            (2.4) 
T f
TC CD TCH TCH              
      (2.5) 
where [CD]T  and [TCH
+]T represents the total (initial) concentrations of β-CD or HP-β-CD 
and TCH+, respectively, the association constant, K,  can be re-written as  
 
    1 T T
f
K
f CD f TCH 

    
       (2.6) 
 
where f  is the fraction of TCH+ complexed with the β-CD and HP-β-CD. 
Since the CD is not fluorescent, the observed fluorescence emission intensity, F, from 
free and complexed tetracaine is given by 
 
1 2f
F k TCH k CD TCH                (2.7) 
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where k1 and k2 are constants. Considering F0 and F∞ the fluorescence intensity of TCH
+ 
in the absence and in excess of cyclodextrin, respectively, f can be represented by 
0
0
F F
f
F F



          (2.8) 
Combining Eqs. (2.6) and (2.8) we obtain  
   
 
0
0
1
T
T
F F K CD
F F
K CD
 
 

        (2.9) 
The experimental data (see Figure 2.7) can be perfectly fitted (R2>0.9965) to Eq. (2.9), 
using a non-linear least-squares algorithm, to obtain the fitting parameters K and F∞. 
Eq. (2.9) can be simplified in order to have information on the stoichiometry of the 
association (Smith et al., 1991). Thus, a linear relationship of (F-F0)/[CD]T as a function 
of (F-F0) is indicative of a 1:1 stoichiometry. 
2.2.4. NMR/Rotating frame nuclear Overhauser effect spectroscopy 
(ROESY) studies 
NMR spectroscopy (1H-NMR), represents one of the most important technique in the 
study of supramolecular structures in solution such the inclusion complexes with CD. 
This technique provides information about stoichiometry, stability constants, energy 
process of complexation and complex structure of the drug/CD (Chao et al., 2004; 
Schneider et al., 1998). Although the phase solubility studies assess the solubility of the 
drug with CD, this technique only give an indication on the possible formation of inclusion 
complexes, however do not distinguish other external associations that may occur 
(Loftsson et al., 2004; Schneider et al., 1998). NMR spectroscopy is based on the 
polarity changes of the environment that results in alterations in the chemical shifts of the 
protons of the drug molecule and CD. Thus, the variation in chemical shifts is used for 
the characterization of those complexes (Schneider et al., 1998). The changes in 
chemical shifts ( ) is calculated by the difference between the chemical shifts of the 
molecule in the presence of other complexing reagent  (complex) and chemical shifts of 
the free molecule  (free). Due to the change of its chemical environment, positive or 
negative changes occur representing a shift of the protons to lower or higher fields, 
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respectively (Loukas, 1997). Changes in chemical shifts on the H3 and H5 protons that 
are found in the internal cavity of CDs allow concluding the formation of an inclusion 
complex as well as its geometry. The protons deviations caused by the molecule which 
penetrates into the cavity of CD are due to anisotropic magnetic effects expressed in 
resonances deviations of higher fields (Ganza-Gonzalez et al., 1994; Veiga et al., 2001). 
Little or no changes in the chemical shifts occur in the protons that are located outside 
the ring (H1, H2, and H4). Usually the proton H6 of the CD, located on board of the 
narrower opening of the CD may suffer more or less change in their chemical shift 
depending on the type of inclusion of the drug molecule (Schneider et al., 1998). 
Changes in chemical shifts of the protons belonging to the CD or drug and the 
sensitivities and detection of the complex formation can be monitored by varying the 
proportion of the drug and CD in solution (Job 1928). Thus, it is possible to obtain 
information on the stoichiometry of the complex formed (Marangoci et al., 2011).  
For more detailed information on the geometry of the complex, two-dimensional NMR 
spectroscopy technique can be used. The effects of nuclear Overhouser (NOE) in the 
steady-state are strongly dependent on a distance internuclear until 4Å, which becomes 
a difficulty to analyze CD complexes with a molecular weight of about 2000 g / mol. In 
these cases, the correlation of molecular parameters has values close to the unity 
leading to NOE low values. Nuclear Overhouser effect on the rotating frame (ROESY) 
can be used to overcome this drawback. This technique is based on the spin truncation 
(spin-lock) where an additional excitation pulse is applied changing the correlation times 
and the NOE becomes measurable (Amato et al., 1998; Schneider et al., 1998). The 
detection of spatial correlations between the protons of the drug and the CD, lead to the 
determination of the structure of the complex formed with sufficient precision in relation 
to the regions of the molecules involved in the process of complexation (Schneider et al., 
1998). 
1H-NMR and ROESY experiments explore aspects of the geometry of the complex 
formed and provide robust evidence of the nature of the host-guest interaction. One-
dimensional 1H-NMR spectra for each different [CD]/[TC] ratios, R, were recorded using 
a 600 MHz Varian NMR spectrometer (Palo Alto, CA) at 25ºC using a 3 mm indirect 
detection NMR probe. The NMR samples were prepared using D2O (99.9%) as solvent, 
and TSP, used as internal reference, at tracer amounts. Solutions were prepared by 
weighting different amounts of CDs to a fix TCH+ concentration at room temperature and 
mixed for 12 h to achieve the equilibrium. Spectra were obtained with residual solvent 
(HOD) pre-saturation and the experimental parameters included 24k data points 
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covering a spectral width of 8 kHz, a radiofrequency excitation pulse was 45º and an 
interpulse delay of 10 seconds to allow complete nuclei relaxation. 
Two-dimensional (2D) rotating frame overhauser effect spectroscopy (ROESY) 
experiments were performed using the same NMR spectrometer and probe. The spectra 
were collected using 2048 data points in the F2 dimension and 512 increments defining 
the F1 dimension. The spectral width was 7.2 kHz in both dimensions and 32 free 
induction decays were acquired per increment. ROESY spectra were processed using 
the VNMR 6.1 software (Varian Inc., Palo Alto, CA, USA). Zero-filling and apodization 
Gaussian functions were employed in both dimensions before Fourier transformation, to 
improve resolution and signal to noise ratios, respectively. The cross-peaks volumes 
were directly correlated with inter-nuclear distance, r, of the two observed protons, via 
the known r−6 dependence. The fixed and well-known intramolecular distances between 
two vicinal aromatic protons (2.48A°) of BZC – ortho and meta – were used for 
calibration. 
2.2.5. Drug release studies 
The in vitro release studies were conducted in vertical Franz diffusion cells (PermeGear, 
Inc., PA, USA) with a volume of 5.1 cm3 and a surface area of 0.64 cm2. The dialysis 
membranes were placed between the two chambers of the cell. The receptor 
compartment was filled with PBS solution (pH 7.4), maintained at 37 (± 0.1) ºC and 
under stirring during the diffusion experiments. Each donor compartment (n=3) was filled 
with different TC hydrogel formulations (95 mM), composed of different amounts of CD 
and immediately covered with Parafilm® to prevent evaporation. Samples were taken at 
predetermined times (0, 1, 2, 3.5, 5, 6, 16, 24, 32, 46, 73, 110 and 142 h) from the 
receptor compartment and replaced by fresh PBS solution. In vitro studies provided the 
release profiles of TC and TCH+ in the presence of different amounts of HP-β-CD, as a 
function of time. It is worth noticing that the HP-β-CD derivative was selected because it 
promoted the highest increase in solubility of TC. 
2.2.5.1. Composition and preparation of the HPMC gel  
Drug-loaded HPMC hydrogels were prepared by adding 2.5% (w/w) of TC with different 
amounts of HP-β-CD in water and sodium acetate buffer aqueous solution to 1% (w/w) of 
dry polymer powder (HPMC), at room temperature. The polymer solutions were kept 
stirring for 24 h before use. 
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2.2.5.2. Drug quantification 
Tetracaine quantification was carried out using a Shimatzu LC-20AD apparatus 
equipped with a quaternary pump, an autosampler unit, and a L2450 UV/visible dual 
wavelength detector. A Phenomenex (Torrance, CA, USA), reverse phase C18 column 
Luna (5µm pore size, 250mm x 4.6mm) with a guard column as the stationary phase, at 
25°C was used to quantified tetracaine. The mobile phase was prepared by mixing 
methanol, acetonitrile and ammonium acetate solution on the proportions 7:7:6 
respectively. The solution was subsequently filtered using a 0.45 µm Nylon membrane 
(Supelco Analytical, Bellefonte, USA) and sonicated for 1 h prior to use. The detection 
was at 311 nm, the injection volume was 25 µL and the mobile phase flow rate was set 
to 1.0 mL min-1. In these conditions the retention time of tetracaine was ca. 6.5 minutes. 
2.2.5.3. Data analysis in the release studies 
The steady state flux (J, µg cm-2 h-1) which represents the rate transfer of diffusion 
substance through unit area of a section (A) was calculated by  
𝐽 =
𝑉
𝐴
 
𝑑𝑐
𝑑𝑥
          (2.10) 
where J is the cumulative drug amount permeated at time (t) calculated from the slope of 
the linear portion of the plot of cumulative drug amount permeated and V is the volume 
of the receptor compartment. Taking the Eq. 2.10 the permeability coefficient can be 
calculated by using  
𝑃 = 𝐽 
𝑙
𝑄0
           (2.11) 
where Q0 is the initial amount of drug in the donor compartment and l the thickness of the 
membrane.  
The Q6 express in µg/cm
2 refers to the cumulative drug amount present in the receptor 
compartment solution after 6 h and was calculated using Eq. (2.12) 
𝑄𝑛 =  (𝐶𝑛 ×  𝑉0 +  ∑ 𝐶𝑖 𝑥 𝑉𝑖
𝑛−1
𝑖=1 )/𝐴       (2.12) 
where n is the number of aliquots collected during the 6 h period, Cn correspond to the 
drug concentration in the receptor medium, Ci is the concentration in the sample, A is the 
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diffusion area, V0 and Vi stand for the volumes of the receptor compartment and the 
sample. Results are presented as mean ± standard deviation (SD). 
2.2.5.4. Release Models 
The release mechanism has been assessed using the power law equation (Korsmeyer et 
al., 1983). 
Ct/C∞ = kt
n
          (2.13) 
where Ct and C∞ are cumulative concentrations of the drug released at time t and at 
infinite time, respectively, and k and n are fitting parameters, giving the latter useful 
information on the release mechanism; from Eq. (2.13), the mean dissolution time 
(MDT), which characterizes the drug release rate from a dosage form and to indicate the 
drug-release-retarding efficiency of the polymer (Sriamornsak and Sungthongjeeh, 2007) 
can be calculated using Eq. 2.14 (Möckel and Lippold, 1993).  
1
1
nnMDT k
n
   
 
        (2.14) 
The application of Eq. (2.13) is restricted to a cumulative release below 60 %.The 
release kinetics was evaluated through first and second order rate law equations (Eqs. 
2.15 and 2.16, respectively); we attempted to fit the experiments data to a zero order law 
equation but these fits were poor. For both cases the release rate is concentration-
dependent. 
0 1ln lnQ Q k t            (2.15) 
1
𝑄
=  
1
𝑄0
−  𝑘2𝑡           (2.16) 
In equations (2.15) and (2.16), Q and Q0 are the amount of drug remaining in the matrix 
at time t and at t=0, respectively, Q∞ is the total amount of all released drug and k0 and k1 
are first and second order rate constants. Both the release kinetics and the mechanism 
of release were analyzed by using the Weibull function (Eq. 2.17). 
[1 exp( ) ]dt WC C k t           (2.17) 
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where kW and d are constants related to the release rate and mechanism, respectively 
(Papadopoulou et al., 2006). 
2.3. Results and Discussion 
2.3.1. Physicochemical characterization of the complexes 
The formation of complex with CD alters the physicochemical properties of the drug. In 
general by adding CD to a poorly soluble drug aqueous solution it will increase of its 
solubility (Marques et al., 1990). The solubility phase diagrams (Loftsson et al., 2005; 
Loftsson and Masson, 2004) were obtained for tetracaine/β-CD and tetracaine/HP-β-CD 
mixed aqueous solutions at a pH of 9.0, at this pH, tetracaine occurs in its neutral form. 
 
Figure 2.2 Solubility of tetracaine in water aqueous solution (pH 9) as function of CD concentrations at room 
temperature. 
According with previous work an increase of either β-CD or HP-β-CD, leads to an 
increase in the concentration of TC dissolved in water (Sadlej-Sosnowska, 1997; Szejtli, 
1998). Unionized TC is poorly soluble in water (51.4 µg/mL) and that the solubility was 
enhanced respectively by 14-fold and 69-fold respectively using β-CD (10 mM) and HP-
β-CD (45 mM), as a consequence of formatting the drug-CD complexes (Connors and 
Mollica, 1966). The data shown in Figure 2.2 fitted to a straight linear Eq. (2.1) with a 
good correlation coefficient R2=0.999. By applying the fitting parameters mentioned in 
Figure 2.2 into Eq. (2.1), the following stability constants, K, for the formation of TC:β-CD 
and TC:HP-β-CD complexes, in a 1:1 stoichiometry (Figure 2.3), were computed and are 
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equal to 1052 M-1 and 1051 M-1, respectively. These results are in agreement to those 
reported by other authors (Franco de Lima et al., 2012; Loukas et al., 1998).  
 
Figure 2.3 Job’s plot analysis for tetracaine/HP-β-CD showing a maximum for a tetracaine molar fraction 
equal to 0.47 (± 0.10). 
Table 2-1 Summarizes the association constants values (K), the maximum solubility and 
the efficiency of the complexation for TC:CD complexes, as computed from Figure 2.2.  
 
Table 2-1 Effect of cyclodextrins on the solubility of tetracaine (TC) (n=3). 
System 
Solubility 
(g/mL) a 
Efficiency of the 
complex b 
Slope 
=[TC]/[CD] 
R
2
 K (M
-1
) 
TC: β-CD 734
c
  0.05 14 0.2671 0.9947 1052  118 
TC: HP-β-CD 3539
d
  0.14 69 0.2874 0.9923 1051  46 
a
 Maximum of solubility of TC in the CD complexes.  
b
 Ratio between TC solubility in the CD aqueous solution and the intrinsic solubility (51.4 g/mL). 
c
 Solubility computed by taking [β-CD]=10mM. 
d
 Solubility computed by taking [HP-β-CD]=45mM. 
 
Both CDs forms have similar stability constants (Table 2-1), but the HP-β-CD 
significantly improves the solubility of TC due to its higher solubility in water (Mura et al., 
1995). From the analysis of tetracaine ionization constants it was noted that only 
approximately 9% of the total amount of TC was protonated at pH 9. The proportion was 
calculated considering the pKa of TC and according to Henderson-Hasselbalch equation 
(Becker and Reed, 2012). In order to investigate the effect of the protonated form of 
tetracaine in CD interactions, similar experiments were carried out at pH 4.1. At the acid 
pH, TC solubilized even in the absence of CDs (Figure 2.4). 
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Figure 2.4 Solubility of tetracaine in buffer aqueous solution (pH 4.1) as function of CD concentrations at 
room temperature. 
At pH 9, the higher solubility of TC observed in the presence of CD was due to a more 
efficient complexation of the neutral form of TC with CD when compared with its ionized 
form. However, at pH 4, TC was completely ionized, the concentration of dissolved TC 
only slightly change as a function of CD concentration, indicating  a more limited 
interaction between TC and CD. Similar results regarding the effect of ionization of drugs 
and its affinity for CD have been reported elsewhere (Brewster and Loftsson, 2007). 
2.3.2. Stoichiometry and association constant as seen by 
fluorescence spectroscopy measurements 
In order to further understand the interactions of CD with ionized TC, fluorescence 
spectrophotometry of TC/CD mix solutions, at different molar ratios at pH 4.1, were 
carried out (Figure 2.5). Fluorescence spectroscopy is very sensitive to changes in the 
surrounding environment of the fluorophore. Therefore, this technique is able to provide 
accurate information of possible interactions occurring between TCH+ and CD. This 
procedure has been reported in a previous study to calculate the concentrations of free 
(uncomplexed) ligands, needed for the calculation of the association constants (Sadlej-
Sosnowska, 1997).  
At pH 4.1 TCH+ is the main species in solution although a small percentage of 
diprotonated tetracaine TCH2
2+ (ca. 16 %) is also present. Figure 2.5 shows the 
fluorescence emission spectra of TCH+ at different TC/CD molar ratios. The relative 
fluorescence emission intensity of tetracaine, at 363 nm, increases in the presence of the 
cyclodextrins. 
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Figure 2.5 Fluorescence emission spectra of Tetracaine (1.0×10
-5
 M) in sodium acetate buffer aqueous 
solution pH = 4.1 at different a) β-CD (0.0mM -10 mM) and b) HP-β-CD concentration (0.0mM - 40 mM). 
The emission enhancement can be used to determine the stoichiometry and the 
association constant of the TCH+:CD complexes. Figure 2.5 shows the variation of the 
fluorescence intensity (F) as a function of CD concentration for solutions where the 
[TCH+] concentration was kept constant and equal to 1.0×10-5 M. The experimental data 
of F can be fitted to Eq. (2.9) (see solid lines in Figure 2.6), using a non-linear least-
square algorithm, to obtain the fitting parameters K and F∞, assuming a 1:1 complex was 
formed.  
 
Figure 2.6 Relative fluorescence intensity of tetracaine in the presence of β-CD and HP-β-CD. [TCH
+
]= 
1.0×10-5 M. Solid lines were obtained by fitting the experimental data to Eq. (2.9). 
Chapter 2 
57 
 
Further support for the 1:1 association assumption is observed from the linear 
relationship of ((F−F0)/[CD]T) as function of ((F−F0)) for β-CD and HP-β-CD respectively, 
indicating that a 1:1 interaction stoichiometry is occurring Figure 2.7 (Smith et al., 1991). 
This stoichiometry was also in agreement with complexation studies between TCH+ and 
CD reported elsewhere (Fernandes et al., 2007). The fitting parameters obtained by 
mapping the data to Eq. 2.9 (Figure 2.6) are: K=628 ( 24) M−1 and F∞=292 ( 3), and 
K=337 ( 11) M−1 and F∞=503 ( 4), for β-CD and HP-β-CD, respectively. It can be 
concluded from fluorescence spectroscopy studies, that TCH+ form more stable 
complexes with β-CD than with HP-β-CD. Since both TCH+ and HP-β-CD are highly 
soluble in water, it should be expected that a possible complexation would not cause a 
significant gain in the free energy of complexation. The same is not observed for β-CD, 
which can be justified by the relatively low solubility of this CD in water and 
consequently, the TCH+ induces a stabilization effect on the β-CD in water interaction. 
These K values are lower than those obtained for neutral TC by using phase solubility 
diagrams but indicate that although interactions between CD: TCH+ are weaker they 
should not be neglected. The TCH+ structure could be  incorporated inside CD cavity and 
if this was the case then the positive charge located at secondary amine induces a weak 
interaction between TCH+ and CD (when compared with the corresponding neutral 
structure). Alternatively the TCH+ may only interact with hydroxyl groups located at the 
extremities of the CD cavity. Although it is known that CD cavities can be penetrated by 
positive charged structures (Nilsson et al., 2008), the later hypothesis seems to be more 
reliable.  
 
Figure 2.7 Effect of the normalized fluorescence relative intensity by the initial concentration of cyclodextrin 
as a function of fluorescence relative intensity for assessment on the stoichiometry of association. (o) β-CD 
and (□) HP-β-CD. 
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2.3.3. NMR analysis of TCH+: CD complexes by 1H-NMR and 
ROESY 
In order to test if the TCH+ did penetrate the CD cavity the interactions between TCH+ 
and CD was characterized by 1H-NMR and ROESY analysis on 1:1 and 1:2 TCH+:CD 
mixtures. Figure 2.8 shows the ROESY spectrum for a 1:1 TCH+:HP-β-CD mixture. The 
attribution of each resonance on the 1D 1H-NMR spectrum is given on the projection. A 
full analysis of the cross-correlations present in the ROESY spectrum shows 
intramolecular nuclear Overhauser interactions between TCH+ protons (dotted lines) and 
HP-β-CD protons (solid lines), but not even a single intermolecular interaction between 
TCH+ and HP-β-CD protons. The absence of any intermolecular cross-correlation in 
ROESY spectra is evidence of the TCH+ inclusion by the CDs at pH 4.1, thus the TCH+ 
and CD interactions were assayed to the formation of fast equilibria hydrogen bonds.  
 
Figure 2.8 600 MHz 1H-NMR and ROESY spectra of a 1:1 complex of TCH+:HP-β-CD complex. 
Intramolecular nuclear Overhauser effects are detected for TCH+ (dotted lines) and HP-β-CD protons (solid 
lines). No intermolecular correlations are observed. 
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2.3.4. Effect of cyclodextrins on the tetracaine delivery: In vitro 
release studies 
2.3.4.1. Steady-state transport 
The transport of TC from the HPMC gels, in the presence of different amounts of HP-β-
CD, across the dialysis membrane, shows a steady state flux in the first 6 h of the 
experiment (see inset in Figure 2.9). It can be seen that Q6 (Table 2-2) decreases 
linearly with the increase of CD concentration, showing that CD controls the release of 
the drug.  
 
Figure 2.9 Cumulative release of neutral (a) and ionized (b) tetracaine across dialysis membrane as a 
function of time, at different initial cyclodextrin concentrations: (■,□) 190mM HP-β-CD, (●,○) 431mM HP-β-
CD and (▲,Δ)518mM HP-β-CD. Solid lines show the fitting of eq. (2.10) to experimental data. Inset figures 
show the steady state flux of TC (A) and TCH
+
 (B) occurring in the first 6 h of experiments. 
Such effect can be ascribed to the corresponding formation of less mobile 
supramolecular structures (Loftsson et al., 2007), which might be explained by the 
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occurrence of complexation equilibrium between the drug molecules and hydroxyl 
groups located at both ends of cyclodextrins cavities.  
The role of CD (either in the complex or free forms) on the transport of tetracaine can be 
assessed through the analysis of equilibria equations and the corresponding K values. 
Thus, for TC:HP-β-CD systems an increase of initial cyclodextrin concentration from 190 
to 518 mM leads to an increase of free CD concentration from 96 to 406 mM, which 
corresponds to an increase of free CD from 51 to 81 %, respectively. On the other hand, 
such increase of CD concentration only leads to a decrease of free TC from 1 to 0.2 %, 
giving indication that for both systems the amount of complexed TC is higher than 99%. 
Similar values are obtained for the ionized TC system. Once TC aggregation can be 
ruled out, it can be hypothesized that the increase of free CD plays an important role on 
the depletion of TC flux. 
Table 2-2 Effect of the HP-β-CD concentration on tetracaine delivery across dialysis membrane. 
Formulation J (µg cm
2
 h-1) Q6 (µg cm
2
) P (10
-3
cm
2
 h
-1
) 
TC: HP-β-CD (190mM) 203 ± 7 1215 ± 41 8.2 ± 0.3 
TC: HP-β-CD (431mM) 152 ± 5 923 ± 34 6.1 ± 0.2 
TC: HP-β-CD (518mM) 122 ± 5 740 ± 27 5.0 ± 0.2 
TCH
+
: HP-β-CD (190mM) 362 ± 22 2168 ± 146 14.5 ± 0.9 
TCH
+
: HP-β-CD (431mM) 234 ± 14 1415 ± 68 9.3 ± 0.6 
TCH
+
: HP-β-CD (518mM) 204 ± 6 1247± 41 8.1 ± 0.2 
2.3.4.2. Release kinetic models  
In the previous section we have found that the release of TC, either neutral or 
protonated, across the dialysis membrane, at short-range times, follows a steady-state 
flux. However, that is not valid for long-time range (i.e., for t > 6 h) (Figure 2.9). On the 
basis of the discussion carried out in the previous section it is expected that the release 
mechanism of TC can be described by a power law equation with the exponential factor 
around 1. In fact, taking into account the cumulative release of TC at equilibrium, and 
applying Eq. (2.13) in its linear form, we obtain n values ranging from 0.95 to 1.09 (Table 
2-3), for TC:HP-β-CD (190 nm) and TCH+:HP-β-CD (190 nm), respectively. Due to the 
cylindrical shape of the donor Franz cell compartment, those values are indicative of a 
complex mechanism, known as Super-Case II transport; such mechanism indicative of 
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coupling of diffusional and relaxational mechanism (Costa et al., 2011; Polishchuk and 
Zaikov, 1997), occurs for processes with n values higher than 0.89 (Costa et al., 2010) 
 Table 2-3 Fitting parameters of Eqs. (2.13) to (2.17) to experimental release data of 
tetracaine from HPMC matrices to receptor phase, at 37 ºC. 
  TC: HP-β-CD 
190 mM 
TC: HP-β-CD 
431 mM 
TCH
+
: HP-β-CD 
190 mM 
TCH
+
: HP-β-CD 
431 mM 
 C∞ (µM) 5801 4016 7521 7253 
PL* N 0.95 (± 0.05) 0.97 (± 0.04) 1.09 (± 0.03) 1.01 (± 0.04) 
 K 7.94×10
-6
  
(± 3.12×10
-7
) 
5.09×10
-6
 
(±1.90×10
-7
) 
3.86×10
-6 
 (± 9.80×10
-8
) 
5.17×10
-6
  
(± 1.61×10
-7
) 
 R
2
 0.9874 0.9888 0.9982 0.9945 
 MDT (h) 31.6 41.1 13.9 22.3 
FO k1 (h
−1
) 3.01×10
−6
  
(± 8.47×10
−8
) 
1.45x10
-06
  
(± 4.04×10
−8
) 
6.18×10
−6 
 (± 3.92×10
−7
) 
2.74×10
−6
  
(± 1.35×10
−7
) 
 R
2
 0.99294 0.99304 0.9649 0.97843 
SO K2 (M
−1
h
−1
) 4.37  
(± 0.18×10
-10
) 
1.76  
(± 0.03×10
−10
) 
1.32 
 (± 0.13×10
−9
) 
3.794  
(± 0.128×10
−10
) 
 R
2
 0.98539 0.99684 0.91521 0.98989 
W kW (h
−1
) 6.51×10
−6
  
(± 3.02×10
−7
) 
4.75×10
-6
  
(± 2.1×10
−7
) 
1.13×10
−5
  
(± 1.16×10
−6
) 
8.61×10
−6
  
(± 4.23×10
−7
) 
 D 1.06 (± 0.09) 1.12 (± 0.086) 0.87 (± 0.134) 1.03 (± 0.093) 
 R
2
 0.9876 0.98827 0.96447 0.98798 
* Fitting has been performed to cumulative release < 60%. R
2
: correlation coefficient; PL: power law Eq. (2.13); FO: first 
order, Eq. (2.15); SO: second order, Eq. (2.16); Weibull function, Eq. (2.17). 
The MDT parameter characterizes the drug release rate from a dosage form, indicating 
drug release delaying efficiency of the polymer; the MDT of the drug increases with CD 
concentration, from 32 to 41 h when the drug is in the neutral form (TC) and from 14 to 
22 h when it is in the ionized form (TCH+). However, by comparing these two forms of 
tetracaine, the effect is more pronounced for TCH+ (38 %) than for TC (23 %). It can be 
concluded from release data and mechanism analysis that TC release kinetics is 
dependent on the protonation state of TC and CD concentration. C∞ was determined for 
each formulation. By fitting of first- and second-order kinetics equations (eqs. 2.15 and 
2.16) to the experimental release data, we can conclude that, in general, good 
correlation coefficients were found for both cases. Assuming the analysis of those 
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correlation coefficients as a condition to conclude about what kinetics law characterizes 
a system, it was found that, for the release of TC in the presence of less concentrated 
CD, the release follows a first-order kinetics. However in the presence of the highest 
concentration of CD, the release of TC is characterized by a second-order kinetics law. 
This is close agreement with the previous discussion. When the CD increases from 190 
to 431 mM, the percentage of free (not bound) CD decreases from 47 % to 24 % for TC-
containing solutions (46 % to 23 % for TCH+- containing solutions). Consequently, for the 
most concentrated mix solution, the release is controlled by free and complexed TC, 
whilst for solutions with 190 mM CD, the release kinetics seems to be only dependent on 
the TC concentration. Considering the analysis of the rate constants, they are in close 
agreement with such a CD concentration effect (by decreasing with an increase of CD 
concentration). 
The equation that best fits the entire set of TC release data is the Weibull function (Eq. 
2.17). This empirical equation provides, simultaneously, information on the mechanism 
(d) and rate kW of release. d values are higher than 1 (except for TCH
+ with the lower CD 
concentration), characteristic of a sigmoid S-shaped, with upward curvature followed by 
a turning point concomitantly, and of a Super-Case II release. With respect to rate 
constants (kW), they are quite similar to those calculated through a first order rate law 
equation. It is also worth noticing that the release rate constants for the whole time range 
follows the same trend than that found for the first 6 h. Consequently, the Weibull 
function seems to be reliable for an assessment of both mechanism (d) and rate kW of 
release of TC. 
2.4. Conclusion  
The work presented in this Chapter focuses on the effects of CD on the transport of TC 
across a model membrane. The results obtained show that the interaction between CD 
and TC causes changes in water solubility (14 and 69-fold for β-CD and HP-β-CD, 
respectively) and release profile of the latter. HPLC and fluorescence spectroscopy data 
revealed that TC interacts with both CD (β-CD and HP-β-CD) on a 1:1 stoichiometry. An 
interesting finding arises from analysis of the stability constants between TC and both 
CD. These values are very similar for TC in its neutral form (1052 and 1051 M-1 for TC:β-
CD and TC:HP-β-CD respectively) but different when TC is ionized (628 and 337 M-1 for 
TC:β-CD and TC:HP-β-CD respectively), indicating that the TC forms more stables 
complexes with CD than with TCH+. Additionally, ROESY experiments provided specific 
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information concerning the non-inclusion nature of the interaction between TCH+ and 
cyclodextrins. Despite the stability constant values are relatively low, in vitro studies data 
show that the flux of TC and TCH+ across the dialysis membrane decreased with 
cyclodextrin concentration, following a Super-Case II transport mechanism. This work 
showed that such behavior does not depend on the formation of inclusion host-guest 
compounds, but due to the formation of weak supramolecular compounds. The 
conclusions obtained are very important as the CD concentration used was found to be 
critical; it should be sufficiently high to improve bioavailability of the drug, but not 
excessively as it could result in drug retention within the formulation. 
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Chapter 3 
3. Lysine-based surfactants as chemical permeation 
enhancers for dermal delivery of tetracaine and 
ropivacaine 
In this Chapter the studies between tetracaine and cyclodextrin (Chapter 2) are 
addressed, but now in a hydrogel formulation that includes new, biocompatible, lysine-
based surfactants. The efficacy of these surfactants as chemical permeation enhancers 
for these two different drugs was investigated. The cytotoxicity profiles and the effect on 
skin integrity by light microscopy and scanning electron microscopy (SEM) was also 
investigated. Molecular dynamics simulation (in silico) results provided a rationale for the 
experimental observations, introducing a mechanistic view of the action of the 
surfactants molecules upon lipid membranes.  
Based on the findings, this class of surfactants can be selected to influence the 
permeation of drugs without having significant deleterious effects upon the skin structure. 
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3.1. Introduction 
As previously mentioned, the stratum corneum is the outermost layer of the skin and it is 
a highly organized structure that constitutes the major barrier to the permeation of drugs 
applied topically. In order to reversibly alter the barrier properties of the SC, and 
consequently increase the efficacy of the delivery of drugs across the skin, many 
strategies have been employed (Madison, 2003b). Chemical penetration enhancers are 
compounds that are known to have the ability of reducing the barrier properties of the SC 
and also increasing the partition of the drugs to the skin – see section 1.3.2.2. (Asbill and 
Michniak, 2000; Bach and Lippold, 1998; Finnin and Timothy M. Morgan, 1999). 
However, the practical use of CPE requires a careful balance between the toxicity to the 
skin and permeation enhancement benefits. Surfactants comprise a broad class of 
amphiphilic compounds, with surface-active properties, consisting of a lipophilic chain 
linked to a hydrophilic headgroup. These compounds are usually added to formulations 
to solubilize lipophilic active ingredients and therefore have a great potential to be used 
as permeation enhancers. Some surfactants are used alone as CPE, or in combination 
with other active methods (Ashton et al., 1992; Babu et al., 2005a; Cappel and Kreuter, 
1991; Kitagawa et al., 2000; Nokhodchi et al., 2003; Shin et al., 2001; Shokri et al., 2001; 
Tan et al., 1993; Walters et al., 1993a). Surfactants have, in general, a low chronic 
toxicity (Williams and Barry, 2012), and the major concerns on its use in dermal delivery 
are associated to the possible occurrence of local irritation, erythema or itching, 
depending on the amphiphilic structure and concentration employed (Effendy and 
Maibach, 1995; Naik et al., 2000a; Scheindlin, 2004). 
Surfactants have often been used either incorporated in a vehicle or dissolved in a 
solvent system, and their activity has been found to be dependent on its lipophilicity, 
charge and chain length (Karande et al., 2005). Nonionic surfactants are generally 
regarded as safe, but reputedly at least as irritating as cationic surfactants, a fact which 
has not excluded its use in cosmetic formulations. Nonionic surfactants have also been 
reported as possessing antibacterial properties (Schott, 1985; Shukla and Tyagi, 2006b).  
Aminoacid-based surfactants, in particular, have attracted considerable interest because 
they are environmentally friendly due to their enhanced biodegradability (Brito et al., 
2009; Infante et al., 2004) and low ecotoxicity (Perez et al., 2005), and also for displaying 
a moderate human cytotoxicity, as determined by their alkyl chain length and headgroup 
properties (Macián et al., 1996; Sanchez et al., 2006; Silva et al., 2013b). It has been 
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found that these class of surfactants exhibit lower toxicity when compared with 
conventional surfactants, making them promising alternatives to commercially available 
anionic and nonionic surfactants in pharmaceutical and cosmetic formulations (Sanchez 
et al., 2004, 2006; Vives et al., 1999; Vives et al., 1997). Additionally, these surfactants 
seem to be promising candidates to be used in topical pharmaceutical formulations, 
since they are less irritating and more biodegradable than the commercially available 
surfactants already tested (e.g., hexadecyltrimethylammonium bromide  and sodium 
dodecyl sulphate) (Doi et al., 2001; Sanchez et al., 2004).  
Unlike conventional surfactants that are composed by a single hydrophobic tail 
connected to a polar headgroup, the lysine-based surfactants employed in this work 
consist of double-chained amphiphiles (Brito et al., 2008; Brito et al., 2013). In fact, as 
can be seen in Figure 3.1a, the lysine side chain (a four-methylene group) acts as a 
spacer group between the two (dissimilar) polar regions, which imparts the surfactants 
with a dimeric type structure. The molecules used are either anionic sodium 
alkylcarboxylates with C10, C12, C14 and C16 long alkyl chains, or nonionic ester 
derivatives with C10 and C16 chains (Figure 3.1b). 
 
 
Figure 3.1 Structure of anionic lysine-based surfactants (a), nLysn(-), where n is the alkyl chain length (n=10, 
12, 14, 16) and nonionic lysine-based surfactants (b) nLysn(0), where n is 10 and 16. 
The efficacy of these lysine-based surfactants as CPE for tetracaine (non-ionized and 
hydrophobic) and ropivacaine hydrochloride (ionized and hydrophilic) across newborn 
porcine skin was investigated following a methodology reported elsewhere (Silva et al., 
2012). The permeation in vitro studies were rationalized by molecular dynamics (MD) 
simulation, as a computational approach. Light microscopy and SEM techniques were 
employed to assess morphological changes of the skin in the presence of the CPE. 
Cytotoxic studies were subsequently performed in cultured human epidermal 
keratinocytes (HEK), establishing a concentration-toxicity response. Data collected from 
several complementary techniques provided new insight on the use of novel lysine-
based surfactants as penetrations enhancers, which is crucial for their prospective use 
as delivery agents. 
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3.2. Experimental section 
3.2.1. Materials 
TC, ammonium acetate, PG (Reagent Plus, 99%), sodium bicarbonate, glucose, 
penicillin G potassium salt and streptomycin were purchased from Sigma Aldrich (Saint 
Louis, MO, USA). RPC was a kind gift from AstraZeneca (London, United Kingdom), and 
HPMC K15M a kind gift from Dow Chemical Company (Midland, MI, USA). HP-β-CD with 
97% of purity, with an average degree of substitution of 2 to 6 units of 2-hydroxypropyl 
(C3H7O) per glucose unit, and with an average molecular weight of 1380 g/mol, was 
purchased from Acros Organic (Geel, Belgium). MeOH and ACN HPLC grade were 
purchased from LiChroSolv Merck (Darmstadt, Germany). PBS was purchased from TIC 
Gums (Belcamp, MD, USA). Newborn porcine skin tissue was obtained from young pigs 
(3 weeks, ~5 kg, acquired at a local slaughterhouse). The lysine-based surfactants used 
in this study were synthesized and purified according to a method described in previous 
works (Brito et al., 2006; Gomes et al., 2008). The purity of the compounds was 
determined by NMR, elemental analysis, surface tension and differential scanning 
calorimetry (DSC) (Brito et al., 2006; Brito et al., 2008; Gomes et al., 2008). The anionic 
lysine based surfactants, comprising 10, 12, 14 and 16 carbon atoms are referred in this 
manuscript as 10Lys10(-), 12Lys12(-), 14Lys14(-) and 16Lys16(-), in an obvious 
notation, while the nonionic ones are referred as 10Lys10(0), 16Lys16(0). The Tissue-
Tek® O.C.T™ compound was purchased from VWR international (Radnor, Pennsylvania, 
USA). Formaldehyde solution min. 37% was purchased from Merck (White House 
Station, NJ, USA). The Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum 
(FBS) and trypsin were purchased from Invitrogen™ (Carlsbad, CA, USA). HEK were 
obtained from DKFZ (Im Neuenheimer Feld, Heidelberg, Germany). Finally, the Alamar-
Blue® Cell Viability reagent was obtained from Thermo Scientific (Waltham, MA, USA). 
All reactants were used as received. 
3.2.2. Porcine skin preparation 
Newborn porcine skin tissue used as skin model, was excised and dermatomed using a 
Padgett® Model B Electric Dermatome (Integra LifeSciences, Plainsboro, NJ), Figure 3.2. 
The skin samples with 700 μm thickness were stored at −20ºC for no more than 3 
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months. Prior to the experiments, skin samples were thawed at room temperature, 
before immersion in PBS (pH=7.4) for 1 h, for equilibration. 
 
Figure 3.2 Dermatomed newborn porcine skin using a dermatome. 
3.2.3. Composition and preparation of the hydrogels and enhancer 
solutions 
Tetracaine hydrogel contained 2.5% (w/w) TC, mixed with appropriate amounts of HP-β-
CD (Teixeira et al., 2014b), 1% (w/w) HPMC K15M and deionized water. Ropivacaine 
hydrogel was composed of 2.5% RPC, 1% (w/w) HPMC and deionized water. The 
polymers solutions were kept stirring for 24 h before use at low speed (50 rpm) to ensure 
complete homogenization. The enhancer solutions were prepared at a concentration of 
0.15 M in PG by stirring at room temperature until complete solubilization. Generally, the 
compounds were soluble in PG at the concentration used, and produced clear solutions. 
However, when necessary, some samples were heated prior to use. 
3.2.4. In vitro permeation studies 
In vitro permeation studies were performed for 24 h using Franz diffusion cells 
(PermeGear, Inc., PA, USA) (Figure 3.3) with a diffusion area of 0.64 cm2 and a receptor 
compartment of 5.1 mL filled with PBS solution (pH=7.4). Dermatomed porcine skin 
pieces (0.70 mm thickness) were placed between the donor and receptor compartments, 
with the epidermal side up. The receptor medium was maintained at 37.0 ± 0.1 ºC and 
stirred at 600 rpm during the permeation experiments. The drug loaded hydrogel was 
placed in each donor compartment, and immediately covered with Parafilm® to prevent 
evaporation. At predetermined time points (0, 2, 4, 6, 8, 18, 20, 22 and 24 h) 300 µL 
samples were collected from the receptor compartment and immediately replaced with 
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300 µL of fresh PBS solution. Samples were kept in the refrigerator prior to HPLC 
analysis. All the skin samples, except the ones used in control, were pretreated with 60 
µL of the various enhancer solutions, for 1 h, prior to the application of the drug loaded 
hydrogel in the donor compartment (t = 0).  
 
Figure 3.3 Franz diffusion cells (PermeGear, Inc., PA, USA) with a diffusion area of 0.64 cm2 and a receptor 
compartment of 5.1 mL. 
3.2.4.1. Drug quantification 
All samples were analyzed using HPLC. The system consisted of a Shimadzu LC-20AD 
apparatus equipped with a quaternary pump, an autosampler unit, and a L2450 
UV/visible dual wavelength detector. The quantification of TC and RPC were carried out 
using a reverse-phase C18 column (250 x 4.6 mm C18 (2) 100 A Luna 5 µm, 
Phenomenex® (Torrance, CA, USA) with a guard column as the stationary phase, at 
25°C. The mobile phase was prepared by mixing methanol, acetonitrile and ammonium 
acetate solution on the proportions 7:7:6 respectively. The solution was subsequently 
filtered using a 0.45 µm Nylon membrane (Supelco Analytical, Bellefonte, USA) and 
sonicated for 1 h prior to use. The flow rate was set to 1.0 mL/min and the injection 
volume was 25 µL. TC was detected at 311 nm and the retention time was ca. 6.9 
minutes. The method showed a linear response in the 0.1–100 µg range (R2 = 0.9999) 
with a daily relative standard deviation (RSD) < ± 5.0%. RPC was detected at 210 nm 
and the retention time was ca. 9 minutes. The method showed a linear response in the 
0.1-50 mg/mL (R2=0.9998) with a daily RSD < ± 6.0%.  
3.2.4.2. Data analysis in the permeation studies 
According to Fick’s first law of diffusion, the steady state flux (µg cm-2 h-1), J, can be 
expressed by Eq. 3.1 
𝐽 =
𝐷𝐶0𝑃
ℎ
          (3.1) 
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where D is the diffusion coefficient of the drug in the SC, C0 represents the drug 
concentration applied in the donor compartment, P is the partition coefficient between 
vehicle and the skin and h is the diffusional path length. The flux J can be calculated 
from the slope of the linear portion of the plot of cumulative drug amount permeated per 
unit area. Also calculated was Q24, the cumulative drug amount present in the receptor 
compartment solution after 24 hours, expressed in µg/cm2 (Eq. 3.2) 
𝑄𝑛 =  (𝐶𝑛  × 𝑉0 +  ∑ 𝐶𝑖  ×  𝑉𝑖
𝑛−1
𝑖=1 )/𝐴      (3.2) 
where Cn corresponds to the drug concentration in the receptor medium, Ci is the 
concentration in the sample, A is the diffusion area, V0 and Vi stand for the volumes of 
the receptor compartment and the sample. The enhancement ratio (ER) for flux was 
calculated using Eq. 3.3 
𝐸𝑅 =
flux for treated skin with enhancer
flux for untreated skin (control)
       (3.3) 
Results are presented as mean ± standard deviation (n), where n is the number of 
replicates. Differences between flux values were examined for significance using 
unpaired Student’s t-test. The p value was set to 0.05, with p < 0.05 indicating statistical 
significance in the differences between control and enhancers tested. 
3.2.5. Simulation details 
The effect of the introduction of the lysine-based surfactants on a fully hydrated 
dipalmitoylphosphatidylcholine (DPPC) bilayer was studied by molecular dynamics 
simulation. DPPC is a relatively common lipid often chosen to monitor membrane 
structure and dynamics when exposed to external agents (Almeida et al., 2010; Bennett 
et al., 2009; Kukol, 2009). This simple and well-characterized model has been used 
specifically in studies similar to that described in this work, so as to assess effects on the 
permeation and membrane behavior (Almeida et al., 2011; Cerezo et al., 2011; 
Gurtovenko and Anwar, 2007; Kyrikou et al., 2004; Notman et al., 2006). DPPC and SPC 
(simple point charge) water were described using the original definitions of the GROMOS 
53a6 force field (Schuler et al., 2001). This force field and variants have been extensively 
used for modeling membrane properties along with a variety of organic molecules 
(Bennett et al., 2009; Piggot et al., 2012; Poger and Mark, 2009; Schuttelkopf and van 
Aalten, 2004). Supported on this force field, topology for each surfactant was generated 
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using the ATB (Malde et al., 2011) platform. A DPPC bilayer, consisting of 128 
phospholipid molecules equally distributed by two leaflets and 3655 SPC water 
molecules was used, as made available by Kukol (Kukol, 2009). In each system, a single 
molecule of surfactant was considered. This was found suitable for studying the 
interaction of each solute with the surrounding lipids, as well as assessing the 
preferential positioning and respective action on the bilayer. The system was solved 
using the GROMACS package, version 4.5.5 (Hess et al., 2008; van der Spoel et al., 
2012). All MD simulations were carried out in the NPT ensemble and under periodic 
boundary conditions. A standard time step of 2 fs was used for both the equilibration and 
production runs. Non-bonded interactions were computed on the basis of a neighbor list, 
updated every 10 steps. Long-range electrostatic contributions were computed using the 
particle mesh Ewald (PME) method. For Lennard–Jones energies, a cut-off of 1.4 nm 
applied. Temperature and pressure were coupled to the Berendsen external baths, 
maintained at 325 K and 1 bar, with coupling constants of 0.1 and 0.5 ps, respectively. 
To obtain the starting configuration, each system was firstly subjected to an energy 
minimization step. The systems were then left to evolve for up to 80 ns, using the LINCS 
algorithm (Hess et al., 1997). The first 20 ns were considered sufficient to attain 
equilibration, while the last 60 ns of the production runs were subsequently subjected to 
standard analysis, including the determination of order parameters, mean square 
displacements (MSD), density probability distributions and radial distribution functions 
(rdf). MD trajectories were visualized, and configuration images extracted using the VMD 
1.9 software (Humphrey et al., 1996). 
3.2.6. Skin integrity evaluation 
After the permeation studies, skin samples were rinsed with deionized water, dried and 
stored at -20ºC. These samples were later investigated for the occurrence of 
morphological changes caused by the CPE and methodology employed. 
3.2.6.1. Histology- light microscopy studies  
Skin samples used in the permeation studies were carefully cut in small pieces and fixed 
with 10 % of buffered formalin during 24 h at room temperature. They were subsequently 
dehydrated with different volumes of ethanol (50 %, 75 %, 95 %, and 100 %) for 1 h 
each, and embedded in Tissue-Tek® O.C.T. and frozen (Hoppert, 2003). Cross-section 
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slices of 7 m thickness were obtained using a cryostat (Figure 3.4) SLEE medical 
GmbH (Carl-Zeiss, Mainz, Germany).  
 
Figure 3.4 Cryostat for the cross-section slices.  
The samples were subsequently stained following the Ellis Hematoxylin and Eosin (H&E) 
staining protocol (Ellis, 2010) and were analyzed using a Nikon Eclipse 50i light 
microscope (Melville, NY, USA) at 10, 20 and 40 magnifications. A Nikon Digital Camera 
(Model DS-FI 1) equipped with a Digital Sight DS-U2 microscope camera controller was 
used to capture images. Images were processed using NIS-Elements Imaging Software. 
3.2.6.2. Scanning Electron Microscopy studies  
SEM analysis was performed in order to investigate the morphological characteristics of 
the skin that could not be observed using conventional light microscopy. After the in vitro 
studies, the skin samples were placed in a plastic former, were submerged in Tissue-
Tek® O.C.T. and frozen. Cross-section slices of the frozen samples were cut (10 m 
thickness) using a cryostat SLEE medical GmbH (Carl-Zeiss, Mainz, Germany).  
Skin samples were defrosted, washed and fixed with formalin for 1.5 h and subsequently 
rinsed and placed in deionized water, at room temperature, for 2 h. They were 
subsequently dehydrated using solutions of 30 %, 50 %, 75 %, and 95 % ethanol in 
water for 25 minutes and finally, were put in two changes of absolute ethanol (100 %) for 
2 h, at room temperature. Prior to analysis, the sample was placed on a double-side 
carbon tape mounted onto an aluminum stud, and dried in a desiccator. The sample was 
then coated with gold in order to make it conducting. Surface and cross-sections pictures 
of the samples were taken using SEM – JEOL, model JSM-6010LV/6010LA. 
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3.2.7. Cytotoxicity studies  
Cell viability was evaluated by the Alamar Blue assay protocol. Alamar Blue cell viability 
assay is a colorimetric method used to determine the number of viable cells in 
cytotoxicity assays, widely reported in the literature for similar systems (O'Brien et al., 
2000). Viable cells are able to reduce the resazurin compound [7-Hydroxy-3H-
phenoxazin-3-one-10-oxide sodium salt] (a non-fluorescent blue dye) into resorufin (pink 
colored and fluorescent). The number of viable cells is directly proportional to the 
quantity of resorufin product formed as measured by the absorbance at 570 and 600 nm 
(alamarBlue® Cell Viability Assay Protocol). The levels of resorufin formed were 
quantified using a Microplate Power Wave X Scanning Spectrophotometer (Bio-TEK 
Instruments, Inc. Winooski, VT, USA). Cytotoxicity studies were carried out in cultured 
human keratinocyte cell line HaCaT with a density of 0.1x105/mL, in a final volume of 0.2 
mL/well under sterile conditions. Subculturing was performed by splitting cells at ratios 
between 1/5 and 1/10 and cells were used after reaching 70–80 % confluence. HaCaT 
was seeded in 96-well plates in 200 L/well of DMEM® medium supplemented with 
sodium bicarbonate (3,7 g/L), glucose (25 mM), 10% heat inactivated FBS, 100 U/mL 
penicillin, and 100 µg/mL streptomycin and were incubating for 24 h at 37 ºC, 5 % CO2 
and 90 % R.H. After seeding, the culture medium was removed and cells were exposed 
to medium (control) and various concentrations, 1600 (S1), 160 (S2), 16 (S3), 1.6 (S4), 
0.16 (S5) M of 10Lys10(-), 12 Lys12(-), 14 Lys14(-), 16Lys16(-), 10Lys10(0), 
16Lys16(0) solutions in PG, diluted in culture medium and were placed in the incubator 
for another 24 h in the same environmental conditions. After 20 h of reagents exposure, 
50 μM of resazurin solution (in sterile PBS) was added to each well and the plates were 
read after 4 h. Results are presented as % cell viability (mean ± standard deviation, n=3), 
C.V. calculated according to Eq. 3.4 
𝐶. 𝑉. =
abs read in treated cells
abs read in control (untreated) cells
 × 100      (3.4) 
3.3. Results and Discussion 
3.3.1. In vitro permeation studies using lysine-based surfactants 
Firstly, the focus is the analysis of six lysine-based surfactants as CPE. Each of these 
surfactants will be, in turn, used for the two drugs employed in this study. 
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3.3.1.1. Percutaneous drug delivery of tetracaine 
Surfactants were dissolved in PG at a concentration of 0.15 M. The respective solutions 
were applied to the epidermal side of dermatomed porcine skin placed between the 
donor and receptor compartments of Franz diffusion cells for 1 h prior to the application 
of tetracaine loaded hydrogels. The tetracaine permeation results obtained are 
presented in Table 3-1 while the permeation profiles are shown in Figure 3.5. 
Table 3-1 Effect of the chemical permeation enhancers on percutaneous permeation of tetracaine across 
porcine skin samples. Data are presented as means ± S.D. (4≤N≤6). 
Penetration modifier Flux / µg cm
-2
 h
-1
 Q24 / µg cm
-2
 ER 
Control - PG 19.83 ± 2.47 417 ± 53 - 
0.15 M 10Lys10(-)  15.31 ± 0.61 335 ± 16 0.77 
0.15 M 12Lys12(-)  19.88 ± 0.58 429 ± 15 1.00 
0.15 M 14Lys14(-)  20.32 ± 0.91 449 ± 15 1.02 
0.15 M 16Lys16(-)  25.21 ± 2.52 563 ± 44 1.27 
0.15 M 10Lys10(0)  20.75 ± 0.67 463 ± 16 1.05 
0.15 M 16Lys16(0)  26.31 ± 2.68 620 ± 71 1.33 
 
Figure 3.5 Cumulative amount of tetracaine permeated across porcine skin as a function of time. Skin was 
pretreated for 1 h with enhancer solutions in PG, prior the start of the permeation experiments. 
The lysine-based surfactants tested, generally caused an increase on tetracaine 
permeation, when compared to the control as measured by the flux (19.83 µg cm-2 h-1), 
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with the exception of 10Lys10(-), which displayed a value of 15.31g cm-2. Surfactant 
16Lys16(0) has shown to be the most effective permeation enhancer, resulting in a 1.33-
fold increase of the ER, closely followed by 16Lys16(-) (ER = 1.27). In contrast, lysine-
based surfactants with shorter alkyl chains (10Lys10(0), 10Lys10(-); 12Lys12(-) and 
14Lys14(-)) did not promote a significant increase in terms of drug permeation. 
3.3.1.2. Percutaneous drug delivery of ropivacaine 
The results obtained with ropivacaine in its salt form are summarized in Table 3-2 and 
Figure 3.6. It should be noted that the overall effect of the surfactants on the 
percutaneous drug delivery of ropivacaine is clearly different from that of tetracaine 
(base form). All anionic surfactants statistically increased the ropivacaine permeated 
after 24 h, when compared to control. In contrast, nonionic surfactants did not affect 
significantly the ropivacaine permeation. 
Table 3-2 Effect of the chemical permeation enhancers on percutaneous permeation of ropivacaine across 
porcine skin. Data are presented as means ± S.D. (6≤N≤9). 
Penetration modifier Flux (µg cm
-2
 h
-1
) Q24 (µg cm
-2
) ER 
Control – PG 1.94± 0.10 36.87 ± 0.67 - 
0.15 M 10Lys10(-)  3.95* ± 0.24 86.63* ± 4.32 2.03 
0.15 M 12Lys12(-)  5.46 ± 0.34 103.57 ± 6.43 2.81 
0.15 M 14Lys14(-)  8.27* ± 0.48 172.75* ± 11.40 4.26 
0.15 M 16Lys16(-)  11.89* ± 0.55 237.49* ± 17.03 6.12 
0.15 M 10Lys10(0)  1.64 ± 0.13 31.02 ± 1.70 0.89 
0.15 M 16Lys16(0)  1.79 ± 0.10 34.45 ± 2.14 0.92 
* Statistically significant difference between enhancer and control at p < 0.05 (Student’s t-test) 
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Figure 3.6 Cumulative amount of ropivacaine permeated across porcine skin as a function of time. Skin 
sample was pretreated for 1 h with enhancer solutions in PG, prior the start of the permeation experiments. 
The anionic 16Lys16(-) surfactant was the most effective CPE with a 6-fold increase in 
the flux, followed by 14Lys14(-), with a value of 4, 12Lys12(-), with 3, and 10Lys10(-), 
with 2. In contrast, both nonionic surfactants (10Lys10(0) and 16Lys16(0)) have shown a 
modest performance in terms of penetration enhancement, causing only a slight increase 
in the value of the flux of ropivacaine permeated, which is not statistically significant. In 
terms of the amount of drug permeated in 24 h (Q24), it was observed that the anionic 
surfactants also performed better, with a significant increase in Q24 (36 to 238 µg/cm
2). 
3.3.1.3. Overall behavior  
It is known that the effect of surfactants on the skin are complex and the mechanisms 
are based on different factors that affect permeability (Torchilin, 2001). The protective 
lipid barrier of skin is composed of highly organized lipid layers located between the cells 
of SC. Surfactants may interact with the lipid bilayers, disorganizing them and therefore 
altering the skin barrier function. However, these effects depend on the surfactant 
structure, since both the hydrophobic alkyl chain and the hydrophilic headgroup exhibit 
some influence. It was observed that the most effective CPE are those with the longest 
alkyl chains. 
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Figure 3.7 ER obtained pretreating the skin using the various CPE for tetracaine. 
In the case of tetracaine (Figure 3.7) the maximum ER was found with the nonionic 
lysine surfactant with 16 carbons (16Lys16(0), ER=1.3), while the least effective was the 
anionic compound with the shortest chain (10Lys10(-)). However, the trend changes 
when the drug is in ionized (cationic) form. In the case of ropivacaine (Figure 3.8) the 
anionic surfactant 16Lys16(-) was clearly the most effective CPE accounting for a 6-fold 
increase in the flux. The effects of both 16Lys16(0) and 10Lys10(0) were found 
negligible in comparison with the control. 
 
Figure 3.8 ER obtained pretreating the skin using the various CPE for ropivacaine. 
The anionic surfactants are likely to strongly interact with both keratin and lipids, 
producing large alterations in the barrier properties (Rieger and Rhein, 1997). An 
additional mechanism involves the hydrophobic interaction of the alkyl chain with the skin 
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structure, which leaves the end carboxylate group of the surfactant exposed, creating 
additional sites in the membrane where the drug may permeate. This may result in the 
development of repulsive forces that separate the protein matrix, uncoil the filaments, 
and expose more water binding sites, hence increasing the hydration level of the skin 
(Froebe et al., 1990) (see next section). Anionic surfactants may cause a larger 
enhancement than nonionic surfactants, but the effects probably are dependent on the 
exposure time (Williams and Barry, 2012). 
Another related effect to be taken into account is that the anionic headgroup of the 
n(Lys)n(-) compounds may promote electrostatic interactions with the ropivacaine 
molecules in their cationic form (HCl salts). In fact, once inserted in the skin bilayer 
membranes, the anionic surfactants might well enhance surface binding and overall 
permeation of the drug owing not only to direct coulombic anionic-cationic interactions 
but to the entropy increase associated with counterion release (sodium and chloride ions 
in this case). These findings are consistent with previous work in which terpenes and 
alkylammonium C12-Gemini surfactants were used as CPE for drugs with different 
hydrophobicities and charge (El-Kattan et al., 2001; Silva et al., 2013a). 
3.3.2. Molecular dynamics simulations 
In an attempt to provide molecular-level insight into the permeation effects induced by 
the lysine-based surfactants, MD simulations were carried out. The procedure described 
in Section 3.2.5. was applied to five systems, a neat DPPC bilayer, as reference, and 
four other systems comprising DPPC and one molecule of lysine-based surfactants, both 
anionic and nonionic, with different tail lengths. The latter were denoted DPPC/10Lys10(-
), DPPC/16Lys16(-), DPPC/10Lys10(0), DPPC/16Lys16(0), in an obvious notation. The 
vertical positioning of some key groups relative to the membrane center was firstly 
analyzed, resorting to the probability density functions. This analysis provides relevant 
information about the structural modifications induced on DPPC bilayers as a 
consequence of the surfactant molecule incorporation.  
Figure 3.9 depicts the density profiles of these groups across the bilayer, namely the 
positioning of the P and N atoms of the headgroups and the terminal methyl groups of 
DPPC. The nitrogen atom of the surfactant headgroups and the respective end methyl 
groups of the surfactant tails were also considered. The distributions of the SPC water 
molecules and the polar heads of DPPC, represented by the nitrogen atom, are 
symmetrical around the center of the z-coordinate, being depicted in both sides of the 
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bilayer. On the other hand, the distribution of the terminal methyl groups of DPPC appear 
as a single curve with its maximum at Z=0, indicating a clear overlapping of the terminal 
part of both leaflets.  
Additionally, the distributions concerning the nitrogen atom of the surfactants reflect the 
presence of only one molecule. Also included in the representations is the center of 
mass of each molecule. The profile of characteristic groups referring to the single-
component DPPC system, shown in Figure 3.9 - panel (a), agrees with the data reported 
in the literature (Vitorino et al., 2013). The incorporation of the surfactant molecules 
(Figure 3.9 - panel (b) to (e)) introduces some modifications in the bilayer structure. From 
panels (d) and (e) it is seen that the lysine-based nonionic surfactants are mostly 
embedded in the hydrophobic region, while anionic molecules (panels (b) and (c)) are 
preferentially positioned close to the interface, as can also be seen in Figure 3.10, in 
which four representative snapshots are presented.  
The anionic surfactants, as a consequence, interact more strongly with the lipid polar 
heads, displaying a reduced probability of crossing the center of the bilayer. Additionally, 
the polar heads of both anionic surfactants (represented by the nitrogen atoms) are fully 
embedded in the membrane. The more hydrophilic nature and the smaller tail length of 
the anionic 10Lys10(-) molecule prevent the terminal methyl groups from reaching the 
center of the bilayer. In contrast, the end methyl groups of the anionic 16Lys16(-) 
surfactant tails are almost leveled with those of DPPC, fully reaching the inter-leaflet 
region. As it was already observed for the shortest anionic surfactant, the polar heads 
are placed below those of DPPC. In panels (d) and (e) of Figure 3.9, the wide distribution 
of the surfactant polar heads indicates that the mobility into the membrane is high, and 
even the polar heads are fully embedded in the inter-leaflet region of the DPPC 
membrane (Figure 3.9 - panel d).  
The nonionic 10Lys10(0) molecule, panel (d), is likely to be found at the inter-leaflet 
region, easily switching between the two leaflets, as suggested by the MSD profile of 
DPPC  obtained from the simulation trajectories (Figure 3.11). Based on the MSD 
results, the anionic 10Lys10(-) molecule is, among the lysine-based surfactants under 
study, the one that promotes the highest lateral diffusion of DPPC molecules. 
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Figure 3.9 Probability density profiles of key atom/groups relative to the Z-axis, extracted from the MD 
simulations carried out at 50°ºC for (a) single DPPC, (b) DPPC/10Lys10(-), (c) DPPC/16Lys16(-), (d) 
DPPC/10Lys10(0) and (e) DPPC/16Lys16(0) systems. SPC water groups (••); DPPC groups - ammonium 
nitrogen (dark blue), and end methyl groups of tail chains (black); surfactant groups – ammonium nitrogen 
atoms (blue) and terminal methyl groups of both tails (red). The Z-coordinate represents the normal to the 
bilayer plane. 
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Figure 3.10  Representative configurations, showing the positioning of lysine-based molecules embedded in 
the bilayer. Water, surfactant molecules and DPPC are represented in red, light and dark blue, respectively. 
 
Figure 3.11 Mean square displacements of DPPC molecules, calculated from the MD simulations for the 
DPPC/lysine-based systems. 
A more detailed analysis on the order of the membrane is presented from the estimated 
order parameter, SCD, for the carbon atoms in DPPC tails (Figure 3.12). All the 
surfactants, with the exception of the longest anionic molecule, 16Lys16(-), induce a 
similar disordering effect close to the interface. A strongest action is observed for the 
nonionic 16Lys16(0) and 10Lys10(0) surfactants in comparison to that of 16Lys16(-). For 
the internal part of the carbon tails, the main differences appear between carbons 5 and 
10. The effect of the longest anionic surfactant (16Lys16 (-)) increases, while the effect 
of its nonionic homologous decreases. On the most internal part of the membrane, the 
shortest tail nonionic surfactant (10Lys10(0)) presents a higher disorder effect, with a 
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behavior similar to that of both anionic molecules and nonionic 16Lys16 for the terminal 
carbon. 
 
Figure 3.12 Deuterium order parameter, SCD, estimated from the MD simulations, along the bilayer depth for 
DPPC chains, averaged over sn-1 and sn-2 chains, in the presence of the lysine-based surfactants. 
Changes in the hydration level were also assessed by the analysis of rdfs of SPC water 
molecules around the polar heads of both DPPC and surfactants, represented by the 
ammonium groups (Figure 3.13). In what concerns the polar heads of DPPC, Figure 3.13 
- panel (a), it is observed that the presence of the surfactants molecules promotes a 
decrease in the amount of water accessible. However, no significant differences were 
found in terms of the hydration of the ammonium groups of DPPC in the presence of the 
different surfactant structures. Conversely, for the surfactant polar heads, panel (b), the 
same analysis indicates an increased solvation of the anionic molecules. Figure 3.14 
presents the rdfs of SPC water molecules relative to the carbonyl-ester atoms of DPPC 
chains (panel (a)) and the surfactants polar heads. No significant differences were found 
in terms of the hydration of the carbonyl-ester atoms of DPPC tails, corresponding to the 
upper part of the hydrophobic region. From panel (b), an increase in the amount of water 
is observed in the proximity of the anionic molecules. In contrast, panel (c) shows the 
absence of water close to the nonionic molecules. Such behavior is compatible with the 
previous analysis: nonionic molecules are fully embedded in the inter-leaflet region of the 
DPPC membrane, which may explain their reduced action upon permeation. 
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Figure 3.13 Radial distribution function of water molecules relative to DPPC (panel (a)) and lysine-based 
surfactants (panel(b)) ammonium groups, calculated from the MD simulations carried out at 50°C. 
 
Figure 3.14 Radial distribution functions of water molecules around the carbonyl-ester atoms for the sn1 and 
sn2 chains of DPPC (panel (a)) and the polar heads for both anionic (panel (b)) and nonionic (panel (c)) 
lysine-based surfactants. 
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3.3.3. Skin integrity  
Histology-light microscopy and SEM were used to visualize potential morphological 
changes and effects on the skin after the in-vitro studies caused by the use of the 
chemical penetration enhancers and formulations. 
3.3.3.1. Histological studies 
After the permeation studies, the skin samples pretreated with various lysine-based 
surfactants were stored at -20ºC. Prior to use, the samples were defrosted and submitted 
to histological procedures for observation using light microscope at different 
magnifications (10x, 20x and 40x). 
 
Figure 3.15 Pictures of control porcine skin sample taken in an optical light microscope at different 
magnifications: 10x - a), 20x - b), 40x - c). 
 
Figure 3.16 Pictures of porcine skin sample used in the permeation studies, taken at different magnifications: 
10x - a), 20x - b), 40x - c) after permeation experiments employing (16Lys16(-)), the most effective CPE. 
It can be observed that no significant morphological or structural changes have been 
detected when comparing the control samples (Figure 3.15) with the surfactant treated 
ones (Figure 3.16). Although minor changes were visible regarding cell cohesion, with 
some areas of the SC detaching or peeling off from the adjacent layer. However this 
effect can be related to the sample handling, since this is also observed in the control 
skin samples. 
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3.3.3.2. Scanning Electron Microscopy studies  
Skin integrity evaluation was further analyzed by using SEM studies after the drug 
permeation experiments in order to observe the occurrence of potential harmful effects 
caused by the use of CPE. This technique has a large depth of field compared to 
conventional light microscopy and for that reason the images obtained have a three-
dimensional appearance, high-resolution at high magnifications, revealing details of the 
surface of the skin. 
 
Figure 3.17 SEM cross section of control porcine skin sample at 400x, 600x and 1000x magnification. 
From the images it can be seen the details of the skin structure with different layers such 
as the SC (the outermost multi-layered structure), viable epidermis (the darker area) and 
dermis (the thicker structure mostly composed of connective tissue under the viable 
epidermis). Unlike the control samples shown in Figure 3.17 presented for comparative 
purposes, the pictures presented in Figure 3.18 were obtained from skin samples 
previously used in the permeation studies, reported in section 3.2.4. It can be observed 
that some SC cells are naturally shedding however this effect can be seen both in the 
control and treated samples. Also noticed is some expected variability between the 
samples analyzed, mostly regarding the thickness of the SC, but changes or damage to 
the skin structure caused by the CPE used that could result in permanent alterations or 
loss of integrity are not detected. 
 
Figure 3.18 Skin samples treated with the anionic surfactant 16Lys16 at 400x, 600x and 1000x magnification 
taken after permeation studies. 
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3.3.4. Cytotoxicity studies 
Skin irritation is a reversible inflammatory reaction produced by the arachidonic acid 
cascade and cytokines in the viable skin cells like keratinocytes and fibroblasts. To 
determine the cytotoxicity profiles of all CPE used in this work, cultured human epidermal 
keratinocytes (Figure 3.19) were exposed to various concentrations of the lysine based 
surfactant, following the Alamar assay protocol (O'Brien et al., 2000).  
 
Figure 3.19 Pictures of cultured HEK 20x (on the left) and 40x (on the right), seeded at 10.000 cells/well in 
appropriate culture medium, prior to the start of the Alamar Blue assay. 
To ensure the linearity of the Alamar Blue assay method used, standard plots for HEK 
(R2 = 0.975) were constructed based on the absorbance readings at 570 and 600 nm for 
0, 10.000, 20.000, 40.000, 60.000 cells/well. Although, the groups of cells cultured for 
the alamar assay is noticeably less complex in number and in cell types when compared 
to the skin tissue, the results are a good indication of potential, relative toxicity and 
irritation of these compounds to the skin cells. The results obtained in the Alamar Blue 
assays are presented in Figure 3.20. 
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Figure 3.20 Alamar Blue assay results for HEK. The bars represent the cell viability (%) for each permeation 
modifier and concentration tested. The error bars represent the standard deviation (n=6).  
The results summarized in Figure 3.20, demonstrate that HEK show a good tolerance to 
the presence of all the CPE tested, as the cell viability is similar to the control. PG 
exposure resulted in a slight reduction in HEK viability (20 %), yet not statistically 
significant from the control. It can be concluded that all the concentrations tested are not 
considered harmful to the cells, as the cell viability is always close to PG. Note that the 
presence of an hydrogel in the actual formulations has probably some impact on the 
diffusion of the molecules under scrutiny, but it is not likely to promote an overall change 
in the respective effect upon living cells. A global analysis of the Alamar assay results 
obtained with HEK suggests that the cytotoxicity of the surfactants studied it is not 
dependent on the alkyl chain length. 
3.3.5. Analysis of trends and effects 
In this work it is observed that all the surfactants act as chemical permeation enhancers, 
with different degrees of efficacy. The simulation results sum up to the experimental 
data, including data on, e.g., the order parameter and diffusion, both indicating a certain 
degree of membrane perturbation. The experimental results pointed out to a more 
pronounced effect of the anionic surfactants, a result that is also observed in the 
molecular dynamics studies. The incorporation of the nonionic surfactants in the interior 
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of the lipid membrane, should promote the permeation of hydrophobic drugs (albeit 
marginally) and, in contrast, preclude that of ionic drugs, as indeed experimentally 
observed. In terms of the variation in effect due to chain length, there is no visible 
correlation between experimental and simulation data. All the surfactants employed 
seemed to promote a limited degree of membrane disruption, as computationally 
extracted, which is in direct agreement with the absence of cytotoxicity found for the 
concentrations employed. As previously discussed, in the case of ropivacaine, one 
cannot discard electrostatic effects by the anionic surfactants, which should favor binding 
and thus enhanced permeation of the cationic drug (an effect particularly significant for 
the C16 compound). 
3.4. Conclusions 
This work presents a systematic approach to the use of a series of lysine-based 
surfactants as permeation. The two classes of lysine-based molecules, anionic and 
nonionic, possess varying alkyl chain length, comprising 10, 12, 14 or 16 carbon atoms 
for the anionic and 10 and 16 for the nonionic. It was observed that the most effectives 
CPE were the compounds with the longest alkyl chain (16Lys16) for both drugs. The 
highest enhancing effect was achieved for ropivacaine, presumably due to a combination 
of membrane perturbation, surface exposure of the anionic surfactant headgroups and 
ensuing favorable electrostatic interactions with the drug. In this case, the 16Lys16(-) 
was the most effective (ER=6.12), while in the case of tetracaine this was observed for 
16Lys16(0), likely due to a combined perturbation/hydrophobic effects (comparatively 
weaker, in any case, than the electrostatic effect mentioned above). Results thus 
suggest that lysine-based surfactants are promising candidates to increase drug 
transport, especially for hydrophilic drugs, through the SC without changing the skin 
tissue morphology and with the advantage of being non cytotoxic. Molecular dynamics 
simulations have proved to be a useful tool for a mechanistic rationalization of the 
system behavior. 
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Chapter 4 
4. Serine-based gemini surfactants: a comprehensive study 
on structure-activity relationships, molecular dynamics and 
skin penetration enhancement of local anesthetics  
This Chapter provides new insights on the efficacy of biocompatible, serine-based 
gemini surfactants as CPE for tetracaine and ropivacaine. In vitro permeation and in 
silico studies combined with cytotoxicity profiles were performed to obtain relevant data 
on the permeation of both drugs and how such interactions affect the skin integrity. 
Results show that the selected permeation enhancers do not have significant deleterious 
effects on the skin structure and do not cause relevant changes on cell viability. Cationic 
chemical enhancers with long alkyl chain and shorter spacer showed to be the most 
promising chemical permeation enhancers for both drugs. Molecular dynamics 
simulation results provided a mechanistic view of the action of the surfactants molecules 
on lipid membranes that essentially corroborated the experimental observations. 
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4.1. Introduction 
The principal goal in the development of dermal drug delivery systems is the temporary 
disturbance of the skin barrier without causing negative effects such as erythema, itching 
and local irritation (Effendy and Maibach, 1995; Naik et al., 2000b). 
Surfactants are amphiphilic molecules that are employed in a wide range of technical 
applications, such as cosmetic, drug delivery and food formulations, and in fundamental 
studies as models for biological membranes. Surfactants have also been used as 
chemical permeation enhancers (CPE) because they are able to improve drug 
permeation across the skin due to a combination of various mechanisms, including 
increasing the diffusivity and/or in the solubility of drugs in the skin and by reversible 
change of the lipid organization of the stratum corneum (SC), with a consequent 
reduction in the diffusional resistance (Almeida et al., 2010; Karlsson et al., 2002; Kirby 
et al., 2003). The use of this class of compounds must be carefully monitored as local 
irritation of the skin may occur, depending on the nature and concentration employed. 
Intense efforts have been made to solve this problem, including the incorporation of 
natural amino acids, sugars, and fatty acids in the surfactant structure (Blunk et al., 
2006; Clapés and Rosa Infante, 2002; Moran et al., 2004). As a result of the search for 
novel surfactants with higher efficiency, better biocompatibility and biodegradability 
profiles, gemini surfactants have been extensively explored (Borde et al., 2008; Infante 
et al., 2010; Menger and Littau, 1993; Tehrani-Bagha et al., 2007; Zana et al., 1991). 
Unlike conventional monomeric surfactants, which are usually composed by one or two 
hydrophobic tails connected to a single polar head group, gemini surfactants consist of 
two hydrophilic headgroups linked covalently by a spacer and two hydrophobic main 
chains (Menger and Littau, 1991). The chemical nature of the polar headgroups can be 
varied, as well as the length of the main alkyl chains. Considering that the spacer may 
also possess different characteristics, namely it can be made short or long, flexible or 
rigid, polar or nonpolar, a significant structural diversity and variable physico-chemical 
behavior can be obtained for this class of compounds. The enhancement of skin 
permeability is generally related to the ability of the surfactant molecules to penetrate in 
the hydrophobic domains of the SC, and therefore increasing the fluidity of the lipid 
structures (Walters et al., 1993b; Zana, 2002b). Recent studies have been performed to 
evaluate the potential of some alkyl surfactants as CPE for numerous drugs (Ashton et 
al., 1992; Babu et al., 2005b; Tan et al., 1993; Walters et al., 1993b) and have focused 
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on the influence of the alkyl chain length in the efficacy of the surfactants. It was reported 
that the highest enhancer activity was found for surfactants with C12 alkyl chains (López 
et al., 2000). Because of the enhanced interfacial properties of gemini surfactants, these 
molecules are more efficient and safe for delivery of drugs across the skin. Furthermore, 
it has been observed for a series of n-s-n bis-quat gemini that these properties are 
considerably influenced by the spacer length, s (Brun et al., 2003; Menger et al., 1999; 
Shukla and Tyagi, 2006a; Tehrani-Bagha et al., 2007; Zana, 2002a, b; Zana and 
Talmon, 1993). Gemini surfactants based on sugars, peptides and, particularly amino 
acids based on lysine and arginine derivatives, have been recently synthesized to 
overcome toxicity and biocompatibility issues (Blunk et al., 2006; Colomer et al., 2012). 
This class of surfactants is more environmentally friendly and less toxic to human cells 
(specially the lysine-based derivatives) (Teixeira et al., 2014a; Yang et al., 2010). 
Although the nonionic surfactants are reportedly the least irritant (Effendy and Maibach, 
1995), cationic gemini surfactants have recently attracted significant attention due to 
their biocompatibility, very important for applications in the biomedical field and have 
been suggested as highly promising in gene therapy and drug delivery (Badea et al., 
2005; Cardoso et al., 2011; Kirby et al., 2003; Vieira and Carmona-Ribeiro, 2006; 
Viscardi et al., 2000). However their toxicity represents a limitation to the respective use 
in skin formulations, due to the irritancy potential to eyes and skin. More recently, a novel 
group of cationic gemini surfactants containing serine residues as the polar headgroup 
have been synthesized and characterized physicochemically (Silva et al., 2013b). 
 
Figure 4.1 Molecular structure of the cationic serine-based surfactants [(nSer)2Nm];  n is number of C atoms 
in the main alkyl chain (n=10, 12, 14) and m is the number of methylene groups included in the spacer (m = 
5). Nonionic surfactants possess non-quaternized N atoms in the polar head groups. For both families, a 
longer spacer, m = 10, was also considered. 
The objective of the present study was to evaluate the potential of a series of novel 
gemini surfactants, nonionic and cationic, as CPE for tetracaine and ropivacaine, across 
newborn porcine skin, following a similar methodology to that previously reported by the 
authors and using a systematic variation in the structure of the gemini surfactants (Silva 
et al., 2013a; Silva et al., 2012; Teixeira et al.). The choice of the serine-based 
surfactants used in this work was dictated by the optimal toxicological profile presented 
by these compounds in previous work on various cationic monomeric surfactants (Brito 
et al., 2009; Silva et al., 2013b; Silva et al., 2009). A series of nonionic (non-quaternized 
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N) and cationic (quaternized N, as shown in Figure 4.1) serine-based gemini surfactants 
of the amine series compounds were designed and synthesized, by imposing variations 
in the type of linkage of the spacer to the quaternary N atom (amine, ester or amide 
linkage), spacer length (number of methylene groups) and main chain length. For both 
families the spacer length is kept constant (m = 5) and the main alkyl chain length (n) is 
varied between 10, 12 and 14 carbon atoms, allowing to study both the influence of 
charge and main chain length on the enhancement efficacy. Furthermore, for the n = 12 
compound a longer spacer, m = 10, was used allowing to assess also the influence of 
spacer length. The two local anesthetics drugs were chosen based on their distinct 
physical-chemical properties where tetracaine is non-ionized and hydrophobic while 
ropivacaine is ionized and therefore hydrophilic. Tetracaine is of the ester type, and 
possesses a logP of 2.79, which compared to the other anesthetics, makes this molecule 
a suitable candidate for topical administration (Covino, 1987; Fisher et al., 1998). 
Ropivacaine hydrochloride is a long-acting local anesthetic with a slower onset of action, 
shorter in duration and less intense, reason why it is well tolerated for regional 
anesthesia (Becker and Reed, 2012). However it is a hydrophilic molecule and, 
consequently, poorly absorbed through intact skin (McClellan and Faulds, 2000; Zink 
and Graf, 2004). 
The effects on the skin structure of these CPE were later evaluated using SEM. The 
analysis of the in vitro results also relied on the insight provided by molecular dynamics 
simulation studies. Additionally, the cytotoxicity profiles of both nonionic and cationic 
serine-based surfactants in HEK) was assessed and compared. Data collected from 
different techniques provided new information about novel serine-based surfactants and 
their potential use as to be used as CPE in transdermal formulations. 
4.2. Experimental section 
4.2.1. Materials 
The eight nonionic and cationic serine-based surfactants used in this study were 
synthesized and purified according to a method previously developed and reported by 
some of the authors (Goreti Silva et al., 2012; Silva et al., 2013b; Silva et al., 2009). The 
purity of the compounds was determined by NMR, high resolution mass spectroscopy 
and surface tension measurements. The nonionic serine-based surfactants, comprising 
10, 12 and 14 carbon atoms with 5 carbon atoms as spacer and 12 with 10 as spacer, 
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respectively referred in this Chapter as (10Ser)2N5(0), (12Ser)2N5(0), (14Ser)2N5(0), 
(12Ser)2N10(0) and the cationic ones are referred as (10Ser)2N5(+), (12Ser)2N5(+), 
(14Ser)2N5(+) and (12Ser)2N10(+). RPC was a gift from AstraZeneca (London, United 
Kingdom) and HPMC K15M a gift from Dow Chemical Company (Midland, MI, USA). TC, 
ammonium acetate, PG (Reagent Plus, 99%), sodium bicarbonate, glucose, penicillin G 
potassium salt and streptomycin were purchased from Sigma Aldrich (Saint Louis, MO, 
USA). HP-β-CD with 97% of purity, with an average degree of substitution of 2 to 6 units 
of 2-hydroxypropyl (C3H7O) per glucose unit, and with an average molecular weight of 
1380 g/mol, was purchased from Acros Organic (Geel, Belgium). PBS was purchased 
from TIC Gums (Belcamp, MD, USA). MeOH and acetonitrile ACN HPLC grade were 
purchased from LiChroSolv Merck (Darmstadt, Germany). HEK were purchased from 
DKFZ (Im Neuenheimer Feld, Heidelberg, Germany). Alamar-Blue® Cell Viability reagent 
was purchased from Thermo Scientific (Waltham, MA, USA).Tissue-Tek® O.C.T™ 
compound was purchased from VWR international (Radnor, Pennsylvania, USA). 
Formaldehyde solution min. 37 % was purchased from Merk (White House Station, NJ, 
USA). DMEM, FBS and trypsin were purchased from Invitrogen™ (Carlsbad, CA, USA). 
All reactants were used as received. 
4.2.2. Drug delivery studies  
In vitro studies were used to determine the permeation profile of each drug through the 
skin and were carried out using Franz diffusion cells (PermeGear, Inc., PA, USA) with a 
diffusion area of 0.64cm2. The receptor compartment of 5.1 mL was filled with PBS 
solution (pH=7.4) kept at 37.0 ± 0.1 °C and stirred at 600 rpm during the entire 
permeation experiments. Dermatomed newborn porcine skin pieces (section 4.2.2.1.) 
were placed between the donor and receptor compartment, with the epidermal side 
facing up. All the skin samples, except the control, were pretreated with 60 L of the 
various serine-based surfactant enhancer solutions prepared in section 4.2.2.3., for 1 h 
prior to the application of the formulations in the donor compartment (t = 0). Drug loaded 
hydrogel formulations (500 µL) prepared in section 4.2.2.2 were placed in each donor 
compartment and were occluded with Parafilm® to prevent evaporation. Subsequently 
300 L of each Franz Cell receptor compartment samples were collected at 0, 2, 4, 6, 8, 
18, 20, 22 and 24 h, and immediately replaced with the same volume of fresh PBS 
solution. The samples were placed in 0.350 mL inserts supported by adequate vials and 
storage at -20 ºC. 
Chapter 4 
97 
 
4.2.2.1. Porcine skin preparation 
The skin model used in the permeation studies was newborn porcine skin tissue (3 
weeks, ~5 kg) acquired from a local slaughterhouse. The tissue was then removed with a 
scalpel and dermatomed using a Padgett® Model B Electric Dermatome (Integra 
LifeSciences, Plainsboro, NJ) Figure 3.2. The skin with 650-750 μm thickness was cut in 
small pieces and stored at −20 ºC no longer than 3 months. Prior to use, skin samples 
were defrosted at room temperature and submerged in PBS (pH=7.4) during 1 h to 
promote equilibration.  
4.2.2.2. Composition and preparation of hydrogels formulation  
Tetracaine HPMC hydrogel was composed of 2.5% (w/w) TC mixed with appropriate 
amount of HP-β-CD (Teixeira et al., 2014b), 1% (w/w) HPMC K15M and deionized water. 
Ropivacaine hydrochloride HPMC hydrogel was prepared by adding 2.5% (w/w) RPC to 
1% (w/w) HPMC K15M and deionized water. The polymers solutions were kept stirring at 
low speed (50 rpm) during 24 h to ensure complete solubilization.  
4.2.2.3. Preparation of the serine enhancer solutions 
After obtaining the synthesized and purified serine-based surfactants, all enhancer 
solutions were added to PG to a final concentration of 0.15 M and left stirring overnight 
at room temperature until homogenization. Generally the compounds produced clear 
solutions, however in some cases the solutions needed to be heated prior to use. 
4.2.2.4. HPLC quantification of tetracaine and ropivacaine  
All samples were quantified by HPLC using a Shimadzu UFLC apparatus with SPD-
M20A UV/visible dual wavelength detector. The quantification of both drugs were carried 
out at 25°C using a reverse-phase C18 column (250 x 4.6mm C18 (2) 100 A Luna 5 m, 
Phenomenex® (Torrance, CA, USA) with a guard column as the stationary phase. A 
methanol, acetonitrile and ammonium acetate solution on the proportions 7:7:6 
respectively, was used as mobile phase. The prepared mixing solution was filtered using 
a 0.45 µm Nylon membrane (Supelco Analytical, Bellefonte, USA) and sonicated during 
1 hour prior use. The injection volume (25 L) and the flow rate (1.0 mL/min) was 
maintained constant during all the analysis. Tetracaine was detected at 311 nm with a 
retention time of ca. 6.9 minutes. The method showed a linear response in the 0.01–100 
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g range (R2 = 0.9998) with a daily relative standard deviation (RSD) < ± 5.0%. 
Ropivacaine was detected at 210 nm and the retention time was ca. 9.1 minutes. The 
method showed a linear response in the 0.01-500 mg/mL (R2=0.9973) with a daily RSD 
< ± 6.0%. 
4.2.2.5. Data analysis in the permeation studies 
The cumulative amount of tetracaine and ropivacaine present in the receptor 
compartment solution after 24 hours of permeation experiment (Q24) was calculated by 
Eq. 3.2.  
The steady state flux (µg cm-2 h-1), J, that describes the amount of drug passing through 
a unit area per unit of time was also calculated according to Fick’s first law of diffusion, 
resorting to Eq. 3.1.  
The enhancement ratio (ER) for flux was calculated for comparison among formulations 
using Eq. 3.3. 
Results are presented as mean ± SD (n), where n is the number of replicates. The 
significance of differences between the flux values of different formulations was 
evaluated using Student’s t-test at the probability level of 0.05. 
4.2.3. Skin integrity evaluation after permeation studies 
Skin samples were rinsed with deionized water and, subsequently dried, to evaluate 
morphological changes caused by the CPE after the permeation studies.  
4.2.3.1. Scanning Electron Microscopy studies 
Skin samples were analyzed by SEM to evaluate if any morphological changes occurred 
after the in vitro studies. The samples were placed in a plastic mold and were 
submerged in Tissue-Tek® O.C.T. compound. Cross-section slices of frozen samples 
were cut with 10 m of thickness using a cryostat SLEE medical GmbH (Carl-Zeiss, 
Mainz, Germany). The samples were defrosted, rinsed with deionized water and fixed 
with 4% formaldehyde during 1.5 h. Afterwards skin samples were rinsed and placed in 
deionized water during 2 h at room temperature. Skin samples were subsequently 
dehydrated using different solutions of ethanol in water (30 %, 50 %, 75 %, and 95 %) for 
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25 minutes each. Finally, skin samples were placed in two changes of absolute ethanol 
(100 %) for 2 h at room temperature and placed on a double-side carbon tape mounted 
onto an aluminum stud. The samples were coated with gold and the respective pictures 
were taken at 600x and 1000x magnification using a SEM – JEOL, model JSM-
6010LV/6010LA. 
4.2.4. Simulation details 
Molecular dynamics simulations were performed on systems containing novel serine-
based gemini surfactants, nonionic and cationic, in a fully hydrated DPPC bilayer, 
consisting of 256 lipid molecules (128 per leaflet). DPPC/surfactant systems have been 
proven to be adequate models to investigate the mechanisms of enhancement of drug 
permeation through inspection of the effects induced by the drug in this type of 
membranes (Almeida et al., 2011; Cerezo et al., 2011; Gurtovenko and Anwar, 2007; 
Kyrikou et al., 2004; Notman et al., 2006; Teixeira et al.). DPPC and SPC water (3655 
molecules) were described using the original definitions of the GROMOS 53a6 force 
field, which has been shown previously to accurately reproduce the experimental area 
per lipid, lateral self-diffusion constant, and deuterium order parameters for the acyl 
chains of DPPC bilayers in solution (Kukol, 2009; Piggot et al., 2012; Poger and Mark, 
2009; Schuttelkopf and van Aalten, 2004). In each system, a single molecule of 
surfactant was considered. This was shown to be sufficient to provide a rationale for the 
experimental results. The interaction of each solute with the surrounding lipids and the 
preferential positioning and respective action on the bilayer was assessed. 
Equilibrium properties, structure, and dynamics for the various DPPC/surfactant systems 
were calculated over the 80ns simulation runs using GROMACS package, version 4.5.5 
(Hess et al., 2008; van der Spoel et al., 2012). To maintain the stability of the lipid 
system, all simulations were performed above the experimental liquid-crystalline phase 
transition temperature (325 K) for pure DPPC as reported by Curtis and Hall (Curtis and 
Hall, 2013). 
4.2.4.1. Simulations parameters 
All MD simulations were carried out in the NPT ensemble under periodic boundary 
conditions. A standard time step of 2 fs was used for both the equilibration and 
production runs. Non-bonded interactions were computed on the basis of a neighbor list, 
updated every 10 steps. Long-range electrostatic contributions were computed using the 
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PME method as recommended for charged polymer simulations. For Lennard–Jones 
energies, a cut-off of 1.4 nm was applied. The Berendsen thermostat was used to keep 
the temperature and pressure constant at 325 K and 1 bar, respectively, throughout the 
simulation with time constants of 0.1 ps and 0.5 ps, respectively. To obtain a starting 
configuration each system was firstly subjected to an energy minimization step. The 
systems were subsequently left to evolve up to 80 ns, using the LINCS algorithm (Hess 
et al., 1997). The first 20 ns were considered sufficient to attain equilibration, while the 
last 60 ns of the production runs were subsequently subjected to standard analysis, 
including the determination of density probability distributions, order parameters, mean 
square displacements and rdf. Throughout the GROMACS simulation the coordinates of 
each atom were written to an output trajectory file every 1 ps. MD trajectories were 
visualized, and configuration images extracted using the VMD 1.9 software (Humphrey 
et al., 1996). 
4.2.5. Cytotoxicity studies  
Cytotoxicity was assessed by the Alamar Blue assay, a colorimetric cell viability method 
that has been widely reported in the literature for similar systems (O'Brien et al., 2000). 
The objective was to evaluate the toxic effects of the serine-based surfactants on 
cultured HEK, and establish a concentration-toxicity response. The number of viable 
cells is directly proportional to the quantity of resorufin (a pink colored and fluorescence 
compound) that is a product of reduction of resazurin [7-Hydroxy-3H-phenoxazin-3-one-
10-oxide sodium salt] (a non-fluorescent blue dye). The levels of resorufin formed were 
quantified by absorbance readings at 570 and 600nm (alamarBlue® Cell Viability Assay 
Protocol) using a Microplate Power Wave X Scanning Spectrophotometer (Bio-TEK 
Instruments, Inc. Winooski, VT, USA). Cytotoxicity studies were carried using a skin cell 
line HaCaT seeded at 10x105 cells/well in 96-well plates, under sterile conditions. Before 
this, HEK were seeded in 200L/well of DMEM® medium supplemented with sodium 
bicarbonate (3,7 g/L), glucose (25 mM), 10% heat inactivated FBS, 100 U/mL penicillin, 
and 100 µg/mL streptomycin and were incubating for 24 h at 37ºC, 5 % CO2 and 90 % 
R.H. After seeding the cells were exposed to medium (control), PG and various 
concentrations (160 (S1), 16(S2), 1.6(S3), 0.16(S4) M) of cationic and neutral serine 
based-surfactant solutions diluted in culture medium. Subsequently, well plates were 
placed in the incubator for another 24 h in the same conditions. 4 h before the 
absorbance measurements, cells were exposure to the resazurin compound and 
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returned to the incubator. The 96-well plates were read, and the results presented as % 
cell viability (mean ± standard deviation, n=6), C.V., calculated according to Eq. 4.4 
𝐶. 𝑉. =
abs read in treated cells
abs read in control (untreated) cells
       (4.4) 
4.3. Results and Discussion 
4.3.1. In vitro permeation studies using serine-based surfactants  
4.3.1.1. Percutaneous drug delivery of tetracaine 
All serine-based surfactants were dissolved in PG in a final concentration of 0.15 M. 
Prior to the permeation experiments 60 L of each serine enhancer solution was applied 
to the epidermal side of dermatomed porcine skin placed between the donor and 
receptor compartments of Franz diffusion cells. 500 µL of tetracaine loaded hydrogel was 
applied. The permeation parameters (Flux, Q24 and ER) presented in Table 4-1 and the 
permeation profiles shown in Figure 4.2 were determined using the equations described 
in section 4.2.2.5. 
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Table 4-1. Effect of the chemical permeation enhancers on percutaneous permeation of tetracaine across 
porcine skin. Data are presented as means ± S.D. (4≤N≤6). 
Penetration modifier Flux (µg cm
-2
 h
-1
) Q24 (µg cm
-2
) ER 
Control – PG 19.83 ± 2.47 417 ± 53 - 
0.15M (12Ser)2N10(0)  18.03 ± 1.34 402.98 ± 34 0.9 
0.15M (10Ser)2N5(0)  20.22 ± 0.94 425.32 ± 18 1.02 
0.15 M (12Ser)2N5(0)  22.91 ± 1.24 477.21 ± 34 1.15 
0.15M (14Ser)2N5(0)  24.67 ± 0.71 526.52 ± 13 1.24 
0.15M (12Ser)2N10(+)  24.84 ± 5.15 537.39 ± 103 1.25 
0.15M (10Ser)2N5(+)  22.35 ± 0.62 515.18 ± 18 1.13 
0.15 M (12Ser)2N5(+)* 28.25 ± 2.94 618.83 ± 79 1.42 
0.15M (14Ser)2N5(+)* 37.08 ± 1.85 690.14 ± 42 1.87 
* Statistically significant difference between enhancer and control, at p < 0.05 (Student’s t-test) 
 
Figure 4.2 Cumulative amount of tetracaine permeated across porcine skin as a function of time. Skin was 
pretreated for 1 hour with enhancer solutions in PG, prior the application of the drug hydrogel in the donor 
compartment of the franz cells (t=0). 
Serine-based surfactants promote an increase on the flux and Q24 values of tetracaine, 
with exception of (12Ser)2N10(0). However, only the results for (12Ser)2N5(+) and 
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(14Ser)2N5(+) cause a statistically significant difference (p<0.05) in tetracaine 
permeation. 
It is clear that the highest values of flux and Q24 were achieved when the cationic 
compounds where applied. It is also interesting to note that the compound with the 
longest alkyl chain and shortest spacer, (14Ser)2N5(+), was the most effective 
permeation enhancer, resulting in a 1.9-fold increase of the flux, closely followed by 
(12Ser)2N5(+) (ER = 1.4). In contrast, serine-based surfactant with a longer spacer 
(12Ser)2N10(0) displayed a modest performance when compared with the control. 
4.3.1.2. Percutaneous drug delivery of ropivacaine 
The permeation profiles and permeation parameters (Flux, Q24 and ER) of ropivacaine 
permeated across the newborn porcine skin, during 24 h are presented in Figure 4.3 and 
in Table 4-2. 
Table 4-2 Effect of the chemical permeation enhancers on percutaneous permeation of ropivacaine across 
newborn porcine skin. Data are presented as means ± S.D. (6≤N≤9). 
Penetration modifier Flux (g cm
-2
 h
-1
) Q24 (g cm
-2
) ER 
Control - PG 1.94 ± 0.02 36.9 ± 1.6 - 
0.15M (12Ser)2N10(0) 1.31 ± 0.08 27.9 ± 2.3 0.68 
0.15M (10Ser)2N5(0)  1.87 ± 0.15 40.5 ± 2.5 0.96 
0.15M (12Ser)2N5(0)  2.60 ± 0.43 42.8 ± 2.7 1.34 
0.15M (14Ser)2N5(0)* 5.14 ± 0.24 102.4 ± 3.1 2.65 
0.15M (12Ser)2N10(+)  1.44 ± 0.05 19.9 ± 1.8 0.74 
0.15M (10Ser)2N5(+)  1.54 ± 0.06 21.8 ± 2.3 0.79 
0.15 M (12Ser)2N5(+)* 4.86 ± 0.74 82.9 ± 9.8 2.50 
0.15M (14Ser)2N5(+)* 5.74 ± 0.74 105.4 ± 15 2.96 
* Statistically significant difference between enhancer and control at p < 0.05 (Student’s t-test) 
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Figure 4.3 Cumulative amount of ropivacaine permeated across porcine skin as a function of time. Skin was 
pretreated for 1 hour with enhancer solutions in PG, prior the start of the permeation experiments. 
Skin samples treated with all the serine-based surfactant tend to increase the 
permeation of ropivacaine, but statistical significance was only observed for 
(14Ser)2N5(+), (12Ser)2N5(0) and (12Ser)2N5(+). Results showed that the highest 
ropivacaine permeation was attained when serine-based surfactants with longer alkyl 
chain and shorter spacer were employed, resulting in a 3-fold increase for (14Ser)2N5(+), 
2.7-fold for (14Ser)2N5(0) and 2.5 for (12Ser)2N5(+) increase in the flux values. The 
effect of the spacer is also remarkable, as the compounds with longer spacer 
((12Ser)2N10(+) and (12Ser)2N10(0)) showed a lower permeation of ropivacaine HCl, 
compared with the control, with values of ER of 0.74 and 0.68, respectively. 
4.3.1.3. General trends 
Overall, the steady-state permeation was obtained after a period not exceeding 8 hours, 
and maintained for the full period of observation of 24 h. It can be seen that the most 
effective CPE are the cationic compounds with longer alkyl chain and shorter spacer 
length, namely (14Ser)2N5(+), resulting in a 2-fold and 3-fold permeation enhancement 
for tetracaine (Figure 4.4) and ropivacaine (Figure 4.5), followed by (12Ser)2N5(+), with a 
ER of 1.4 and 2.5, respectively. In contrast, the CPE with the longer spacer, 
(12Ser)2N10(+) and (12Ser)2N10(0), and shorter alkyl chain, (10Ser)2N5(+); 
(10Ser)2N5(+), are the least effective for both drugs. In these cases, the effect of 
charge/ionization was found to be negligible. 
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Figure 4.4 ER obtained pretreating the skin using the various CPE for tetracaine. 
 
Figure 4.5 ER obtained pretreating the skin using the various CPE for ropivacaine. 
Since tetracaine is a lipophilic molecule and permeates the SC more easily, the results 
obtained indicate that the effects of the CPE are especially relevant in the case of 
ropivacaine, which is a charged and hence hydrophilic molecule. These results are in 
agreement with previous work, where CPE were tested for drugs with different 
hydrophobicities (El-Kattan et al., 2000; Silva et al., 2013a; Teixeira et al., 2014a). 
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4.3.2. Skin integrity evaluation 
After the in vitro permeation experiments, skin samples were rinsed with water and 
further analyzed by light microscopy and SEM to evaluate if any skin damage or 
morphological changes occurred during the in vitro permeation experiments. 
After the in vitro permeation experiments, skin samples used in the permeation 
experiments and pre-treated with serine based-surfactant were rinsed with water and 
further analyzed by SEM to evaluate if any skin damage or morphological changes 
occurred during the in vitro permeation experiments. Figure 4.6 shows untreated 
newborn porcine skin (control) and Figure 4.7 represents the skin sample treated with 
the most effective enhancer in terms of drug permeation (14Ser)2N5(+). Details of skin 
layers such as the SC (the outermost multi-layered structure), viable epidermis and 
dermis (the thickest structure mostly composed of connective tissue under the viable 
epidermis) are visible due to the large depth of field of this technique. 
 
Figure 4.6 SEM cross section of untreated porcine skin (control) at 600x and 1000x magnification. This skin 
sample was not subjected to permeation studies. 
 
Figure 4.7 Skin samples treated with the cationic surfactant (14Ser)2N5(+) at 600x and 1000x magnification 
taken after permeation studies. 
Chapter 4 
107 
 
The tissue of the skin samples remains compact, consolidated and organized. Although 
no major morphological or structural changes are detected when comparing with the 
control samples, minor changes in cell morphology and cohesion can be seen, at the 
level of organization of the tissues, and also some areas of the SC seem to be separated 
from the subsequent layer. However, this occurrence is probably the result of natural 
peeling or sample handling since this effect was also observed in the untreated samples.   
Overall, SEM studies confirmed that there are no significant changes on the skin tissue 
when comparing the CPE treated samples with the untreated one (control). The use of 
these compounds does not cause permanent alterations or loss of integrity. 
4.3.3. Simulation results 
Molecular dynamics simulations were performed on seven systems, a neat DPPC 
bilayer, taken as reference, and six other systems each comprising DPPC and one 
molecule of six different serine-based bis-quat gemini surfactants [(nSer)2Nm] (Goreti 
Silva et al., 2012), both nonionic and cationic, with different lipophilic alkyl chain and 
spacer lengths. The latter were denoted DPPC/(10Ser)2N5(0), DPPC/(12Ser)2N5(0), 
DPPC/(10Ser)2N5(+), DPPC/(12Ser)2N5(+), DPPC/(14Ser)2N5(+) and 
DPPC/(12Ser)2N10(+).  
The structural characteristics of the DPPC bilayers with gemini incorporation were firstly 
analyzed using the probability density functions, that reflect the vertical positioning of key 
groups relatively to the membrane center (defined as the central plane between the 
bilayer leaflets). 
Figure 4.8 depicts the density profiles of these groups across the bilayer, namely the 
positioning of the P and N atoms of the head groups and the terminal methyl groups of 
DPPC. The nitrogen atom of the gemini head groups and the respective end methyl 
groups of the gemini tails were also considered. The distribution of the terminal methyl 
groups of DPPC appear as a single curve, with its maximum at Z=0, indicating a clear 
overlapping of the terminal part of the leaflets. Additionally, the distributions concerning 
the nitrogen atom of the gemini surfactants reflect the presence of only one molecule.  
On the other hand, the distributions of the SPC water molecules and the polar heads of 
DPPC, represented by the nitrogen atom, are symmetrical around the center of the z-
coordinate, being depicted in both sides of the bilayer.  
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The profile of key groups pertaining to the single-component DPPC system, shown in 
Figure 4.8 panel (a), is correlated with the profiles previously reported (Teixeira et al., 
2014a). The incorporation of the gemini molecules (Figure 4.8 panels (b) to (g)) 
introduces some modifications in the bilayer structure. From Figure 4.8 panels (f) and (g) 
it is seen that the serine-based nonionic molecules are mostly embedded in the 
hydrophobic region, while cationic molecules (Figure 4.8 panels (b) to (e)) are 
preferentially positioned close to the interface, as can also be seen in Figure 4.9, in 
which six representative configurations are presented. The cationic molecules, as a 
consequence, interact more strongly with the lipid polar heads, displaying a reduced 
probability of crossing the center of the bilayer. Both (10Ser)2N5(+) and (12Ser)2N5(+) 
cationic surfactants (Figure 4.8 panel (b) and (c), respectively) are, among the six gemini 
surfactants under study, the ones that interact more strongly with the lipid polar heads, 
with evidence of establishing hydrogen-bonding. The (14Ser)2N5(+) and (12Ser)2N10(+) 
cationic molecules have a similar behavior, but the strong interaction with the lipid polar 
heads becomes less pronounced. The more hydrophilic nature and the smaller tail length 
of the cationic gemini surfactants prevents the terminal methyl groups from reaching the 
center of the bilayer. In contrast, the terminal methyl groups of the (14Ser)2N5(+) cationic 
gemini tails (see panel (d), Figure 4.8) are almost leveled with those of DPPC, reaching 
the inter-leaflet region.  
In Figure 4.8 panel (f), the wide distribution of the gemini terminal methyl groups of the 
(12Ser)2N5(0) nonionic surfactant indicates that the mobility of the tails within the 
membrane is high, with the chains easily switching between the two leaflets. It is also 
seen that the polar heads are fully embedded in the inter-leaflet region of the DPPC 
membrane (see Figure 4.9) and are less mobile, as suggested by the MSD profile in 
Figure 4.10.  
The above observations are compatible with the fact that serine-based bis-quats 
[(nSer)2Nm] contain hydrogen bonding donor and acceptor groups. A more detailed 
analysis on the order of the membrane is presented from the estimated order parameter, 
SCD, for the carbon atoms in DPPC tails. A summary of these SCD values obtained for the 
DPPC tails is presented in Figure 4.11. A typical membrane profile was obtained for the 
neat DPPC system. As one moves towards the end of the tails, the high ordering found 
in the first carbons, close to the interface, gives place to a decreased order, with a 
minimum degree found in the terminal carbons. 
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Both (10Ser)2N5(0) and (12Ser)2N5(0) nonionic molecules induce an increased 
organization near the interface. An opposite effect, although weaker, is found close to 
the bilayer center. All the cationic molecules, with the exception of the longest molecule, 
(14Ser)2N5(+), induce a similar disordering effect close to the interface. The strongest 
effect is observed for the (12Ser)2N10(+) cationic molecule in comparison to that of 
(14Ser)2N5(+). For the internal part of membrane, a stronger action is observed for the 
(12Ser)2N5(+), (12Ser)2N10(+) and (10Ser)2N5(+) cationic molecules, with emphasis in 
the former. The (12Ser)2N5(+) cationic surfactant promotes a larger disorder, with a 
behavior similar to that of both (12Ser)2N10(+) and (10Ser)2N5(+) cationic molecules for 
the terminal carbon. As stated before, no pronounced effect is found for both the 
nonionic molecules ((12Ser)2N5(0) and (10Ser)2N5(0)).  
The MSD analysis performed from the simulation trajectories and reported in Figure 4.10 
allows observing relevant structural modifications in comparison to the well-ordered 
DPPC system for only one molecule of surfactant. MSD results are well correlated with 
the previous analysis. Figure 4.10 clearly shows that the incorporation of (12Ser)2N5(+) 
cationic surfactant is responsible for a significant increase in the DPPC lateral diffusion, 
when compared to its nonionic homologues, and the shortest cationic molecule 
((10Ser)2N5(+)). The (12Ser)2N5(+) cationic molecule is, among the serine-based 
surfactants under study, the one that promotes the highest lateral diffusion of DPPC 
molecules. Based on the membrane perturbation MD results, (12Ser)2N10(+) and 
(12Ser)2N5(+) cationic molecules are identified as the most effective and both nonionic, 
(12Ser)2N5(0) and (10Ser)2N5(0), as the least effective permeation enhancers of the 
study. In general, the MD results corroborate the experimental observations, both in what 
pertains to the deuterium order parameters and mean-square displacement values. The 
experimental ER values are in the order (10Ser)2N5(0), (12Ser)2N5(0), (12Ser)2N10(+) 
and (12Ser)2N5(+), corresponding to a decrease in order and an increase in 
displacement. This confirms, in general, both chain length and charge effect. 
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Figure 4.8 Probability density profiles of key atom/groups relative to the Z-axis, extracted from the MD 
simulations carried out at 50°C for (a) single DPPC, (b) DPPC/(10Ser)2N5(+), (c) DPPC/(12Ser)2N5(+), (d) 
DPPC/(14Ser)2N5(+), (e) DPPC/(12Ser)2N10(+), (f) DPPC/(10Ser)2N5(0) and (g) DPPC/(12Ser)2N5(0) 
systems. SPC water groups (··), DPPC groups - ammonium nitrogen (dark blue), and end methyl groups of 
tail chains (black); gemini groups – ammonium nitrogen atoms (blue) and terminal methyl groups of both tails 
(red). The Z-coordinate represents the normal to the bilayer plane. 
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Figure 4.9 Snapshots of the typical positioning of serine-based molecules embedded in the bilayer. Water, 
surfactant molecules and DPPC are represented in red, cyan and blue, respectively. 
 
Figure 4.10 Mean square displacement of DPPC molecules, calculated from the MD simulations for the 
DPPC/serine-based systems. 
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Figure 4.11 Deuterium order parameter, SCD, estimated from the MD simulations, along the bilayer depth for 
DPPC chains, averaged over sn-1 and sn-2 chains, in the presence of the serine-based surfactants. 
Radial distribution function analyses of SPC water molecules around the polar heads of 
both DPPC and gemini surfactants, displayed in  
Figure 4.12, were also used to inspect changes in the hydration level. In what concerns 
the polar heads of DPPC, represented by the ammonium groups,  
Figure 4.12 panel (a), it is observed that the presence of the gemini surfactants promotes 
a decrease in the amount of water accessible. However, no significant differences were 
found in terms of hydration of the ammonium groups of DPPC in the presence of the 
different gemini structures. On the other hand, for the gemini polar heads, also 
represented by the ammonium groups,  
Figure 4.12 panel (b), the same analysis indicates an increased solvation of the cationic 
surfactants, with a pronounced effect for the (12Ser)2N5(+) molecule. 
Figure 4.13 presents the rdfs of SPC water molecules relative to the (i) carbonyl atoms of 
DPPC chains (Figure 4.13 panel (a)) and surfactants polar heads (Figure 4.13 panel (b)), 
(ii) carbonyl-ester (Figure 4.13 panel (c)) and (iii) hydroxyl atoms (Figure 4.13 panel (d)) 
for both cationic and nonionic surfactants polar heads. The profiles displayed in Figure 
4.13 panel (a) indicate more accessible water in the presence of the (12Ser)2N5(+) 
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cationic molecule, while no significant differences were found in terms of the hydration of 
the carbonyl atoms of DPPC tails in the presence the remaining structures, 
corresponding to the upper part of the hydrophobic region. Panel (b) of Figure 4.13 
shows an increase in the amount of water in the proximity of the cationic molecules. The 
absence of water near the nonionic molecules is a common pattern in Figure 4.13 panels 
(b), (c) and (d). Such behavior is compatible with the membrane perturbation analysis: 
nonionic molecules are fully embedded in the inter-leaflet region of the DPPC 
membrane. From these profiles it is also seen that the longer spacer cationic surfactant 
(12Ser)2N10(+) induces some decrease of the respective solvation. In addition to the 
charge effect, the gemini tail length is relatively important in this regard, with the shorter 
tail cationic surfactant (10Ser)2N5(+) promoting a more pronounced hydration effect. 
Figure 4.12 Radial distribution function of water molecules relative to the DPPC (panel (a)) and gemini 
(panel(b)) ammonium groups, calculated from the MD simulations carried out at 50°C. 
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Figure 4.13 Radial distribution functions of water molecules around the  carbonyl atoms for the sn1 and sn2 
chains of (a) DPPC and the polar heads for (b) both cationic and nonionic molecules, and (c) carbonyl-ester 
and (d) hydroxyl atoms for the polar heads of the serine-based gemini surfactants. 
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4.3.4. Cytotoxicity studies 
The cytotoxicity profiles of each serine based-surfactant were determined in HEK (Figure 
4.14).  
 
Figure 4.14 Pictures of cultured HEK 10x, seeded at 10.000 cells/well in appropriate culture medium, prior to 
the start of the Alamar Blue assay. 
A calibration curve was performed based on the absorbance readings of standards plots 
of HEK (R2 = 0.975) with 0, 10.000, 20.000, 40.000, 60.000 cells per well, in order to 
ensure the linearity of the Alamar Blue assay method used. The results obtained in the 
Alamar assay are displayed in Figure 4.15. 
 
Figure 4.15 Alamar Blue assay results for nonionic and cationic serine-based surfactant. The bars represent 
the cell viability (%) for each permeation modifier and concentration tested. The error bars represent the 
standard deviation (n=6). 
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The cytotoxicity assay revealed that, in the range of concentrations studied, generally 
nonionic compounds are less toxic than the cationic ones and the PG exposure resulted 
in a slight reduction in HEK viability, yet not statistically different from the control. 
Nonionic surfactants tested did not cause a significant reduction in HEK viability, when 
compared to the control, except for (10Ser)2N5(0) (S1). When this compound was 
applied to the cells, it was observed that approximately 50 % cell death occurred.  
The results for cationic serine-based surfactants are slightly different from those obtained 
with the nonionic counterparts. The exposure of HEK to higher concentrations of 
(10Ser)2N5(+), (12Ser)2N5(+), (14Ser)2N5(+) and (12Ser)2N10(+) (S1) caused 
approximately 50% cell death. However, the presence of a concentration not higher than 
16 µM (S2) of any CPE did not have a negative effect in the HEK viability, except for 
(12Ser)2N5(+) (S2). In this case cell viability was reduced in approximately 50 % when 
HEK were exposed to a concentration of 16 µM (S2). 
A global analysis of the Alamar assay results obtained with HEK suggests that the 
cytotoxicity of the serine-based gemini surfactants studied is dependent on the charge of 
the compounds, since HEK showed a higher tolerance to the nonionic compounds. In 
fact, (10Ser)2N5(0), (12Ser)2N5(0), (14Ser)2N5(0) and (12Ser)2N10(0) were found to be 
less toxic to HEK when compared to (10Ser)2N5(+), (12Ser)2N5(+), (14Ser)2N5(+) and 
(12Ser)2N10(+). 
4.4. Conclusions 
This work presents a systematic study on the use of a series of serine-based gemini 
surfactants as permeation enhancers for drugs from the same therapeutic group, with 
different ionization state and hydrophobicity. The two classes of serine-based molecules, 
nonionic and cationic, possess different alkyl chain length, comprising 10, 12, 14 or 16 
carbon atoms. It was observed that the most effective CPE for both drugs were cationic, 
with longer alkyl chains. The highest permeation of ropivacaine was achieved when the 
cationic surfactant with the longest alkyl chain (14Ser)2N5(+) was employed (ER = 3). 
Interestingly, in the case of tetracaine, the cationic surfactant with the longest alkyl chain 
(14Ser)2N5(+) (ER=1.9) was also the most effective CPE followed by (12Ser)2N5(+) (ER= 
1.4). These results suggest that serine-based surfactants are suitable, safe and 
promising candidates to increase drug transport across the skin, especially for 
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hydrophilic/ionized drugs. Molecular dynamics simulations provided results in 
accordance with the experimental observations. 
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Chapter 5 
5. Novel vesicular liposomes systems containing aminoacid-
based surfactants for topical administration of tetracaine 
and ropivacaine 
This Chapter addresses a study that, again, aims the improvement of a formulation 
containing tetracaine and ropivacaine, for topical administration, now using liposomes, 
prepared with aminoacid-based surfactants (previously reported in Chapter 3 and in 
Chapter 4). Liposomes were prepared following thin layer evaporation method and were 
characterized regarding its size, zeta potential and encapsulation efficiency. A 
conventional liposomal formulation was prepared with L-α-phosphatidylcholine, 
cholesterol and both drugs, following the same methodology and was used as the 
control. In vitro permeation studies were performed in Franz diffusion cells to assess the 
efficacy of liposomal formulations prepared with aminoacid-based surfactants on drug 
permeation. 
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5.1. Introduction 
One of the most important requirements for the intrinsic anesthetic potency of a drug is 
its lipid solubility. The duration of anesthetic effectiveness is related to the extent of the 
protein binding that are located within lipids of the cell membrane (Alster, 2013). 
Tetracaine is considerably more lipophilic and intrinsically more potent than ropivacaine 
due to the binding of the latter to a butyl group and the aromatic group. In order to 
increase the onset of action of both drugs, especially ropivacaine, liposomes were the 
selected strategy. 
Liposomes are concentric vesicles in which an aqueous volume is entirely enclosed by a 
lipid bilayer (Barenholz, 2001; Meisner and Mezei, 1995) (Figure 5.1). Liposomes are 
able to encapsulate hydrophilic drugs in their aqueous compartment, while lipophilic 
drugs are encapsulated in their lipid bilayer and retained until their destination. The 
accommodation of lipophilic compounds in the lipid phase can be problematic as some 
drugs may interfere with bilayer formation and stability, limiting the range and amount of 
drugs that can be formulated with liposomes (Gillet et al., 2009; McCormack and 
Gregoriadis, 1998). 
Liposomal formulations are commonly used in the pharmaceutical field as drug delivery 
systems namely for oral and parenteral routes, due to their versatility and clinical efficacy 
(Maestrelli et al., 2006). Liposomes have been intensively studied as carriers for dermal 
and transdermal administration of drugs and skin care products since it is a non-invasive 
alternative to the oral route (Maestrelli et al., 2006). Liposomes act as penetration 
enhancers for the active ingredient into the skin. Liposomes can improve drug deposition 
within the skin at the site of action, providing a local effect with little or negligible 
systemic activity, desirable in the case of local anesthetics minimizing the occurrence of 
side effects (Manosroi et al., 2004). Liposomes can also provide targeted delivery to skin 
appendages in addition to their potential in transdermal delivery (Glavas-Dodov et al., 
2002; Maghraby et al., 2006). Compared to conventional formulations, drugs 
encapsulated in liposomes generally exhibit improved efficacy and less negative effects 
than conventional topical formulations such as ointments, creams or lotions (Honzak et 
al., 2000b; Reimer et al., 1997). 
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Figure 5.1 Schematic representation of a liposome. Adapted from (Lopes et al., 2013). 
Despite some controversy in the literature about possible vehicle-mediated phenomena 
of skin uptake, the majority of authors agree that liposomes contribute to an effective 
drug penetration and enhance clinical efficacy, due to the similarity with a biological 
membrane. Moreover, liposomes are similar to the epidermis in terms of lipid 
composition, reason why liposomes are able to permeate into the epidermal barrier to a 
greater extent than other dosage forms (Verma et al., 2003a, b). 
The biggest challenge of topically applied drugs is that, in order to be effective, drugs 
must reach the site of action above the therapeutic concentration, for a certain period of 
time (Schmid and Korting, 1996). Another issue arises from the fact that some lipids of 
the liposomes may penetrate into the stratum corneum cause a modification on the its 
structure and altering its barrier properties (Weiner et al., 1994). 
Some classical liposomes have little interest as carriers for transdermal drug delivery as 
they do not penetrate into the deeper layers of the skin, but instead remain confined to 
its upper layers (Elsayed et al., 2007). Intensive research led to the introduction and 
development of a new class of lipid vesicles capable of reaching deeper layers of the 
skin, highly deformable (elastic or ultraflexible) liposomes, known as Transfersomes® 
(Cevc and Blume, 1992).  
These elastic and ultraflexible vesicles comprise a phospholipid (e.g. 
phosphatidylcholine) as its main component, and 10 to 24 weight percent of a surfactant. 
The flexibility of the liposome is given by the high radius of curvature of the surfactant 
that acts as an 'edge activator'. Some data on the literature, has shown that these 
vehicles are able to squeeze through a pore of approximately 20 nm diameter (Cevc, 
2002). The ‘edge activator’ present in the formulation has the ability to accumulate at the 
Chapter 6 
122 
high stress sites of the vesicles forming a highly curved area which will eventually move 
through narrow skin pores to a more hydrophilic environment of the deeper layers of the 
skin. There is still some controversy about the mechanisms involving skin penetration of 
ultra-deformable or highly flexible liposomes, however some workers have shown that 
these vesicles can clearly improve the delivery of therapeutic agents to and across the 
skin (Jianxin Guo, 2000; Maghraby et al., 2001a, b; van den Bergh et al., 2001). Cevc 
and his co-workers claimed that these vesicles can penetrate intact into the deeper skin 
and even to systemic circulation (Cevc et al., 1997; Cevc et al., 1996; Cevc et al., 1998).  
This Chapter reports the evaluation of the efficacy of liposomal formulations prepared 
with different aminoacid-based surfactants previously selected in Chapter 3 and 4. The 
mentioned formulations are referred in this Chapter as LPS-LP (14Ser)2N5; LPS-LP 
10Lys10(0) and LPS-LP 16Lys16(0). A conventional liposomal formulation referred as 
LPS-LP was prepared with phosphatidylcholine, cholesterol, tetracaine and ropivacaine 
and was used as the control. The liposomal formulations were characterized regarding 
solubility, size, zeta potential, stability and encapsulation efficiency. In vitro studies 
conducted in Franz Cells were performed in order to investigate the effect of the 
combination of the aminoacid-based surfactant and conventional liposomes on 
tetracaine and ropivacaine delivery across porcine skin. 
5.2. Experimental section 
5.2.1. Materials 
TC, ammonium acetate, L-α-phosphatidylcholine (PC), chloroform and CHO were 
purchased from Sigma Aldrich (Saint Louis, MO, USA). RPC was a kind gift of 
AstraZeneca (London, United Kingdom) and HPMC K15 M was a kind gift from Dow 
Chemical Company (Midland, MI, USA). HP-β-CD with 97% of purity, with an average 
degree of substitution of 2 to 6 units of 2-hydroxypropyl (C3H7O) per glucose unit, and 
with an average molecular weight of 1380 g/mol, was purchased from Acros Organic 
(Geel, Belgium). MeOH and ACN HPLC grade were purchased from LiChroSolv Merck 
(Darmstadt, Germany). Deionized water was purified (Millipore®) and filtered through a 
0.22 µm nylon filter before use. PBS was purchased from TIC Gums (Belcamp, MD, 
USA). Newborn pig skin (3 weeks, ~5 Kg) was purchased from a local slaughter 
(Condeixa-a-Nova, Portugal) and was used as skin model. Nonionic lysine (10Lys10; 
16Lys16) and cationic serine-based gemini surfactants ((14Ser)2N5) were synthesized 
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and purified according to a standard method at the Department of Chemistry, Porto 
University (Porto, Portugal) (for details see Chapter 3 and 4) (Goreti Silva et al., 2012; 
Silva et al., 2013b). All other chemicals were used as received. 
5.2.2. Liposome composition and preparation 
Liposomes containing PC, CHO, lysine (10Lys10; 16Lys16) and serine-based surfactant 
((14Ser)2N5) were prepared following the TLE method (Bangham et al., 1965). The lipids 
were dissolved in a small quantity of chloroform which was subsequently removed under 
vacuum using a Buchi - Rotavapor R-210 with a vaccum pump V-700 and a vaccum 
controller V-850. The temperature was set at 55 ºC using a Buchi Heating Bath B-491 
(Figure 5.2). 20 % of (14Ser)2N5, 10Lys10 and 16Lys16 were added to the lipid phase. 
Evaporation continued for 2 h to ensure complete solvent removal. After the dry lipid 
appeared on the flask wall, drug-loaded liposomes composed of 2.5 % (w/w) of TC and 
RPC were prepared following two different methodologies. In the first method (LPS-LP), 
TC was directly dissolved in the lipophilic phase, and the hydrophilic phase constituted 
by water and RPC was subsequently added. In the second method (LPS-AP), the 
aqueous phase constituted by water, TC, HP-β-CD and RPC was used to hydrate the 
lipid phase (PC and CHO). An alternative liposomal formulation without the aminoacids-
based surfactants was prepared and used as control (LPS-LP). 
 
Figure 5.2 Buchi - Rotavapor R-210 with a vaccum pump V-700 and a vaccum controller V-850. 
After adding the hydrophilic phase, the suspension was alternately shaken using a vortex 
mixer and sonicated using a bath sonicator, (Clifton Ultrasonic Bath, London, United 
Kingdom) at 55 ºC during 30 min to allow vesicle formation. In order to obtain a 
homogeneous size distribution, the liposomes suspension was extruded through a 100 
nm polycarbonate membrane using a LipoFast extrusor Avestin® (Mannheim, Germany). 
To obtain viscosity values adequate for dermal application, a 1% (w/w) hydrogel of 15 M 
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HPMC was prepared and left to hydrate at lower speed (50 rpm), during 24 h, to ensure 
complete homogenization. 
5.2.3. Liposome characterization 
5.2.3.1. Solubility studies and HPLC quantification 
The solubility of TC and RPC was determined for the conventional liposomes and for the 
liposomes containing (14Ser)2N5, 10Lys10 and 16Lys16. In brief, an excess of each 
drug was added to the different vesicles prepared as mentioned in section 5.2.2. The 
samples were subsequently centrifuged for 60 min at 13229 rpm in a Minispin® 
(Eppendorf Ibérica S.L., Madrid, Spain). A small portion of the suspension was diluted 
with mobile phase and quantified. Drug quantification was carried out in a Shimadzu 
UFLC with SPD-M20A UV/visible dual wavelength detector. The quantification was 
carried out at 25 °C using a reverse-phase C18 column 250 x 4.6mm C18 (2) 100 A Luna 
5 m, Phenomenex® (Torrance, CA, USA) with a guard column as the stationary phase. 
The mobile phase was prepared with methanol, acetonitrile and ammonium acetate 
solution on the proportions 7:7:6 respectively, filtered using a 0.45 µm Nylon membrane 
(Supelco Analytical, Bellefonte, USA) and sonicated during 1 h prior use. Samples of 25 
L were injected at a constant flow rate of 1.0 mL/min. Tetracaine was detected at 311 
nm with a retention time of ca. 6.9 minutes. Ropivacaine was detected at 210 nm and the 
retention time was ca. 9.1 minutes. Both methods showed a linear response in the 0.01-
500 mg/mL with a daily RSD < ± 6.0%. 
5.2.3.2. Particle size analysis 
Liposome size distribution was measured by DLS that provides the mean particle size 
(Z-average), and the PI. Measurements were performed in a Delsa Nano C Submicron 
(Beckman Coulter, Krefeld, Germany) apparatus, at 25 °C, with a fixed angle of 
160°.Sizes are expressed as average values of the liposomal hydrodynamic diameter. 
To avoid multi-scattering phenomena, liposome suspensions were diluted with 
ultrapurified water. Samples were analyzed 24 h after preparation. The PI is a measure 
of a unimodal size distribution. A value of PI < 0.1 indicates the existence of a 
homogenous population, while a PI > 0.3 indicates a higher heterogeneity. Results are 
presented as mean ± SD, extracted from the cumulate algorithm (Goll and Stock; 
Kaszuba et al., 2008). 
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5.2.3.3. Zeta Potencial 
Zeta potential of diluted liposomal dispersions was determined from electrophoretic 
mobility measurements using a Delsa Nano C Submicron (Beckman Coulter, Krefeld, 
Germany) at 25 °C. The Zeta Potential was calculated using the Helmholtz–
Smoluchowsky equation (Lyklema and Overbeek, 1961). 
5.2.3.4. Liposome encapsulation efficiency 
Liposome encapsulation efficiency is defined as the ratio between the masses of original 
drug added to solution and the drug encapsulated in the liposome formulation, and was 
determined indirectly. The ultrafiltration-centrifugation method was carried out across 
centrifugal filters (Amicon® Ultra-4, Millipore, Germany) with a 100 kDa molecular weight 
cut-off. The samples were centrifuged during 60 min at 13229 rpm using a Minispin® 
(Eppendorf Ibérica S.L., Madrid, Spain). Non-entrapped drug obtained from the 
supernatant solution was quantified by HPLC. The encapsulation efficiency (EE %) was 
calculated according to the equation (5.1), 
𝐸𝐸% =
[𝑄𝑡−𝑄𝑠]
[𝑄𝑡] 
× 100         (5.1) 
where the Qt is the theoretical amount of each drug that was initially added to the system 
and Qs is the amount of each drug detected in the supernatant. 
5.2.4. In vitro permeation studies 
The in vitro permeation studies were carried out in vertical Franz diffusion cells 
(PermeGear, Inc., PA, USA), with an average volume of 5.1 cm3 and an average surface 
area of 0.64 cm2. Prior to the experiments, skin samples (prepared as mentioned in 
section 5.2.4.1.) were submerged in PBS (pH=7.4) during 1 h for equilibration and placed 
between the donor and receptor compartments, with the epidermal side up. The receiver 
chamber was filled with PBS with 1 % of CD to ensure sink conditions. Each chamber 
jacket was maintained at 37 ºC ± 0.1 and kept stirring at 600 rpm during the permeation 
experiments. 0.5 mL of drug-loaded liposome in hydrogels optimized as mentioned in 
section 5.2.3, were placed in each donor compartment and immediately covered with 
Parafilm® to prevent evaporation. At predetermined time points (0, 2, 4, 6, 8, 18, 20, 22 
and 24 h) 300 L samples were collected from the receptor compartment and 
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immediately replaced with the same amount of PBS solution. Samples were kept in the 
refrigerator prior to HPLC analysis. 
5.2.4.1. Porcine skin preparation 
Newborn porcine skin tissue used as skin model, was excised and dermatomed with 700 
μm of thickness using a Padgett® Model B Electric Dermatome (Integra LifeSciences, 
Plainsboro, NJ) and frozen at -20ºC. Prior to the experiments, the frozen skin samples 
were thawed at room temperature, immersed in PBS (pH=7.4) for 1 h, for equilibration. 
5.2.4.2. Data analysis in the permeation studies 
The cumulative drug amount present in the receptor compartment solution after 24 h 
(Q24) and expressed in µg/cm
2 was calculated as before. Flux and enhancing ratio also 
followed the procedures described in previous Chapters 3 and 4. 
Results are presented as mean ± standard deviation (n), where n is the number of 
replicates. 
5.2.4.3. Statistical analysis 
Differences between flux values were examined for significance using unpaired 
Student’s t-test. The p value was set to 0.05, with p < 0.05 indicating statistical 
significance in the differences between control and enhancers tested. This analysis was 
performed using Origin® graphing and analysis (OriginLab Corp, Northampton, USA). 
5.2.5. Stability studies 
Particle size, zeta potential values and entrapment efficiency were monitored during a 
period of 6 months to evaluate the stability of the formulation LPS-LP 16Lys16(0). 
5.3. Results and Discussion 
Preliminary solubility studies were performed to select the best method to prepare the 
liposomes. The formulations were optimized according to size, zeta potential and 
encapsulation efficiency described below. 
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5.3.1. Solubility studies 
The choice of PC and CHO was based on previous data available in the literature 
(McCormack and Gregoriadis, 1994a, b, 1998). PC is considered a skin permeation 
enhancer, whose effects are attributed to an intercalation into the structured lipids of the 
SC and disturbance of the lipid packing (Williams and Barry, 2012). The solubility of the 
drugs in different vesicles is presented in Table 5-1. 
Table 5-1. Solubility of both drugs in different liposomal formulations. Data are expressed as mean ± SD, 
n=3. 
Formulation Tetracaine solubility (mg/mL) Ropivacaine solubility (mg/mL) 
LPS-LP 24.6 ± 1.7 3.8 ± 0.2 
LPS-AP 21.3 ± 1.6 1.4 ± 0.1 
LPS-LP (14Ser)2N5 20.7 ± 2.3 4.1 ± 0.3 
LPS-LP 10Lys10(0) 20.3 ± 1.4 3.5 ± 0.2 
LPS-LP 16Lys16(0) 24.6 ± 1.6 5.8 ± 0.5 
 
According to the results presented in Table 5-1, the method LPS-LP, where TC was 
directly dissolved in the lipophilic phase and the RPC in the hydrophilic phase, was 
selected because it provided maximal solubility for both drugs. The liposomes prepared 
with aminoacid-based surfactant, namely lysine-based surfactant 16Lys16(0), showed 
higher solubility particularly in the case of RPC. The solubility of the drugs in the lipid 
phase is known to be an important condition to obtain a satisfactory encapsulation 
efficiency (Jannin et al., 2008). Based on these results, the concentration of lipid phase 
was adjusted to obtain the maximal solubility for both drugs. 
5.3.2. Liposomes characterization 
Encapsulation efficiency, size and zeta potential of liposomes with different lipid 
composition were determined. The influence of the liposomes preparation methods was 
also evaluated. The results are presented in Table 5-2. 
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Table 5-2 Mean particle size (PS), average polydispersitivity index (PI), zeta potential (Zeta) and 
encapsulation efficiency (EE). Samples identified with an LPS-LP were prepared by directly dissolving the 
drug in the lipid phase. LPS-AP refer to samples in which TC-CD complexes were pre-dissolved in the 
aqueous solution used to hydrate the lipid film. 
Formulation Molar  
Ratio 
PS  
(nm) 
PI Zeta  
Potential (mV) 
EE/%  
TC 
EE/%  
RPC 
LPS-LP 70:30 201.3 ± 2.8  0.184 33.99 ± 0.31 56.1 ± 0.3 64.2 ± 0.1 
LPS-AP 70:30 205.5 ± 5.3 0.192  49.31 ± 0.16 61.3 ± 0.2 43.1 ± 0.3 
LPS-LP 60:40 178.6 ± 1.9 0.170  63.33 ± 0.21 59.6 ± 0.3 67.4 ± 0.4  
LPS-AP 60:40 206.5 ± 1.0 0.203  64.13 ± 0.28 74.2 ± 0.2 63.0 ± 0.1 
LPS-LP 50:50 174.4 ± 2.0 0,175  31.47 ± 0.18 47.6 ± 0.4  64.3 ± 0.2 
LPS-AP 50:50 210.9 ± 2.6 0.265  45.12 ± 0.24 62.7 ± 0.5  42.4 ± 0.2 
LPS-LP (14Ser)2N5(+) 60:30:10 149.8 ± 1.2 0.137  33.16 ± 0.39 65.1 ± 0.2 61.4 ± 0.3 
LPS-LP 10Lys10(0) 60:30:10 176.0 ± 3.7  0.145  30.43 ± 0.38 66.7 ± 0.3 62.3 ± 0.1 
LPS-LP 16Lys16(0) 60:30:10 151.6 ± 1.8 0.124  32.66 ± 0.17 75.3 ± 0.4 73.1 ± 0.1 
All liposomal formulations showed a satisfactory PI (below 0.3), which indicates 
reasonable size homogeneity of the liposomes. The mean diameter of the various 
liposomal suspensions ranged from 150 to 210 nm. The average zeta potential stayed 
within the stability limits (> 30 mV) in all formulations. According to the results, the 
increase the amount of L-α-phosphatidylcholine in the liposomes (LPS-LP) caused an 
increase in the mean particle size and in the polydispersitivity index. In contrast, the 
entrapment efficiency did not vary significantly. 60PC:40CHO formulations showed the 
highest absolute value of the zeta potential indicating an excellent stability (> 60 mV). 
Results obtained showed that the most efficient encapsulation and smallest particle size 
were achieved when TC was directly dissolved in the lipophilic phase and RPC in the 
aqueous phase (LPS-LP). The formulation (60mol PC: 40mol CHO: 10mol 16Lys16(0)) 
showed to be a promising formulation for drug delivery, since it combines a good stability 
with a good EE %. This formulation was selected to proceed in the in vivo studies 
(Chapter 6) and its stability was evaluated for a period of 6 months  
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5.3.3. In vitro permeation studies 
5.3.3.1. Percutaneous drug delivery of tetracaine 
The focus of this Chapter was the evaluation of the permeation of TC and RPC from the 
liposomal formulations. Prior to the in vitro permeation studies, formulations were 
previously optimized, as described in section 5.3.2. The formulations selected were 
applied to the epidermal side of dermatomed porcine skin placed between the donor and 
receptor compartments of Franz diffusion cells. The results obtained are presented in 
Table 5-3, and the permeation profiles shown in Figure 5.3. 
 
Figure 5.3 Cumulative amount of tetracaine permeated across porcine skin as a function of time.  
The liposomes prepared with lysine-based surfactant caused a significant increase (p< 
0.05) on tetracaine permeation when compared to control. The surfactant with longer 
alkyl chain (16Lys16(0)) was the most effective permeation enhancer, resulting in higher 
flux (34 µg/cm-2/h, control 29 µg/cm-2/h), a higher value of Q24 (767 µg/cm
-2, control 451 
µg/cm-2) and a significantly lower lag time (1.4 h, control 4.4 h). In contrast, the 
liposomes prepared with serine-based surfactant determined a slight reduction in the 
permeation flux (26 µg/cm-2/h) and lag time of 3.7 h. 
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Table 5-3 Tetracaine percutaneous permeation from liposome formulations across porcine skin. Data are 
presented as means ± S.D. (4≤N≤6). 
Liposomal formulation Flux / µg cm
-2
 h
-1
 Q24 / µg cm
-2
 Lag Time / h
-1
 ER 
Control 29.09 ± 1.39 451 ± 23 4.41 ± 0.21  
LPS-LP (14Ser)2N5 26.06 ± 2.43 457 ± 27 3.74 ± 0.17 0.90 
LPS-LP 10Lys10(0) 32.80* ± 2.88 747* ± 66 1.94* ± 0.24 1.14 
LPS-LP 16Lys16(0) 33.71* ± 2.82 767* ± 71 1.41* ± 0.34 1.16 
* Statistically significant difference between Control and liposomes, at p < 0.05 (Student’s t-test) 
5.3.3.2. Percutaneous delivery of ropivacaine 
The results obtained with ropivacaine are presented in Table 5-4 and the permeation 
profiles shown in Figure 5.4. 
 
Figure 5.4 Cumulative amount of ropivacaine permeated across porcine skin as a function of time. 
Similarly with the previous results, obtained with TC, the liposomal formulations prepared 
with lysine-based surfactant with longer alkyl chain 16Lys16(0) showed a higher flux 3 
µg/cm-2/h (1.4-fold higher than control). The value of Q24 obtained (76 µg/cm
-2) was also 
significantly higher than the control (18 µg/cm-2). The lag time was significantly reduced 
to 1.2 h (control 4.1 h). Liposome formulation containing serine-based surfactant (LPS-
LP(14Ser)2N5) exhibited a permeation profile very similar to the control. 
It is worthy of note that the incorporation of the lysine-based surfactants in the liposomal 
formulation clearly determined an increase in the flux of ropivacaine, however, the 
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absolute values of permeation attained are generally small. This result is due to the 
hydrophilic nature of the drug. In this case, it is seen that the composition of the 
liposomes strongly influences the permeation of RPC. Clearly, the liposomes containing 
lysine-based surfactants resulted in higher values of permeation. 
Table 5-4 Ropivacaine percutaneous permeation from liposome formulations across porcine skin liposome 
on percutaneous permeation of tetracaine across porcine skin. Data are presented as means ± S.D. 
(4≤N≤6). 
Liposome formulation Flux / µg cm
-2
 h
-1
 Q24 / µg cm
-2
 Lag Time / h
-1
 ER 
Control 1.40 ± 0.12 17.95 ± 1.84 4.12 ± 0.17  
LPS-LP (14Ser)2N5 1.23 ± 0.14 17.25 ± 1.72 3.45 ± 0.25 0.90 
LPS-LP 10Lys10(0) 2.61 ± 0.34 59.58 ± 8.6 1.18 ± 0.12 2.12 
LPS-LP 16Lys16(0) 2.97* ± 0.35 75.72* ± 12.36 1.23 ± 0.30 2.14 
* Statistically significant difference between control and liposomes, at p < 0.05 (Student’s t-test) 
5.3.3.3. Overview and comparison 
In this Chapter, the incorporation of a chemical permeation enhancer in a conventional 
liposome formulation (previously optimized in section 5.3.1. and 5.3.2.) was thoroughly 
investigated. Generally, the incorporation of lysine-based surfactant promoted higher 
fluxes of tetracaine and ropivacaine when compared to the liposomal formulations 
containing serine-based surfactant. The synergistic effect of lysine-based surfactants has 
already been addressed in this thesis (Chapter 3). The permeation of both drugs 
significantly increased when the lysine-based surfactant with higher alkyl chain were 
employed, yielding a flux enhancement for TC and RPC (1.16 and 2.14-fold) compared 
to the formulation considered as control, followed by (LPS-LP 10Lys10(0)) with a ER of 
1.14 and 2.12 for TC and RPC respectively (Table 5-3 and Table 5-4). 
According to findings addressed in Chapter 4, serine-based surfactant with longer alkyl 
chain ((14Ser)2N5) led to an increase in the tetracaine permeation. This was the reason 
why the ((14Ser)2N5) was selected for this study. However, when the latter was 
incorporated in the liposome formulation the differences on the flux observed was 
negligible. This behavior is probably related to the limited solubility of the ((14Ser)2N5). 
Focusing now on the differential behavior of the co-encapsulated drugs, the slower 
permeation observed with tetracaine can be attributed to a difference in the solubility of 
the drugs in the lipid phase. Additionally, the lag time for TC and RPC was reduced when 
lysine-based surfactant was incorporated in the liposomes but no significant difference 
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was found when (14Ser)2N5 was used. These results are quite relevant, particularly with 
of local anesthetics, where the onset of the therapeutic response depends on short lag 
times. 
5.3.4. Stability studies 
 
Figure 5.5 Particle size, zeta potential and efficiency encapsulation of optimized formulation (LPS-AP 
60:30:10 16Lys16(0)) after preparation and after six months (n=3) results are presented as means ± S.D. 
The results presented refer to the physicochemical stability of the formulation with better 
permeation profile (LPS-AP 16Lys16(0)). Data showed that the size, zeta potential and 
encapsulation efficiency of the liposomes was not significantly influenced during a period 
of 6 months (Figure 5.5). 
5.4. Conclusions 
This study shows that liposomal formulations were able to efficiently deliver tetracaine 
and ropivacaine. The highest encapsulation efficiency and smallest particle size were 
achieved when TC was directly dissolved in the lipophilic phase and RPC in the 
hydrophilic phase (LPS-LP). The combination of liposomes (L-α-phosphatidylcholine, 
cholesterol) with lysine-based surfactant with the longer alkyl chain LPS-LP 16Lys16(0) 
resulted in the highest permeation, with a marked synergistic effect. These results 
suggest that these liposome formulations are promising and versatile vehicles for the 
concomitant dermal delivery of tetracaine and ropivacaine. 
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Chapter 6 
6. In vivo studies using tail-flick analgesic test  
This Chapter describes the in vivo pharmacodynamic studies of TC and RPC loaded 
hydrogels and liposomal formulations previously optimized (Chapters 3, 4 and 5). The 
goal was the evaluation of the performance of the above mentioned formulations, applied 
topically in Wistar Rats. The in vivo studies were performed using the tail-flick test that is 
the most frequently method used to measure pain levels and assess the effect of 
anesthesia. 
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6.1. Introduction  
Often, data obtained from in vitro studies may not directly be translated in terms of 
biological equivalence. The differences in the therapeutic responses may be related to 
the active substance and/or its pharmaceutical form or due to the inter-individual 
variability. In vivo studies are used to evaluate formulations and to monitor drug delivery 
after administration in animals or human volunteers. In vivo studies have advantages 
such as the generation of realistic measures of the amount of drug that permeate into the 
skin and reach the systemic circulation.  
Various methods have been employed to observe the effect of local anesthetics (Kokubu 
et al., 1990). The tail-flick (TF) test is the most frequently used perception test for 
measuring the severity of acute or chronic pain. The in vivo pharmacodynamics studies 
were conducted in Wistar rats using the TF technique, in order to examine the ability of 
the formulations to reduce the responsiveness of the animals after increasing the 
temperature (Cargill et al., 1985). The TF equipment consists of a restraining cage, a 
light source with adjustable intensity and a light sensor. The ensemble is connected to a 
chronograph that is triggered at the same time as the light source. The referred light 
sensor stops the timer at the first beam of light it receives. The animal’s tail is positioned 
above the sensor and exactly below the light source, thus, its withdrawal or flick sets off 
the timer by activation of the sensor. The tail flick test is the most frequently used method 
to measure pain levels and assess the effects of anesthesia. The pain evaluation, by 
means of the latency time, depends on the intensity of the stimulus. The withdrawal 
latency, for the animal, shall be set accordingly and might be in the range of 5 – 10 s 
(Barrot, 2012). In order to avoid tissue damage the cut-off time must be set to not 
overpass approximately 3 times the baseline and the latter must be set in order to obtain 
a regular response in the animal, thus differing hypo or hyperalgesic animals from the 
control (EUMODIC, 2014). The test must be performed by an experienced person in a 
calm and quiet space without any external influences. Room temperature and humidity 
must also be taken into consideration. It is important to notice that the stress caused by 
the environment change and the manipulation of the animals may result in misleading 
results (Barrot, 2012; Le Bars et al., 2001). This technique does not require a surgical 
procedure to administer the local formulations anesthetics and the duration of action can 
be easily assessed with a standard tail-flick apparatus. 
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Various passive methods have been used to potentiate drug transport across the skin 
(Alexander et al., 2012). The chemical permeation enhancers and the combination of the 
latter with liposomes have emerged as promising strategies to improve skin permeation 
of drugs (Cevc and Blume, 2001; Cevc et al., 1997; Cevc et al., 1998).  
This Chapter encompasses the physiological effects of a series of selected anesthetic 
formulations. The selection was based on in vitro release studies results addressed in 
Chapter 3, 4 and 5. Here it is reported the assessment of the efficacy of hydrogels and 
liposomes based formulations of tetracaine and ropivacaine prepared with lysine-based 
surfactants. The analgesic response was compared with a commercial formulation 
(Ametop®) and the influence of the concentration of drugs was also evaluated. 
6.2. Experimental section 
6.2.1. Materials 
TC, PC, chloroform and CHO were purchased from Sigma Aldrich (Saint Louis, MO, 
USA). RPC was a kind gift from AstraZeneca (London, United Kingdom), and HPMC 
K15M a kind gift from Dow Chemical Company (Midland, MI, USA). HP-β-CD with 97% 
of purity, with an average degree of substitution of 2 to 6 units of 2-hydroxypropyl 
(C3H7O) per glucose unit, and with an average molecular weight of 1380 g/mol, was 
purchased from Acros Organic (Geel, Belgium). The nonionic lysine (10Lys10(0) and 
16Lys16(0)) and serine-based surfactant (14Ser)2N5 used in this study were synthesized 
and purified according a method previously developed and reported by some of the 
authors (Goreti Silva et al., 2012; Silva et al., 2013b). The purity of the compounds was 
determined by NMR, elemental analysis, surface tension and DSC. Ametop® (4 mg/mL) 
was purchased from Smith&Nephew (Kingston upon Hull, London, UK). The Wistar rats 
were purchased from Charles River (Barcelone, Spain). All materials were used as 
received. 
6.2.2. Animal selection for in vivo studies 
The study has been approved by the ethics committee of the Faculty of Pharmacy, 
University of Coimbra. Wistar rats (Figure 6.1) weighing 417 g ± 29.5 were kept under 
controlled temperature (22 ± 1˚C) and humidity (55 %) during all the experiments. The 
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animals were acclimatized in wire cages in a 12/12 h light/dark cycle and were separated 
in groups of eight prior to start of the experiments (n=8). The animals had free access to 
food (pellets diet) and tap water during the experimental. All procedures were conducted 
in Faculty of Pharmacy, University of Coimbra.  
 
Figure 6.1 Wistar rat used in the in vivo experiments. 
6.2.3. Optimized formulations for in vivo studies 
6.2.3.1. Composition and preparation of tetracaine and ropivacaine hydrogels 
The optimized hydrogels formulations of tetracaine, ropivacaine and its combinations 
(Chapter 3) were mixed with the permeation enhancer (16Lys16(0)) and were prepared 
according to Table 6-2.  
Table 6-1 Hydrogel formulation preparation.  
 HPMC (%) TC (mM) RPC (mM) CPE (mM) 
Hyd_0 1 - - - 
Hyd_TC 1 0.095 - - 
Hyd_RPC 1 - 0.091 - 
Hyd_TC:RPC 1 0.095 0.091 - 
Hyd_L_0 1 - - 0.0031 
Hyd_L_TC 1 0.095 - 0.0031 
Hyd_L_RPC 1 - 0.091 0.0031 
Hyd_L_TC:RPC 1 0.095 0.091 0.0031 
The hydrogel containing 2.5 % (w/w) TC was mixed with appropriate amounts of HP-β-
CD (Teixeira et al., 2014b), 1 % (w/w) HPMC K15M, 16Lys16(0) and deionized water. 
Chapter 6 
138 
Ropivacaine hydrogel was composed of 2.5 % (w/w) RPC, 1 % (w/w) HPMC, 16Lys16(0) 
and deionized water. These formulations were referred in this Chapter as Hyd_L_TC; 
Hyd_L_RPC; Hyd_L_TC:RPC. A control hydrogel formulation containing TC, RPC and 
its combinations, referred as Hyd_TC; Hyd_RPC; Hyd_TC:RPC was prepared without 
16Lys16(0). An alternative hydrogel formulation without drug (Hyd_0) was used as 
placebo. The polymers solutions were kept stirring for 24 h at low speed (50 rpm) before 
use to ensure complete homogenization. The compounds were soluble in the hydrogel at 
the concentration used. 
6.2.3.2. Preparation of liposomal formulation by TLE method 
Liposomal formulations for in vivo studies were prepared by TLE method (Bangham et 
al., 1965) according to Table 6-2.  
Table 6-2 Liposomal formulation preparation. 
 HPMC (%) TC (mM) RPC (mM) CPE (mM) PC (mM) CHO (mM) 
Lip_0 1 - -  0.029 0.014 
Lip_TC 1 0.095 - 0.0031 0.029 0.014 
Lip_RPC 1 - 0.091 0.0031 0.029 0.014 
Lip_TC:RPC 1 0.095 0.091 0.0031 0.029 0.014 
The formulation LPS-LP 16Lys16(0) optimized as reported in Chapter 5 was selected to 
proceed with in vivo studies due to the maximal enhancement permeation, size and zeta 
potential. The lipids (PC: CHO) and lysine-based surfactant (16Lys16) were dissolved in 
a small quantity of chloroform and was afterwards removed under vacuum (Buchi - 
Rotavapor R-210 with a vaccum pump V-700 and a vaccum controller V-850) at 55ºC 
(Buchi Heating Bath B-491). Evaporation was carried out for a period of 2 h to ensure 
that all the traces of solvent were removed. After the dry lipid appeared on the flask wall, 
three different liposomal formulations composed of 2.5 % of TC and RPC were prepared. 
Firstly, the TC was directly dissolved in the lipophilic phase, and the hydrophilic phase 
was constituted only by water (Lip_TC). Secondly, the aqueous phase constituted by 
RPC was added to the lipophilic phase containing TC (Lip_TC:RPC). Finally, a water 
solution containing RPC was used to hydrate the lipid content (Lip_RPC). A placebo 
liposomal formulation prepared without drug and is referred as Lip_0. Note that the 
quantities of both drugs were chosen to ensure maximization of the amount within 
suitable entrapment efficiency, as established from preliminary tests (Chapter 5). After 
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adding the hydrophilic phase, the suspension was alternately shaken using a vortex 
mixer and sonicated using a bath sonicator (Clifton Ultrasonic Bath, London, United 
Kingdom) at 55 ºC, during 30 min to allow vesicle formation. The liposome suspension 
was extruded through a 100 nm polycarbonate membrane using a LipoFast extrusor 
Avestin®. In order to obtain viscosity values adequate for dermal application, a hydrogel 
of 1 % (w/V) of 15 M HPMC was added to the formulation mentioned above at low speed 
(50 rpm) during 24 h to ensure complete homogenization. 
6.2.4. Experimental protocol 
The anesthetic effect of 2.5 % (w/w) of tetracaine, 2.5% (w/w) of ropivacaine and its 
combinations was tested in Wistar rats using the tail-flick analgesic test (D'AMOUR and 
SMITH, 1941). The hydrogels formulations were prepared according to Table 6-2 and 
the liposomal formulation was prepared according to Table 6-2. The effects of the 
anesthetic formulations were compared with a commercially available product (Ametop® 
4mg/mL) and the placebos (Hyd_0; Hyd_P_0; Lip_0). 
Prior to the experiments, the animals were brought from their housing and left to 
acclimatize for 15 min. For each set of experiments (n=8), at time 0 h, 100 µL of each 
formulation was applied to the skin on the proximal third of the tail (1.5 cm from the root 
of the tail). 
 
Figure 6.2 Tail-flick analgesimeter apparatus. 
Rats were restrained on the tail-flick analgesimeter Letica (Scientific instruments, 
Barcelona, Spain) – heat stimulus and chronograph were triggered at the touch of a 
button. Each animal was positioned in the restraining cage and left it still for some 
moments. The luminous heat stimulus and time counter stopped when the exposed rat’s 
tail flicked and cut-off time was set to 30 s to avoid tissue damage. The tail was 
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positioned on the equipment’s groove and the light was turned on; automatically the 
chronograph started to count and at the first flick of the tail the counter was stopped 
(Figure 6.2). 
The animal was removed from the restraining cage when the heat source was cut off. 
The anesthetic effect, as well as the formulations without drugs and the blank group (no 
formulation), was tested hourly during a period of 6 h. 
6.2.4.1. Statistical analysis  
Differences between the values obtained at the chronograph were recorded and 
examined for significance using unpaired Student’s t-test. The p value was set to 0.05, 
with p < 0.05, indicating statistical significance in the differences between formulations 
tested and the commercial formulation. 
6.3. Results and discussion 
In vivo pharmacodynamics studies were performed in Wister rats, in order to evaluate 
the efficiency of selected formulations. All animals were able to move their tails at 
random during the experiments. The dosage of the positive control (commercial) was of 
4 mg/mL and tested formulations had 2.5 mg/mL of tetracaine and ropivacaine. The 
results obtained are represented in Figure 6.3. 
Generally, the response of drugs starts 1 h after the application of the formulations. 
However, a noticeable anesthetic effect reached a maximum at 3 to 4 hours after the 
skin application of the formulation. The effect was maintained for 2 h more and then 
decreased at approximately 6 h. For this reason, the results are shown for the 3rd and 4th 
hour. 
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Figure 6.3. Response time for each different formulation with 2.5 % of the respective drug and their 
combination on the tail-flick analgesimeter. Formulation A was a hydrogel; B formulation was a hydrogel 
containing 16-Lys-16 as CPE. t-student test was carried out to evaluate statistical difference between the 
formulations A and B and the commercial formulation (positive control) * p < 0.05; ** p < 0.01; *** p < 0.001. 
The results showed that a small change in the reflex time was noticed in rats which were 
exposed to the developed formulations. The reflex time values were higher for 
formulations containing tetracaine than for formulations containing ropivacaine. The main 
reason for this might be related to RPC properties: on its hydrochloride form, this 
molecule is ionized and hydrophilic and, consequently, poorly absorbed across the skin.  
The results revealed that the duration of the anesthetic effect increased with the 
hydrogels formulations containing lysine-based surfactant (16Lys16) when compared 
with the hydrogel formulation without lysine-based surfactant (Figure 6.3). These findings 
are in agreement with the in vitro skin permeation studies data, reported in Chapter 3. 
There are no statistical differences between the formulations except Hyd_TC exhibiting a 
prolonged duration of the anesthetic effect compared to Hyd_RPC. However the duration 
of RPC clearly increase when the lysine-based formulation is added to the hydrogel. 
 
Figure 6.4 Response time for each different formulation with the respective drug and their combination on 
the tail-flick analgesimeter. The formulation was a liposome. t-student test was carried out to evaluated the 
statistical difference between the proposed formulations A and B and the positive control (commercial 
formulation (positive control) * p < 0.05; ** p < 0.01; *** p < 0.001. 
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The dermal administration to rats resulted in steady-state levels reached at 
approximately 3 h and maintained for a period of 6 h. The statistical analysis performed 
show that Lip_TC:RPC was the only formulation that showed no significant statistical 
difference (p > 0.05) when compared to the positive control (commercial formulation) 
(Figure 6.4). These findings are also in agreement with the in vitro results, where the flux 
was higher for liposomes (34 and 3 µg cm-2 h-1 for TC and RPC respectively) than in the 
hydrogel formulation (26 and 1.7 µg cm-2 h-1). The main advantage of liposomal 
formulations is the faster onset of analgesia when compared to hydrogels formulations. 
Despite the promising results obtained with the liposomal formulation, the anesthetic 
effect is lower than the anesthetic effect obtained with the commercial formulation 
Ametop®, probably due to the lower tetracaine content (2.5 % (w/w) vs 4 % (w/w) in 
Ametop®). The differences between in vitro and in vivo studies can also be attributed to 
the skin model used; rat versus newborn pig skin. The animals may likewise have 
suffered from test adaptability due to the repetitive measuring (Shin et al., 2004). It is 
important to note that the skin integrity, maintained practically unalterable after 
formulation removal with the exception of the commercial formulation that in some 
causes caused damage in the skin of the tail. 
6.4. Conclusion  
The results clearly demonstrate increases in the local analgesic responses of the 
selected formulations. The in vivo experiments in rats correlated partially the in vitro 
findings and revealed that the hydrogels combined with lysine-based surfactants, results 
in an anesthetic effect higher than the hydrogel without CPE. However the liposomal 
formulations showed a higher analgesic response exhibiting a better in vivo performance 
compared to any hydrogel formulations. Based on data obtained it as concluded that this 
formulation was the most similar to the commercial formulation (Ametop®) regarding the 
analgesic effects produced. These findings support the use of liposomal formulation may 
be an efficient approach for topical application, for the concomitant administration of 
tetracaine and ropivacaine. 
Chapter 7 
143 
 
Chapter 7 
7. Concluding remarks and future work 
The work reported in this thesis highlight the importance of combining different strategies 
to increase the permeation of two distinct local anesthetics across the skin, without 
causing skin irritation or damage. It relies on fundamental approaches for the study of 
the formulation, based on HPMC hydrogels, including systems containing cyclodextrins, 
aminoacid-based gemini surfactants and liposomes. 
Chapter 2 provides a clear indication of the effect of TC protonation on the aqueous 
solubility in the absence and presence of β-CD and HP-β-CD and how such interactions 
affects the transport of TC, at different concentrations, across a model membrane. UV-
Vis and fluorescence spectroscopy data revealed that TC interacts with both CD on a 1:1 
stoichiometry and the presence of latter increase the solubility of TC. However the 
release of TC decreases by increasing the CD concentration, being more effective in the 
protonated form. This work showed that such behavior does not depend on the formation 
of inclusion host-guest compounds, but due to the formation of weak supramolecular 
assemblies. The kinetics and mechanism of TC release from HPMC gels was also 
evaluated providing an insight on the role of CD on the TC transport. This Chapter 
demonstrated that both forms of TC were successfully released from the formulations at 
a controlled rate, following a Super-Case II transport mechanism and the transport of TC 
can be tuned by using CD, especially the HP-β-CD. 
In what concerns the study reporting the evaluation of a series of nonionic and anionic 
lysine-based surfactants as CPE (Chapter 3), it was found that the most effective CPE 
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for both drugs was the compound with the longest alkyl chain comprising 16 carbon 
atoms (16Lys16). The highest enhancing effect was achieved for ropivacaine, a drug that 
is does not easily administered cross the stratum corneum, attaining an approximately 6-
fold enhancement, certainly due to a combination of effects such as membrane 
perturbation, resulting from surface exposure of the anionic surfactant headgroups and 
favorable electrostatic interactions with the drug. In this case, the 16Lys16(-) was the 
most effective (ER=6.12), while in the case of TC this was observed for 16Lys16(0), 
probably due to a combine perturbation/hydrophobic effects (comparatively weaker, in 
any case, than the electrostatic effect mentioned above). Molecular dynamics 
simulations have shown to be a useful tool for a mechanistic rationalization of the system 
behavior. MD data results also suggested that lysine-based surfactants are promising 
candidates to increase drug transport, especially for hydrophilic drugs, through the SC 
without altering the skin tissue morphology and with the advantage of being non 
cytotoxic. 
In Chapter 4, a series of nonionic and cationic serine-based gemini surfactant were 
evaluated as skin permeation enhancers for two tetracaine and ropivacaine. The 
enhancement effects observed were dependent on the penetration modifier and on the 
drug used. It was observed that the most effectives CPE were the cationic surfactants 
with longer alkyl chain and shorter spacer (14Ser)2N5(+) for both drugs. The 
enhancement flux values observed were higher for RPC (ER=3) and lower in the studies 
with TC (ER=2). Molecular dynamics simulations provided results in accordance with the 
experimental observations. Complementary studies such as formulation optimization, 
cytotoxicity studies on the CPE in HEK and electronic microscopy studies provided 
valuable information about toxicity to the skin cells and of irritation or morphological 
changes in the skin tissue. The results obtained showed that the compounds and 
methodology used are suitable, safe and that these compounds are promising 
candidates to be used as CPE. Despite that skin integrity evaluation studies did not 
reveal significant changes in the tissue morphology after the use of the CPE (Chapter 3 
and 4), the long term local and systemic toxicity of the chemical enhancers in the final 
dosage form require further studies and should be carefully assessed. 
Regarding Chapter 5, describes the evaluation of liposomes prepared with aminoacid-
based surfactants in terms of permeation for topical administration. For this purpose, 
size, polidispersivity index, potential zeta and encapsulation efficiency of various 
liposomal formulations containing TC and RPC were assessed and compared. The 
results obtained indicate that liposomal formulations were able to efficiently co-entrap TC 
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and RPC providing a reservoir system for long-term administration. This work showed 
that the efficacy of the liposomes regarding the permeation clearly was improved when 
using lysine-based surfactants were employed. Generally, the amount of TC and RPC 
permeated significantly increased and at the lag time decreased. These results are new 
and significant, confirming that their use as delivery agents, in pharmaceutical 
formulations especially in the case of ropivacaine hydrochloride.  
Chapter 6, addresses the evaluation of a series of previously optimized formulations in 
vivo, using Wistar rats. For this, the tail-flick technique showed to be a simple, reliable 
and useful test for the in vivo assessment of local anesthetic effects. The results showed 
that the analgesic response was found to be dependent on the drug concentration and 
composition of the systems. The application of the tested formulations did not determine 
any macroscopic alteration on the skin of the animals. The liposomal formulation 
containing lysine-based surfactant may constitute a promising formulation for further 
clinical application in the treatment of acute and chronic pain or before a surgery 
procedure. Additionally, supplementary in vivo experiments involving the von Frey fibers 
should be performed in humans in order to evaluate and determine the therapeutic 
efficacy of the final formulations containing both drugs. 
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Appendix 
A. Simultaneous quantification of tetracaine and 
ropivacaine using a rapid reversed-phase HPLC 
method 
The characterization of the formulations in terms of drug content described in the 
previous Chapters followed a suitable and validated method. 
In this appendix, it is reported the development and validation of a simple new HPLC 
method for simultaneous quantification of tetracaine and ropivacaine. The validated 
method was used to determine both the content of TC and RPC incorporated in the 
liposomes. 
Appendix 
166 
1.A. Materials 
TC and ammonium acetate were acquired from Sigma Aldrich (St. Louis, MO, United 
States of America). HP-β-CD with 97% of purity, with an average degree of substitution 
of 2 to 6 units of 2-hydroxypropyl (C3H7O) per glucose unit, and with an average 
molecular weight of 1380 g/mol, was purchased from Acros Organic (Geel, Belgium). 
RPC was a gift from AstraZeneca (London, United Kingdom). MeOH and ACN HPLC 
grade were purchased from LiChroSolv Merck (Darmstadt, Germany). Grade A 
volumetric flasks were purchase from Fisher (Loughbrough,UK). Clear glass HPLC vials 
(2 ml) and 0.350 mL inserts were acquired from Supelco - Sigma Aldrich (St. Louis, MO, 
United States of America). All reactants were used as received. 
2.A. Instrumentation and chromatographic conditions 
The HPLC analysis of TC and RPC was carried out using a Shimadzu LC-2010C HT 
apparatus (Shimadzu Co., Kyoto, Japan) equipped with a quaternary pump, a vacuum 
degasser, an autosampler unit, and a L2450 UV/visible dual wavelength detector and the 
chromatographic analysis were conducted in isocratic mode. The quantification of both 
drugs was carried out using a Phenomenex® reverse phase C18 column Luna (Torrance, 
CA, USA) with 5 µm particle size and 250 mm x 4.6 mm length with a SecurityGuard™ 
cartridge Phenomenex® (Torrance, CA, USA) as the stationary phase, at 25°C. The 
results were processed using Shimadzu LC-solution software version 1.12. The mobile 
phase was prepared by mixing methanol, acetonitrile and ammonium acetate solution on 
the proportions 7:7:6 respectively. The solution was subsequently filtered using a 0.45 
µm Nylon membrane (Supelco Analytical, Bellefonte, USA) and sonicated for 1 h prior to 
use. The detection was carried out at 311 nm for TC and 210 nm for RPC. The injection 
volume used was 25 µL for all standards and samples and the mobile phase flow rate 
was set to 1.0 mL min-1. In these conditions the run time was established for 15 min to 
allow the separation of all compounds (Table 7-1). 
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Table 7-1 Standard HPLC conditions for the analysis of tetracaine and ropivacaine. 
3.A. Preparation of stock solutions, calibration standards 
and quality controls  
Three stock solutions were prepared. TC and RPC together were prepared in a final 
concentration of ca. 1 mg/mL. The drugs were accurately weighed (5 mg) and added to 5 
mL of mobile phase in a Grade A volumetric flask. Eight standard solutions containing 
TC and RPC (0.1, 0.5, 1, 5, 10, 50 and 100 μg/mL) were obtained by diluting each initial 
stock solution with PBS. The calibration standards were run in series. Six injections of 
0.1, 1 and 10 µg/mL standards were prepared and were considered as quality control 
(QC). For determination of the limit of detection (LOD) and limit of quantitation (LOQ) of 
the method, three runs were completed on a single day with the same set of standards, 
followed by two further runs completed on two separate days with a fresh set of 
standards on each day. The standard HPLC conditions were set constant throughout the 
set of experiments. All stock solutions were stored at -20 ºC. 
4.A. Method validation  
The HPLC method was developed and validated according to US Food and Drug 
Administration (FDA) regulations (das Neves et al., 2010; Huber, 1998). The linearity, 
precision, limits of detection and quantification parameters were calculated.  
Conditions Tetracaine Ropivacaine 
mobile phase 
(acetonitrile: methanol: amonium acetate) 
35:35:30 
flow rate (mL/min) 1 
temperature (°C) 25 ± 2 
injection volume (µl) 25 
UV detection wavelength (nm) 311 210 
detection sensitivity 0.025 0.025 
run time ca. 6.9 ca. 9.1 
quantitative method Total peak area 
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4.1.A. System suitability 
The standard solution containing TC and RPC at concentration 10 µg/mL was injected 6 
times to determine the system suitability. The capacity factor (k’), resolution (Rs) tailing 
factor (T) and theoretical plate number (N) were also considered (Shabir, 2003) (Table 
7-2). The capacity factor is a measure of where the peak of interest is located with 
respect to the void volume, i.e., corresponds to the elution time of the non-retained 
components. R is a measure of the degree of separation of two peaks. The tailing factor 
is a measure of the peak symmetry, and the theoretical plate number is a measure of the 
column efficiency, that is, how many peaks can be located per unit run-time of the 
chromatogram. 
Table 7-2 System suitability test parameters. 
 Tetracaine (10 µg/mL) Ropivacaine (10 µg/mL) 
 Retention time Peak area Retention time Peak area 
Mean (n = 6) 6.88 1744801 9.15 859807.5 
S. D. 0.05 28974 0.05 16592.3 
% RSD 0.72 1.64 0.54 1.93 
Theoretical 
plates (N) 
5495.501 7123.755 
Capacity 
factory (K) 
1.696 2.814 
Tailing factor 
(T) 
1.681 1.559 
Resolution 
(Rs) 
15.467 2.710 
According to results the RSD of peak area and retention time for both drugs were lower 
than 2 % that is the acceptance limit according to the guidelines (Table 7-2). These 
values indicate that the two compounds can be analyzed simultaneous for the same 
system. The tailing factor (T), resolution (Rs) and capacity factor (k’) show that the peaks 
were symmetric and generally well resolved indicating optimal column efficiency. 
Appendix 
 
169 
 
4.2.A. Linearity 
Calibration curves from different stock solutions were constructed over the concentration 
range 0.1-50 mg/mL for TC (Figure 7.1) and RPC (Figure 7.2). The regression equation 
and the determination coefficient (R2) obtained from the least squares method was 
estimated. Linearity of the peak area of eight standard solutions as a function of TC and 
RPC concentration was determined through the calculation of a regression line analysis 
using Origin® graphing and analysis (OriginLab Corp, Northampton, USA).  
 
Figure 7.1 Linearity studies for the developed HPLC method: calibration curves obtained for tetracaine. 
 
Figure 7.2 Linearity studies for the developed HPLC method: calibration curves obtained for ropivacaine. 
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Table 7-3 Results obtained from the regression analysis by the least squares method for TC and RPC. 
Analyte Mean R
2
 ± S.E. Mean slope. Mean intercept 
Tetracaine 0.9999 ± 0.0003 2x10
8
 22045 
Ropivacaine 0.9998 ± 0.0005 9x10
7
 25638 
a Intercept is expressed in mg/mL. 
Each calibration curves has a correlation higher than 0.999 indicating a good linearity 
confirming that the method as linear between 0.1 and 50 µg/mL. This complies with 
recommendations e.g. from references (das Neves et al., 2010; Shabir, 2003) (Table 7-
3). 
4.3.A. Specificity 
The specificity of the method was obtained analyzing the solutions in the Franz diffusion 
cells medium (PBS). The specificity is the capability of the method to accurately measure 
the analyte in the presence of all potential sample components. As shown, the medium 
supernatant did not exhibit any peaks interfering with analytes retention times, thus 
indicating that the method is specific (Figure 7.3).  
 
Figure 7.3 Chromatograms 3D of TC and RPC determined in the receptor medium (PBS pH = 7.4). 
4.4.A. Limits of detection and quantification 
The limits of detection and quantitation were determined based on different calibration 
curves obtained from different standard solutions. The limit of detection of an analytical 
procedure (LOD) is defined as the lowest amount of an analyte in a sample that can be 
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quantitatively determined with suitable precision and accuracy (International Conference 
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use 1996) (ICH, 1996). The LOD and LOQ of the system were determined using 
Eq. 7.1 and 7.2, respectively, from peak area data pooled over three days 
LOD = YB + 3SB         (7.1) 
LOQ = YB + 10SB         (7.2)  
where YB is the Y intercept from regression equation and SB the standard error of the Y 
estimate. 
Table 7-4 Detection limit and quantification detection for the analytical procedure 
 Limits of detection (μg/mL) Limits of quantification (μg/mL) 
Tetracaine 0.706 2.353 
Ropivacaine 0.101 0.791 
The limits of detection and quantification were calculated using a summation of the data 
from five calibration curves (shown in Figure 7.1 and Figure 7.2). The estimated LOD 
was 0.706 µg/ml and LOQ 2.353 µg/ml for the tetracaine method. The estimated LOD 
and LOQ found for ropivacaine were 0.101 and 0.791 μg/mL, respectively (Table 7-4). 
4.5.A. Precision  
Precision indicates the degree of scatter between a series of measurements obtained 
from multiple sampling of the same homogeneous sample. Three standard solutions 
(quality controls), 0.1, 1 and 10 μg/mL, respectively were prepared six times each and 
analyzed. Inter-day and intra-day variation were compared using three runs on a single 
day with one set of standards and three individual sets of standards analysed on three 
separate days. The relative standard deviation (RSD) determined at each concentration 
level should not exceed 15%, except for the lower limit of quantitation, where it should 
not exceed 20 % (Ali and Nazzal, 2009). 
Precision for the quality controls in the intra-day and inter-day run are shown in Table 
7-5. The intra- and inter-day RSD values did not exceed 10% which is in agreement with 
acceptance recommendations. These data indicate that the developed method is reliable 
and reproducible. 
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Table 7-5 Intra-day and inter-day precision and accuracy results for TC and RPC 
 Intraday (n=6) Interday (n=18) 
Nominal 
concentration 
(µg/mL) 
 
Measured 
Concentration 
(µg/mL) 
Mean±SD 
Precision 
% RSD 
 
Measured 
Concentration 
(µg/mL) 
Mean±SD 
Precision 
% RSD 
 
TC - 0.1 0.21 ± 0.01 3.24 0.22 ± 0.01 1.61 
TC – 1 0.95 ± 0.04 4.14 0.96 ± 0.02 1.53 
TC -10 8.84 ± 0.32 3.60 8.82 ± 0.14 1.58 
RPC – 0.1 0.355 ± 0.001 0.08 0.356 ± 0.001 0.27 
RPC – 1 1.13 ± 0.01 1.29 1.56 ± 0.05 4.14 
RPC – 10 9.83 ± 0.18 1.87 10.13 ± 0.60 5.99 
5.A. Conclusion  
A specific, linear, suitable, reliable and reproducible new method for the simultaneous 
quantitation of TC and RPC was developed and validated over the range 0.1-100 µg/mL. 
The method was successfully applied to measure the drug content in LPS formulation 
after preparation. 
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“Sentes que um tempo acabou 
Primavera de flor adormecida 
Qualquer coisa que não volta, que voou 
Que foi um rio, um ar, na tua vida 
E levas em ti guardado 
O choro de uma balada 
Recordações do passado 
O bater da velha cabra 
Sabes que o desenho do adeus 
É fogo que nos queima devagar 
E no lento cerrar dos olhos teus 
Fica esperança de um dia aqui voltar 
Capa negra de saudade 
No momento da partida 
Segredos desta cidade 
Levo comigo p'ra vida” 
 
Balada de despedida – Fado de Coimbra 
 
 
 
 
Coimbra – Paço das escolas 31 Julho 2014 
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O espírito do vencer está no acreditar  
